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Abstract 
 
Arthritis is a term which encompasses a number of diseases characterised by 
cartilage degradation and joint destruction which represents an enormous and 
growing healthcare burden. 
Matrix metalloproteinases (MMPs) are a family of enzymes involved in cleavage 
of extracellular matrix proteins. They have many roles in both development and 
normal tissue homeostasis. As well as this they have been shown to be 
important in a number of diseases, including arthritis. MMP-1 and -13 in 
particular have been shown to be important in arthritis, due to their ability to 
cleave type II collagen, a key component of cartilage. A greater understanding 
of the regulation of these MMPs could lead to the potential for new therapeutic 
arthritis treatments. 
Tribbles (Trb) 1-3 are a group of proteins linked with diseases including 
diabetes, multiple sclerosis and cancer. Trb 1-3 are reported to play a role in 
regulating many cellular signalling pathways, such as mitogen-activated protein 
kinase (MAPK), phosphoinositide-3-kinase/Akt (PI3K/Akt) and nuclear factor 
kappa B (NFκB). These pathways are considered important in mediating gene 
expression changes, including MMPs. 
Both Trb1 and Trb3 were shown to regulate MMPs in chondrocytes, with a 
greater effect being on MMP-13 regulation. Trb1 and Trb3 were both shown to 
regulate the major MMP transcription factor AP-1, as well as the ATF3 and 
NFκB transcription factors.  Both Trb1 and Trb3 interacted with MAP2Ks MEK1, 
MKK4, MKK6 and MKK7, and in addition were shown to regulate MAPK 
activation, with Trb3 protein levels appearing to be affected by MAP2K levels. 
Trb3 also had the ability to affect both Akt and STAT activation. 
These data demonstrate that Trb1 and Trb3 can regulate signalling pathways 
that have the ability to alter MMP expression and transcription factors within 
chondrocytes. This would suggest that Trb1 and Trb3 have the ability to affect 
cartilage degradation. This greater understanding of MMP regulation by Trb1 
and Trb3 may help in the development of potential future therapeutic targets for 
arthritic disease. 
 
 
Acknowledgements 
 
Firstly, I would like to thank my supervisors, Professor Drew Rowan, Dr Gary 
Litherland and Dr David Young, for their advice and encouragement over the 
past three years. I also thank Jonathan Baker for advice and discussion towards 
successful completion of this thesis. Thanks also to all the members of the 
Musculoskeletal Research Group. I thank the Oliver Bird and Nuffield 
foundation for funding this PhD. 
 
Declaration 
 
This thesis is based on research performed in the Musculoskeletal Research 
Group (Rheumatology), Institute of Cellular Medicine, University of Newcastle, 
Newcastle upon Tyne, UK. Except for commonly held concepts, and where 
specific reference is made to other work, the content of the thesis is original. No 
part of this thesis has been submitted for the award of any other degree. 
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
TABLE OF CONTENTS I 
LIST OF FIGURES VI 
LIST OF TABLES VIII 
ABBREVIATIONS IX 
CHAPTER 1: INTRODUCTION 1 
1.1 Articular cartilage 1 
1.1.1 Structure and function 1 
1.1.2 Chondrocyte 2 
1.1.3 Extracellular matrix (ECM) 3 
1.1.3.1 Collagens 3 
1.1.3.2 Proteoglycans 4 
1.1.3.3 Minor components of articular cartilage 5 
1.2 Arthritis 5 
1.2.1 Rheumatoid arthritis (RA) 6 
1.2.2 Osteoarthritis (OA) 7 
1.2.3 Arthritis treatment 8 
1.2.3.1 Rheumatoid arthritis 8 
1.2.3.2 Osteoarthritis 9 
1.2.4 Mouse models 10 
1.3 Cartilage degradation 10 
1.3.1 Proteinases 10 
1.3.2 Matrix metalloproteinases 11 
1.3.2.1 Structure of matrix metalloproteinases 11 
1.3.2.2 The collagenases 12 
1.3.2.3 The stromelysins 13 
1.3.2.4 The gelatinases 13 
1.3.2.5 The matrilysins 13 
1.3.2.6 The membrane-type MMPs 13 
1.3.2.7 Regulation of matrix metalloproteinases 14 
1.3.2.7.1 Synthesis 14 
1.3.2.7.2 Activation of proenzymes 14 
1.3.2.7.3 Inhibition 15 
1.3.3 A disintegrin and metalloprotease with thrombospondin motifs (ADAMTS) 16 
1.3.4 Other proteinases involved in cartilage degradation 17 
1.3.4.1 Serine proteinases 18 
1.3.4.2 Cysteine proteinases 18 
i 
 
1.4 Pro-inflammatory cytokines in arthritis 19 
1.4.1 Interleukin-1 (IL-1) 19 
1.4.1.1 IL-1 and arthritis 20 
1.4.2 Oncostatin M (OSM) 21 
1.4.2.1 OSM and arthritis 21 
1.4.3 Tumour necrosis factor-α (TNF-α) 22 
1.5 Anti-inflammatory cytokines in arthritis 22 
1.5.1 Interleukin-4 (IL-4) 23 
1.5.2 Interleukin-10 (IL-10) 23 
1.5.3 Interleukin-13 (IL-13) 24 
1.6 Signalling pathways involved in arthritis/MMP regulation 25 
1.6.1 MAP kinases (MAPK) 25 
1.6.2 Transforming Growth Factor-β/Sma and Mad related protein (TGF-β/Smad) 28 
1.6.3 Janus kinase/signal transducers and activators of transcription (JAK/STAT) 29 
1.6.4 Fibroblast growth factor (FGF) 31 
1.6.5 Protease activated receptor-2 (PAR-2) 32 
1.6.6 Phosphoinositide 3-kinase (PI3K)/Akt 32 
1.7 Transcriptional control of MMPs 34 
1.7.1 Activating protein (AP) 1 34 
1.7.2 Activating transcription factor (ATF) 35 
1.7.3 Hypoxia inducible factor (HIF) 35 
1.7.4 Sry high mobility group box (SOX) 9 36 
1.7.5 Cytidine-Cytidine-Adenosine-Adenosine-Thymidine (CCAAT) enhanced-binding protein (C/EBP)
 37 
1.7.6 Nuclear factor kappa B (NFκB) 37 
1.7.7 Runt related transcription factor (RUNX2) 38 
1.8 Tribbles 1-3 39 
1.8.1 Trb1-3 structure 39 
1.8.2 Trb1-3 location 40 
1.8.3 The regulation of Trb1-3 40 
1.8.4 Trb1-3 regulation of signalling pathways 41 
1.8.4.1 Trb1-3 and the MAPK pathway 41 
1.8.4.2 Trb3 and the TGF-β/Smad pathway 42 
1.8.4.3 Trb2, Trb3 and the PI3K/Akt pathway 43 
1.8.4.4 Trb1-3 and C/EBP 44 
1.8.4.5 Trb1, Trb3 and NFκB 44 
1.8.4.6 Trb1-3 and cytokines 44 
1.8.4.7 Trb1-3 and AP-1 45 
1.8.4.8 Trb3 and ATF 46 
1.8.4.9 Trb3 and RUNX2 46 
1.8.4.10 Trb1-3 and disease 46 
1.9 Summary and aims of this study 47 
1.9.1 Overall aim 48 
1.9.2 Specific aims 48 
 
ii 
 
CHAPTER 2: MATERIALS AND METHODS 49 
2.1 Materials 49 
2.1.1 Antibodies 49 
2.1.2 Cells 49 
2.1.3 Cell culture reagents 50 
2.1.4 Commercially available kits 50 
2.1.5 Molecular Biology Reagents 50 
2.1.6 Immunoblotting reagents 51 
2.1.7 Inhibitors 52 
2.1.8 Cytokines 52 
2.2 Methods 52 
2.2.1 Isolation of Human Articular Chondrocytes (HACs) 52 
2.2.2 Cell culture 53 
2.2.3 Lentivirus production 53 
2.2.4 Lentivirus concentration 54 
2.2.5 siRNA transfection of cells 54 
2.2.6 shRNA transfection of cells 55 
2.2.7 Addition of MG132 proteasomal inhibitor or UO126 MEK inhibitor to cells 57 
2.2.8 Overexpression plasmid transfection 57 
2.2.9 Preparation of plasmid DNA 58 
2.2.10 RT-PCR 60 
2.2.11 Western Blotting 62 
2.2.12 Subcellular fractionation 63 
2.2.13 Nuclear fractionation 64 
2.2.14 Immunoprecpitiation 64 
2.3 Statistical analysis 65 
CHAPTER 3: RNA INHIBITION AND OVEREXPRESSION OPTIMISATION 66 
3.1 Introduction 66 
3.2 Results 67 
3.2.1 Trb1 gene silencing using siRNA in SW1353 cells and HAC 67 
3.2.2 Trb3 gene silencing using siRNA in SW1353 cells and HAC 69 
3.2.3 Trb1 overexpression optimisation in SW1353 cells and HAC 73 
3.2.4 Trb1 immunoprecipitation in SW1353 cells 74 
3.2.5 Trb3 overexpression optimisation in SW1353 cells and HAC 75 
3.2.6 Trb1 gene silencing optimisation using shRNA in SW1353 cells and HAC 77 
3.2.6.1 Optimisation of GFP lentiviral shRNA in HAC and SW1353 cells 77 
3.2.6.2 Optimisation of polybrene concentration in HAC 79 
3.2.6.3 Centrifugation of cells in order to increase transduction of shRNA in HAC 80 
3.2.6.5 Optimisation of inducible TRIPZ Trb1 lentiviral shRNA in HAC and SW1353 cells 81 
3.2.6.6 Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA in HAC 88 
3.3 Discussion 91 
3.4 Synopsis 94 
3.5 Summary 95 
iii 
 
CHAPTER 4: THE REGULATION OF TRB1 AND TRB3 96 
4.1 Introduction 96 
4.2 Results 97 
4.2.1 Trb1 and Trb3 subcellular localisation and the effect of IL-1+OSM stimulation in SW1353 cells 97 
4.2.2 Trb1 and Trb3 protein abundance during 24 hour serum-starvation in HAC 99 
4.2.3 Trb1 and Trb3 mRNA expression and protein abundance during IL-1+OSM stimulation in HAC
 100 
4.2.4 Assessment of proteasomal degradation of Trb1 and Trb3 in HAC 103 
4.2.5 Trb1 and Trb3 interaction 105 
4.3 Discussion 106 
4.4 Synopsis 110 
4.5 Summary 110 
CHAPTER 5: THE EFFECT OF TRB1 AND TRB3 ON MMPS AND TRANSCRIPTION FACTORS WHICH 
REGULATE THESE MMPS 112 
5.1 Introduction 112 
5.2 Results 113 
5.2.1 Effect of Trb1 overexpression on MMP-1 and MMP-13 mRNA expression during IL-1+OSM 
stimulation in HAC and SW1353 cells 113 
5.2.2 Effect of Trb1 overexpression on c-fos and c-jun mRNA expression during IL-1+OSM stimulation 
in HAC 115 
5.2.3 Effect of Trb1 overexpression on ATF3 mRNA expression during IL-1+OSM stimulation in HAC
 116 
5.2.4 Effect of Trb3 siRNA gene silencing on MMP-1 and MMP-13 mRNA expression during IL-1+OSM 
stimulation in HAC and SW1353 cells 117 
5.2.5 Effect of Trb3 overexpression on MMP-1 and MMP-13 mRNA expression during IL-1+OSM 
stimulation in HAC and SW1353 cells 119 
5.2.6 Effect of Trb3 siRNA gene silencing on c-fos and c-jun mRNA expression and protein abundance, 
as well as c-Jun activation during IL-1+OSM stimulation in HAC 121 
5.2.7 Effect of Trb3 siRNA gene silencing on ATF3 mRNA expression and protein abundance during IL-
1+OSM stimulation in HAC 123 
5.2.8 Effect of Trb3 overexpression on ATF3 mRNA expression during IL-1+OSM stimulation in HAC
 125 
5.3 Discussion 126 
5.4 Synopsis 131 
5.5 Summary 131 
CHAPTER 6: THE EFFECT OF TRB1 AND TRB3 ON THE MAP KINASE PATHWAY 133 
6.1 Introduction 133 
6.2 Results 134 
iv 
 
6.2.1 MAPK activation during IL-1+OSM stimulation in SW1353 cells and HAC 134 
6.2.2 The interaction of Trb1 with MAP2Ks 135 
6.2.3 The effect of Trb1 overexpression on MAPK activation during IL-1+OSM stimulation in SW1353 
cells 136 
6.2.4 The effect of combined siRNA gene silencing of the MAP2Ks on Trb1 protein abundance in HAC
 137 
6.2.5 The interaction of Trb3 with MAP2Ks in SW1353 cells 140 
6.2.6 The effect of Trb3 siRNA gene silencing on MAPK activation during IL-1+OSM stimulation in 
SW1353 cells and HAC 141 
6.2.7 The effect of Trb3 overexpression on MAPK activation during IL-1+OSM stimulation in SW1353 
cells 143 
6.2.8 The effect of combined siRNA gene silencing of the MAP2Ks on Trb3 protein abundance in HAC
 144 
6.2.9 The effect of the MEK inhibitor UO126 on Trb3 protein abundance during IL-1+OSM stimulation 
in HAC 146 
6.3 Discussion 148 
6.4 Synopsis 153 
6.5 Summary 154 
CHAPTER 7: THE EFFECT OF TRB1 AND TRB3 ON OTHER SIGNALING PATHWAYS KNOWN TO 
REGULATE MMPS 155 
7.1 Introduction 155 
7.1.1 NFκB 155 
7.1.2 Akt 155 
7.1.3 JAK/STAT 156 
7.2 Results 157 
7.2.1 The NFκB pathway 157 
7.2.1.1 The interaction of Trb1 and the NFκB subunit p65 in SW1353 cells 157 
7.2.1.2 The effect of IKKβ siRNA gene silencing on MMP-1 and MMP-13 expression during IL-
1+OSM stimulation in SW1353 cells 158 
7.2.1.3 The effect of IKKβ siRNA gene silencing on IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells 160 
7.2.1.4 The effect of Trb1 overexpression on IL-8 mRNA expression during IL-1+OSM stimulation in 
SW1353 cells and HAC 161 
7.2.1.5 The effect of Trb1 overexpression on p65 protein abundance and activation during IL-
1+OSM stimulation in SW1353 cells 163 
7.2.1.6 The interaction of Trb3 and the NFκB subunit p65 in SW1353 cells 164 
7.2.1.7 The effect of Trb3 siRNA gene silencing on IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells and HAC 165 
7.2.1.8 The effect of Trb3 overexpression on IL-8 mRNA expression during IL-1+OSM stimulation in 
SW1353 cells and HAC 167 
7.2.1.9 The effect of Trb3 siRNA gene silencing on p65 protein abundance and activation during IL-
1+OSM stimulation in SW1353 cells and HAC 169 
7.2.1.10 The effect of Trb3 overexpression on p65 protein abundance and activation during IL-
1+OSM stimulation in SW1353 cells 171 
7.2.2 Akt 173 
v 
 
7.2.2.1 The effect of Trb1 overexpression on Akt activation during IL-1+OSM stimulation in 
SW1353 cells 173 
7.2.2.2 The effect of Trb3 siRNA gene silencing on Akt activation during IL-1+OSM stimulation in 
SW1353 cells and HAC 174 
7.2.2.3 The effect of Trb3 overexpression on Akt activation during IL-1+OSM stimulation in 
SW1353 cells 175 
7.2.3 JAK/STAT 176 
7.2.3.1 The effect of Trb3 siRNA gene silencing on STAT activation during IL-1+OSM stimulation in 
HAC 176 
7.3 Discussion 178 
7.3.1 NFκB 178 
7.3.1.1 Synopsis 180 
7.3.2 Akt 180 
7.3.2.1 Synopsis 182 
7.3.3 JAK/STAT 182 
7.3.3.1 Synopsis 183 
7.4 Summary 183 
CHAPTER 8: GENERAL DISCUSSION 185 
8.1 Summary of possible future studies 194 
References 197 
Appendix A - Overexpression plasmid maps 243 
 
List of figures 
 
Figure 1.1. The components of cartilage. 5 
Figure 1.2 Domain structures of MMPs. 12 
Figure 1.3 Domain structures of MMPs. 17 
Figure 1.4. The different levels of the MAPK signalling pathway, demonstrating the specific regulation 
within each pathway. 27 
Figure 1.5. The JAK/STAT signalling pathway. 31 
Figure 1.6. The PI3K/Akt pathway, demonstrating the various proteins involved in the signal transduction 
through the pathway. 33 
Figure 3.1. Trb1 gene silencing optimisation using siRNA in SW1353 cells and HAC. 68 
Figure 3.2. Trb3 gene silencing using siRNA in SW1353 cells. 69 
Figure 3.3. Trb3 gene silencing using siRNA effect on Trb3 protein expression in SW1353 cells. 70 
Figure 3.4. Trb3 gene silencing using siRNA in HAC. 71 
Figure 3.5. Trb3 gene silencing using siRNA effect on Trb3 protein expression in HAC. 72 
Figure 3.6. Trb1 overexpression optimisation in SW1353 cells. 73 
Figure 3.7. Trb1 overexpression optimisation in HAC. 74 
Figure 3.8. Trb1 immunoprecipitation in SW1353 cells. 75 
Figure 3.9. Trb3 overexpression optimisation in SW1353 cells. 76 
Figure 3.10. Trb3 overexpression optimisation in HAC. 77 
Figure 3.11. Optimisation of GFP lentiviral shRNA using different concentrations of shRNA in SW1353 
cells. 78 
Figure 3.12. Optimisation of GFP lentiviral shRNA using different concentrations of shRNA in HAC. 79 
vi 
 
Figure 3.13. Optimisation of polybrene concentration in HAC. 80 
Figure 3.14. Centrifugation of cells in order to increase transduction of shRNA in HAC. 81 
Figure 3.15. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA through alteration of serum content and 
doxycycline in SW1353 cells. 84 
Figure 3.16. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA through alteration of serum content and 
doxycycline in SW1353 cells: Assessment of Trb1 gene silencing. 85 
Figure 3.17. Assessment of Trb3 gene silencing during TRIPZ Trb1 lentiviral shRNA transduction in 
SW1353 cells. 86 
Figure 3.18. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA using different concentrations of 
shRNA in HAC. 87 
Figure 3.19. Assessment of the ability of doxycycline to induce lentivirus in HAC. 88 
Figure 3.20. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different concentrations of 
shRNA in HAC. 89 
Figure 3.21. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different concentrations of 
shRNA in HAC: Assessment of Trb1 gene silencing. 90 
Figure 3.22. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different concentrations of 
shRNA in HAC: Assessment of Trb1 protein expression. 91 
Figure 4.1. Trb1 and Trb3 localise predominantly within the nucleus and cytoplasm, as well as increasing 
in protein abundance within the cytoplasm during IL-1+OSM stimulation in SW1353 cells. 99 
Figure 4.2. Trb1 and Trb3 respond to serum-starvation in HAC. 100 
Figure 4.3. IL-1+OSM stimulation leads to an increase in Trb1 and Trb3 mRNA expression in HAC. 101 
Figure 4.4. IL-1+OSM stimulation increases Trb1 and Trb3 protein abundance in HAC. 102 
Figure 4.5. Ubiquitinated protein levels increase with the addition of MG132 in HAC. 103 
Figure 4.6. The addition of MG132 leads to an increase in Trb3 protein abundance but has no effect on 
Trb1 in HAC. 104 
Figure 4.7. Fluorescent images of Trb1 (V1) and Trb3 (V2), as well as MEK1 (V1) and Trb1 (V2) 
overexpression constructs in SW1353 cells. 105 
Figure 5.1. Trb1 overexpression leads to a reduction in MMP-1 and MMP-13 mRNA expression during IL-
1+OSM stimulation in SW1353 cells. 114 
Figure 5.2. Trb1 overexpression leads to a reduction in MMP-13 mRNA expression but has no effect on 
MMP-1 during IL-1+OSM stimulation in HAC. 115 
Figure 5.3. Trb1 overexpression leads to a reduction in c-fos and c-jun  mRNA expression during IL-
1+OSM stimulation in HAC. 116 
Figure 5.4. Trb1 overexpression leads to a reduction in ATF3 mRNA expression during IL-1+OSM 
stimulation in HAC. 117 
Figure 5.5. Trb3 gene silencing leads to a reduction in MMP-1 and MMP-13 mRNA expression during IL-
1+OSM stimulation in SW1353 cells. 118 
Figure 5.6. Trb3 gene silencing leads to a reduction in MMP-13 mRNA expression but has no effect on 
MMP-1 during IL-1+OSM stimulation in HAC. 119 
Figure 5.7. Trb3 overexpression leads to a reduction in MMP-13 mRNA expression, but has no effect on 
MMP-1 during IL-1+OSM stimulation in SW1353 cells. 120 
Figure 5.8. Trb3 overexpression leads to a reduction in MMP-13 mRNA expression, but has no effect on 
MMP-1 during IL-1+OSM stimulation in HAC. 121 
Figure 5.9. Trb3 siRNA gene silencing has no effect on c-fos and c-jun mRNA expression during IL-
1+OSM stimulation in HAC. 122 
Figure 5.10. Trb3 siRNA gene silencing regulates both c-Jun and c-Fos at the protein level during IL-
1+OSM stimulation in HAC. 123 
Figure 5.11. Trb3 siRNA gene silencing leads to a reduction in ATF3 mRNA expression during IL-1+OSM 
stimulation in HAC. 124 
Figure 5.12. Trb3 siRNA gene silencing leads to a reduction in ATF3 nuclear protein abundance during IL-
1+OSM stimulation in HAC. 125 
Figure 5.13. Trb3 overexpression leads to a reduction in ATF3 mRNA expression during IL-1+OSM 
stimulation in HAC. 126 
Figure 6.1. MAPK activation during IL-1+OSM stimulation in SW1353 cells and HAC. 134 
Figure 6.2. Trb1 interacts with MAP2Ks in SW1353 cells. 136 
Figure 6.3. Trb1 overexpression regulates MAPK activation during IL-1+OSM stimulation in SW1353 cells.
 137 
Figure 6.4. siRNA gene silencing of the MAP2Ks in HAC. 139 
Figure 6.5. The combined silencing of MAP2Ks has no effect on Trb1 protein abundance in HAC. 140 
Figure 6.6. Trb3 interacts with MAP2Ks in SW1353 cells. 141 
vii 
 
Figure 6.7. Trb3 siRNA gene silencing regulates MAPK activation during IL-1+OSM stimulation in SW1353 
cells. 142 
Figure 6.8. Trb3 siRNA gene silencing regulates MAPK activation during IL-1+OSM stimulation in HAC.
 143 
Figure 6.9. Trb3 overexpression regulates MAPK activation during IL-1+OSM stimulation in SW1353 cells.
 144 
Figure 6.10. The combined silencing of MAP2Ks leads to a reduction in Trb3 protein abundance in HAC.
 146 
Figure 6.11. The MEK inhibitor UO126 leads to a reduction in Trb3 protein abundance in HAC. 147 
Figure 7.1. Trb1 interacts with the NFκB subunit p65 158 
Figure 7.2. IKKβ siRNA gene silencing. 159 
Figure 7.3. IKKβ siRNA gene silencing leads to a reduction in MMP-1 and MMP-13 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells. 160 
Figure 7.4. IKKβ siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells. 161 
Figure 7.5. Trb1 overexpression shows a trend towards a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in SW1353 cells. 162 
Figure 7.6. Trb1 overexpression shows a trend towards a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in HAC. 163 
Figure 7.7. Trb1 overexpression leads to a reduction in p65 protein abundance and p65 activation during 
IL-1+OSM stimulation in SW1353 cells. 164 
Figure 7.8. Trb3 interacts with the NFκB subunit p65 in SW1353 cells. 165 
Figure 7.9. Trb3 siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells. 166 
Figure 7.10. Trb3 siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation in HAC. 167 
Figure 7.11. Trb3 overexpression leads to a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells. 168 
Figure 7.12. Trb3 overexpression shows a trend towards a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in HAC. 169 
Figure 7.13. Trb3 siRNA gene silencing leads to a reduction in p65 protein abundance and p65 activation 
during IL-1+OSM stimulation in SW1353 cells. 170 
Figure 7.14. Trb3 siRNA gene silencing leads to a reduction in p65 protein abundance and p65 activation 
during IL-1+OSM stimulation in HAC. 171 
Figure 7.15. Trb3 overexpression leads to a reduction in p65 protein abundance and p65 activation during 
IL-1+OSM stimulation in SW1353 cells. 172 
Figure 7.16. Trb1 overexpression does not affect Akt activation during IL-1+OSM stimulation in SW1353 
cells. 173 
Figure 7.17. Trb3 siRNA gene silencing leads to an increase in Akt activation in SW1353 cells. 174 
Figure 7.18. Trb3 siRNA gene silencing has no effect on Akt activation in HAC. 175 
Figure 7.19. Trb3 overexpression leads to a decrease in Akt activation during IL-1+OSM stimulation in 
SW1353 cells. 176 
Figure 7.20. Trb3 siRNA gene silencing leads to a reduction in STAT1 serine activation during IL-1+OSM 
stimulation in HAC. 177 
Figure 8.1. The hypothetical pathway of Trb1 and Trb3 regulation of MMP-13 in HAC. 193 
 
List of tables 
 
Table 2.1. siRNA sequences. 56 
Table 2.2. shRNA sequences. 57 
Table 2.3. Primers and probe sequences used for RT-PCR. 61 
Table 2.4. Subcellular protein fractionation reagent volumes for different packed cell volumes. 63 
Table 2.5. Nuclear protein fractionation reagent volumes for different packed cell volumes. 64 
 
viii 
 
Abbreviations 
 
°C    degree Celsius 
μg    microgram 
μl    microlitre 
ACPA       anti-citrullinated peptides antibody  
ADAM    a disintegrin and a metalloproteinase 
ADAMTS  a disintegrin and a metalloproteinase with thrombospondin         
motifs 
ALK     activator receptor like kinase 
AML     acute myeloid leukaemia 
AP-1    activator protein-1 
APS    ammonium peroxodisulphate 
ATCC    American Type Culture Collection 
ATF     activating transcription factor 
bp    base pairs 
Bcl     B-cell lymphoma 
BSA    bovine serum albumin 
CBP     CREB binding protein 
cdc     cell division cycle 
cDNA    complementary DNA 
CEB     cytoplasmic extraction buffer 
C/EBP  cytidine-cytidine-adenosine-adenosine-thymidine     
enhancer-binding protein                                                                                                                        
CER     cytoplasmic extraction reagent 
CHOP    CCAAT/-enhancer binding protein homologous protein 
CIA    collagen-induced arthritis 
CIS     cytokine inducible SH2 protein 
COP     constitutive photomorphogenic protein 
ix 
 
CTLA    cytotoxic T lymphocyte antigen 
dH2O    distilled H2O 
DMARD    disease modifying anti-rheumatic drug 
DMEM   Dulbecco’s modification of Eagle’s medium 
DMSO   dimethylsulphoxide 
DNA    deoxyribonucleic acid 
DNase   deoxyribonuclease 
DTT     dithiothreitol 
DUSP     dual specificity phosphatase 
ECL     enhanced chemiluminescence 
ECM    extracellular matrix 
EDTA    ethylenediaminetetraacetic acid 
ERK    extracellular regulated kinase 
Ets     E26 transformation specific sequence 
Ezh     enhancer of zeste homolog 
FCS    foetal calf serum 
FGF     fibroblast growth factor 
Fra     fos related antigen 
g    relative centrifugal force 
GAG    glycosaminoglycan 
GAPDH   glyceraldehyde-3-phosphate dehydrogenase 
HAC     Human Articular Chondrocyte 
HEK     human embryonic kidney 
HeLa     Henrietta Lack 
HIF     hypoxia inducible factor 
HLA-DR    human leukocyte antigen 
HRP    horse-radish peroxidase 
Htra     high temperature requirement A 
x 
 
Ig    immunoglobulin 
IGF    insulin-like growth factor 
Ihh     indian hedgehog 
IκB     inhibitor of κ B 
IKK     inhibitor of IκB kinase 
IL    interleukin 
IL-1Ra   interleukin-1 receptor antagonist 
IL-1RAP    interleukin-1 receptor agonist accessory protein 
IL-4R    interleukin-4 receptor 
IRAK     interleukin-1 receptor associated kinase 
JAK    janus kinase 
JNK    c-Jun N-terminal kinase  
kb    kilobase 
kDa    kilodalton 
LB     luria broth 
LIFR     leukaemia inhibitory factor receptor 
MAPK     mitogen-activated protein kinase 
MAP2K    mitogen-activated protein kinase kinase 
MAP3K    mitogen-activated protein kinase kinase kinase 
MEB      membrane extraction buffer 
mg    microgram 
MMP    matrix metalloproteinase 
mRNA   messenger RNA 
miRNA    micro RNA 
MMLV    Molony murine leukaemia virus 
MT-MMP   membrane type MMP 
MW    molecular weight 
MYD     myeloid differentiation primary response protein 
xi 
 
NEB     nuclear extraction buffer 
NER     nuclear extraction reagent 
NFκB    nuclear factor κB 
NSAID    non-steroidal anti-inflammatory drug 
OA    osteoarthritis 
OSM    oncostatin M 
OSMR-β    OSM receptor-β 
PACE    paired basic amino acid cleaving enzyme 
PAGE    polyacrylamide gel electrophoresis 
PAR     protease activated receptor 
PBS    phosphate buffered saline 
PCA     protein complementation assay 
PCR    polymerase chain reaction 
PDGF    platelet derived growth factor 
PEA     polyoma enhancer activator 
PEB     cytoskeletal extraction buffer 
PIAS     protein inhibitor of activated STATs 
PI3K    phosphatidylinositol 3-kinase 
PIP2     phosphoinositol-4,5-biphosphate 
PIP3     phosphoinositol-3,4,5-triphosphate 
PTPN    protein tyrosine phosphatase non-receptor type 
RA    rheumatoid arthritis 
RANKL      receptor activator of nuclear factor kappa B ligand 
RF                            rheumatoid factor 
RFP     red fluorescence protein 
RNA    ribonucleic acid 
RNase   ribonuclease 
RPTK    receptor protein tyrosine kinase 
xii 
 
RT-PCR   reverse transcriptase PCR 
RUNX    runt-related transcription factor  
SDS    sodium dodecyl sulphate 
SFM     serum-free medium 
siRNA    small interfering RNA 
SOC     Super Optimal Broth with Enhanced Catabolite Repression 
SOCS    silencers of cytokine signalling 
SOX     Sry high mobility group box 
SHP     SH2 domain containing protein tyrosine phosphatase 
ShRNA    short hairpin RNA 
SIAH     seven in absentia homolog 
STAT    signal transducer and activator of transcription 
TEMED   N,N,N’N’-tetramethylethylene-diamine 
TGF-β    transforming growth factor-β 
TIMP    tissue inhibitor of metalloproteinases 
TIP     tat interactive protein 
TIR     toll/IL-1 receptor 
TNF    tumour necrosis factor 
TRAF    TNF receptor associated factor 
Trb     Tribble 
Tris    tris(hydroxymethyl)aminomethane 
Triton X-100   t-Octylphenoxypolyethoxyethanol 
Tween 20    polyoxyethylene sorbitan monolaurate 
TYK     tyrosine kinase 
UTR     untranslated region 
v/v    volume/volume 
w/v    weight/volume
xiii 
 
 Chapter 1: Introduction 
 
1.1 Articular cartilage 
 
1.1.1 Structure and function 
 
Articular cartilage is a type of hyaline cartilage, whose primary function is to 
cover the ends of bones to provide low friction movement between bones within 
the joint (Ateshian and Wang, 1995). Articular cartilage is both avascular and 
aneural (Buckwalter and Mankin, 1997), and contains a single cell type known 
as the chondrocyte. This cartilage has a high water content (70-80%) in order to 
withstand the compressive strains imposed on it (Wong and Carter, 2003). 
Cartilage resists large changes in shape when loaded, and this is partly due to 
the cartilage matrix having a low permeability (Mow et al, 1984). 
Cartilage can be divided into 4 zones consisting of the superficial, transitional, 
middle and calcified zones, with each zone differing in terms of its matrix and 
biochemistry. Each of these 4 zones consists of 3 regions; the pericellular, the 
territorial and the interterritorial regions (Temenoff and Mikos, 2000). Each of 
these 3 regions consists of different matrix structure and components, with the 
interterritorial region being responsible for the mechanical properties of the 
cartilage, consisting of large diameter, parallel collagen fibrils (Buckwalter and 
Mankin, 1998). The superficial zone (zone1) is the thinnest of the 4 zones and 
consists of 2 layers; the top layer is acellular and consists of mainly collagen 
fibres, which cover the joint. The second layer consists of chondrocytes which 
are small and flattened lying parallel to the articular surface (Temenoff and 
Mikos, 2000; Goldring and Marcu, 2009). This layer has a high tensile strength 
due to the ratio of collagen to proteoglycans, as well as it containing fibronectin 
and water. The transitional zone (zone 2) is thicker than the superficial zone, 
and contains chondrocytes which are spherical, with the collagen fibrils of the 
interterritorial region being randomly arranged. The middle zone (zone 3) 
consists of the largest diameter collagen fibrils, and has the highest 
1 
 
proteoglycan content of the 4 zones. The middle zone chondrocytes are also 
spherical. The interterritorial fibres in this region are arranged perpendicular to 
the surface (Temenoff and Mikos, 2000). The calcified zone (zone 4) lies 
closest to the bone, providing the link between cartilage and bone. Due to this, 
this zone is exposed to high levels of shear stress (Cohen et al, 1998). The 
chondrocytes in this zone are smaller than the other zones, and as opposed to 
the cells of the middle zone which have high metabolic activity, these cells are 
thought to have low metabolic activity (Temenoff and Mikos, 2000). 
Surrounding this articular cartilage is the synovial membrane which has a 
boundary layer consisting of lubricin and hyaluronic acid produced by 
chondrocytes and synovial cells. This layer provides lubrication which allows 
low friction gliding movement between the joints (Greene et al, 2011). 
Beneath the articular cartilage lies the subchondral bone, and it is thought that 
this plays a role in providing support for the articular cartilage (Radin and Rose, 
1986). Defects within the subchondral bone are a common feature of arthritis. 
This subchondral bone layer can be separated into two layers; a layer of 
mineralised cartilage, which lies next to the articular cartilage, and this can vary 
in thickness. Below this is woven or lamellar bone which is similar to normal 
trabecular bone (Madry et al, 2010). Unlike the articular cartilage, the 
subchondral bone is highly vascularised, and this has been shown to increase 
with greater loading (Lane et al, 1977). It is thought that one of the causes of 
cartilage degradation and its progression may be an increase in stiffness of this 
subchondral bone (Radin and Rose, 1986). 
 
1.1.2 Chondrocyte 
 
Chondrocytes are fairly low in number within cartilage, consisting of only 
approximately 2-5% of the cartilage (Goldring, 2006). Their role is to produce 
the cartilaginous extracellular matrix (ECM) which surrounds them (Temenoff 
and Mikos, 2000). However, once this ECM is formed there is low turnover by 
the chondrocytes, with collagen type II having a turnover of more than 100 
years, and aggrecan having a turnover of 3-24 years (Goldring, 2006). This 
slow turnover is due to the fact that in normal cartilage these chondrocytes are 
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relatively quiescent (Loeser et al, 2012). Some chondrocytes have cilia 
protruding from them into the cartilage, this is thought to allow chondrocytes to 
detect changes within the environment due to loading of the cartilage. This in 
turn can cause the chondrocyte to modify its behaviour such as the production 
of matrix and growth factor expression (Wong and Carter, 2003; Buckwalter and 
Mankin 1998). The oxygen tension within the cartilage is low ranging from 10% 
at the surface to less than 1% in the deep zones; the chondrocytes have 
adapted to be able to work metabolically within this environment (Goldring, 
2006).  
 
1.1.3 Extracellular matrix (ECM) 
 
1.1.3.1 Collagens 
 
Collagens have been shown to be important in all connective tissue types. 
There are 26 known collagens (Sato et al, 2002), all of which are composed of 
trimeric triple helices, consisting of repetitions of Gly-X-Y (Gelse et al, 
2003).The triple helix can either be composed of 3 identical chains, or 2 or more 
different chains (Gelse et al, 2003). Articular cartilage is composed of a number 
of different types of collagen, these are types II, VI, IX, X and XI, with the major 
one being type II, with type IX and XI also being important (Chen and Broom, 
1998).Type II makes up approximately 90-95% of the collagen (Temenoff and 
Mikos, 2000). As mentioned above, the structure and composition of the 
collagen network varies throughout the depth of the cartilage, and compared 
with most connective tissues, the collagen network appears fairly randomly 
arranged (Chen and Broom, 1998).  
Type II collagen provides the cartilage with tensile strength by forming a mesh-
like structure made of collagen fibrils (Temenoff and Mikos, 2000). Type II 
collagen is composed of 3 identical chains within its triple helix, and consists of 
long triple helical domains approximately 300nm in length (Gelse et al, 2003). 
There are 2 splice variants of collagen type II, which are present in either 
mature cartilage or in embryonic cartilage (Sandell et al, 1991). Collagen IX 
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interacts with type II collagen fibrils, this is particularly evident around the 
chondrocyte (Hagg et al, 1998). Collagen XI is cross linked with itself, and is 
thought to prevent lateral growth of type II collagen (Blaschke et al, 2000).  
 
1.1.3.2 Proteoglycans 
 
The other major components of cartilage are proteoglycans. These 
proteoglycans consist of a central protein core, making up approximately 5% of 
the proteoglycan. Associated with this are one or more different 
glycosaminoglycans (GAGs), which consist of unbranched polysaccharides, 
which make up approximately 95% of the proteoglycan. The GAGs are 
negatively charged, due to sulphate and carboxylate groups, and this allows 
interaction with water (Temenoff and Mikos, 2000). This gives the cartilage its 
ability to resist compression during loading (Buckwalter and Mankin, 1998; 
Wong and Carter, 2003). There are a number of GAGs found in articular 
cartilage including hyaluronic acid, chondroitin sulphate and keratan sulphate 
(Roughley, 2006). 
Cartilage proteoglycans can aggregate together and are known as aggrecans, 
consisting of monomers of keratan sulphate and chondroitin sulphate attached 
to the protein core (Roughley, 2006). Aggrecan can consist of up to 300 of 
these monomers linked to a central hyaluronic acid chain (Temenoff and Mikos, 
2000). It is these aggrecan structures, along with type II collagen that are the 
primary components of cartilage (see Fig 1.1). The smaller proteoglycans are 
thought to play a role in the organisation of the collagen as well as cell function 
(Buckwalter and Mankin 1998).  
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 Figure 1.1. The components of cartilage. 
 
1.1.3.3 Minor components of articular cartilage 
 
As well as proteoglycans the cartilage also consists of non-collagenous proteins 
which include anchorin, fibronectin and tenascin. These proteins make up a 
relatively small component of the cartilage. However, they play a number of 
important roles including stabilisation of the ECM, and aiding in the interaction 
of chondrocytes with the surrounding matrix (Temenoff and Mikos, 2000; 
Buckwalter and Mankin, 1998). 
 
1.2 Arthritis  
 
Cartilage is a dynamic tissue, with the balance of synthesis and degradation of 
the matrix under tight control (Rowan et al, 2008). It is when this balance is 
interrupted that excessive cartilage degradation occurs and a disease state 
arises, with the two most predominant diseases being rheumatoid arthritis (RA) 
and osteoarthritis (OA). In particular, it is collagen degradation that is central to 
disease, since when aggrecan is lost this can be replaced but collagen 
degradation is irreversible (Jubb et al, 1980). The causal mechanisms of 
cartilage damage differ from disease to disease, indeed within a particular 
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disease, however, the end point is always characterised by excessive cartilage 
degradation and pain.  
Cartilage degradation is driven primarily by 2 groups of enzymes, the A 
disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) and 
matrix metalloproteinases (MMPs), which cleave the two major components of 
the cartilage; the proteoglycans and collagen. This degradation process is 
driven by a large number of different cytokines including interleukin (IL) -1, -17, -
6 and tumour necrosis factor-α (TNF-α) (Goldring et al, 2011; Boissier, 2010). 
 
1.2.1 Rheumatoid arthritis (RA) 
 
RA is a chronic autoimmune disease affecting between 0.5-1% of people in the 
industrialised world, occurring three times more frequently in women than men 
(Scott et al, 2010). It is an inflammatory disease, associated particularly with 
inflammation of the synovium. This persistent inflammation leads to damage of 
the cartilage, as well as bone and tendon (Scott, 2012). RA can in fact be 
thought of as a number of diseases with the same final outcome (van der Helm-
van Mil and Huizinga, 2008). RA is mediated through the action of a number of 
cell types including B cells, T cells, macrophages, synovial-like fibroblasts, 
neutrophils and macrophage-like synoviocytes. Cytokine production such as IL-
1, TNF, IL-6, IL-10, IL-17 and IL-8 is an important factor in driving RA. These 
different cytokines can be produced by a number of cell types and can lead to 
inflammation and joint destruction, as well as promoting autoimmunity (Feldman 
et al, 1996; Scott et al, 2010; McInnes and Schett, 2007). As well as this, 
osteoclasts also play a role in causing erosion of bone where receptor activator 
of nuclear factor-κB ligand (RANKL) plays an important part (McInnes and 
Schett, 2007). A large number of RA cases can be characterised by the 
presence of rheumatoid factor (RF) and anti-citrullinated peptides antibody 
(ACPA), with 50-80% of patients having one or both of these autoantibodies 
(Scott et al, 2010). Another important aspect of RA is the lack of inhibitory 
cytokines, such as IL-10 and IL-11, which are produced at lower levels in RA 
(Feldmann et al. 1996).  
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The initial cause of RA is still unknown, however it is thought that in many cases 
the disease starts many years before arthritis is apparent, as autoantibodies 
have been found in patients many years before cartilage damage 
(Schaeverbeke et al 2012). Infection may be one cause of RA, with a link 
between RA and periodontitis being suggested (Schaeverbeke et al 2012). 
There is also thought to be a genetic aspect to RA with the human leukocyte 
antigen (HLA)-DR genes, termed shared epitope alleles (in particular HLA-DR4 
and DR1), thought to be the main risk factor. As well as this, polymorphisms in 
protein tyrosine phosphatase non-receptor type (PTPN) 22 and cytotoxic T 
lymphocyte antigen (CTLA)-4 (Andersson et al, 2008), are thought to be 
involved. There are also environmental factors contributing to RA, with a link 
between smoking and RA (Kallberg et al, 2011), and this is thought to be linked 
with shared epitope alleles and ACPA (Klareskog et al, 2006). In addition, 
factors such as child birth and stress have been linked to the onset of RA 
(Schaeverbeke et al 2012). RA is also associated with a number of co-
morbidities, with the major one being cardiovascular disease; patients also have 
an increased risk of infection. The link between RA and many of these co-
morbidities is unknown, however inflammation is thought to be a factor in 
cardiovascular disease (Levy et al, 2008). 
 
1.2.2 Osteoarthritis (OA) 
 
OA is a progressive disease of cartilage, affecting the majority of individuals 
over 65 (Goldring et al, 2007); with an ageing population this is a significant 
problem. OA was initially thought to be a disease caused simply by wear and 
tear, however, it is now thought to be much more complex involving a range of 
factors such as mechanical injury, obesity, joint instability and genetic factors. 
This is then perpetuated by inflammation and an imbalance in cellular signalling 
(Goldring et al, 2007). This leads to progressive degradation of the cartilage and 
bony growths termed osteophytes causing severe pain (Goldring et al, 2007), 
with the only real treatment at present being joint replacement. 
The degree to which genetics plays a role in OA is still under debate, however 
twin studies have suggested this may be a factor in up to 70% of cases 
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(Goldring and Goldring, 2007), and there are a number of genes which may be 
involved. 
In normal cartilage chondrocytes are relatively quiescent, however in OA the 
chondrocytes become more active, start to proliferate and produce matrix 
proteins. In addition to this, they produce matrix degrading enzymes, such as 
MMPs and aggrecanases, which cause cartilage degradation, and an 
imbalance between synthesis and degradation occurs (Goldring et al, 2009). 
The behaviour of the chondrocyte in this way is thought to represent a 
recapitulation of the chondrocyte in development during endochondral 
ossification (Goldring, 2012; Drissi et al, 2005; Tchetina et al, 2005). 
As mentioned, age is the strongest correlating factor in OA, and it is thought 
that this may be due to the cartilage becoming more brittle and therefore more 
susceptible to damage. This may be due to an accumulation of glycation end 
products. In addition, increased cell death (Loeser et al, 2012), and changes in 
the composition of the cartilage matrix components, including proteoglycans 
and type II collagen, are thought to play a role (Goldring and Goldring, 2007). 
OA was long thought not to have any inflammatory aspect to it, however 
recently it has come to be accepted that there is an inflammatory component 
affecting the synovial membrane of the joint. It has been shown that the 
synovium of OA patients contains increased TNFα, IL-1β and nuclear factor κB 
(NFκB) (Benito et al, 2005). 
 
1.2.3 Arthritis treatment 
 
1.2.3.1 Rheumatoid arthritis 
 
Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly 
used to treat the pain caused by RA, but do not treat the underlying cause of 
the disease (Scott et al, 2010). The two main treatments for RA are disease 
modifying anti-rheumatic drugs (DMARDs) and biological agents. The 
mechanism of action of DMARDs is still not fully understood (Scott et al, 2010), 
with the major DMARD for RA being Methotrexate, whilst Sulfasalazine and 
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Leflunomide are also used (Scott et al, 2010). DMARDs have also been shown 
to work effectively in combination (Choy et al, 2005).  
There are a number of biological agents now being used therapeutically, with 
TNF inhibitors being the first to reach the clinic. Subsequent agents including 
Rituximab (RituxanTM and MabTheraTM), a B cell targeting therapy (Edwards et 
al, 2004), Abatacept (OrenciaTM), which affects T cell signalling (Ruderman et 
al, 2005) and Tocilizumab (ActemraTM and RoActemraTM), which affects IL-6 
signalling (Scott et al, 2010; Mihara et al, 2005), are now being used in 
combination with DMARDs (Strangfeld et al, 2009). Glucocorticoids have also 
been used in the past, and they are still currently used for short term treatment 
(Scott et al, 2010), however they can have extreme side effects when used long 
term (Ravindran et al, 2009). In order to treat RA high doses of drugs are used 
initially, in order to reduce inflammation, and in some cases induce remission. It 
is in the early stages that a high amount of cartilage degradation occurs, 
therefore aggressive treatment is required early on which can subsequently be 
reduced to limit side effects (Schneider and Kruger, 2013).  Due to the multi-
factorial nature of RA, many patients still show poor responses to these 
treatments, and many adverse effects to these treatments have been reported 
(Salliot et al, 2009; Dixon et al, 2010). Furthermore, biological agents are very 
costly (Scott et al, 2009), therefore new approaches to RA treatments are 
required. 
  
1.2.3.2 Osteoarthritis 
 
There are few treatment options for OA, with a program of pain management 
and eventual joint replacement being the outcome in most cases. Tissue 
engineering treatments are currently being used, such as microfracture and 
autologous transplantation, however these treatments vary in success and may 
only delay ultimate joint replacement (Goldring and Goldring, 2007). 
Mesenchymal stem cells are currently being investigated to replace cartilage, 
however, much research is still required in this area with regard to their potential 
to form biologically active cartilage in vivo. 
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1.2.4 Mouse models 
 
In order to study arthritis in vivo mouse models are used in order to represent 
the disease in humans. There are various mouse models used; collagen 
induced arthritis (CIA) involves injection of type II collagen emulsified in 
complete Freunds adjuvant into genetically succeptible mice (Brand et al 2007). 
This model mimics the pathological effects of RA, and is used extensively in 
order to study the viability of various drugs to treat RA. Destabilisation of the 
medial meniscus (DMM) involves sectioning of the medial meniscotibial 
ligament, which leads to destabilisation of the medial meniscus. This procedure 
induces OA, and is highly reproducible (Glasson et al, 2007). Injection with 
lipopolysacharide (LPS), a bacterial cell wall component, stimulates the immune 
inflammatory response (Capkova et al, 2012), and is used in order to study 
inflammatory diseases more broadly. 
 
1.3 Cartilage degradation 
 
1.3.1 Proteinases 
 
There are 5 main classes of proteinases; these are aspartic proteinases, 
cysteine proteinases, threonine proteinases, serine proteinases and 
metalloproteinases (Cawston et al, 2006). Within the metalloproteinase class 
the major group of enzymes involved in cartilage degradation are those of the 
MMP family and the ADAMTS enzymes (Rowan et al, 2008). It is thought that 
for cartilage degradation to occur aggrecan must first be degraded by 
ADAMTSs which then allows collagen to be degraded via MMPs (Rowan et al, 
2008). This is demonstrated by ADAMTS-5 gene depletion in a mouse model, 
which confers protection against OA (Glasson et al, 2005). 
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1.3.2 Matrix metalloproteinases 
 
MMPs are a group of 23 enzymes which cleave ECM, and have been shown to 
be important in degrading cartilage ECM (Clark et al, 2008; Rowan et al, 2008). 
MMPs are divided into collagenases, gelatinases, stromelysins and membrane 
type MMPs (MT-MMPS). There are however MMPs which do not fit into these 
categories (MMP-7, MMP-12, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-
23B, MMP-26, MMP-27 and MMP-28) (Clark et al, 2008; Rowan et al, 2008). 
MMPs are generally regarded as being extracellular proteins, however, there 
are MMPs that can also work intracellularly (MMPs -1, -2 and -11) (Limb et al, 
2005; Kwan et al, 2004; Luo et al, 2002). MMPs are important in terms of 
normal development and homeostasis (Cawston et al, 2005), but it is when their 
regulation is not under the correct control that excessive ECM degradation 
occurs and a disease state arises. As well as arthritis, MMPs have been linked 
with a number of other diseases such as cancer and cardiac disease (Nagase 
et al, 2006). 
 
1.3.2.1 Structure of matrix metalloproteinases 
 
MMPs share a common domain structure consisting of a signal peptide, a pro-
peptide of approximately 80 amino acids, a catalytic domain of approximately 
170 amino acids, a hinge region which can vary in length and a C-terminal 
haemopexin-like domain of approximately 200 amino acids (except MMP-7, 
MMP-23 and MMP-26) (Nagase et al, 2006; Clark et al, 2008; Rowan et al, 
2008) (see Fig 1.2). As well as these common domains there are common 
structures within these domains including a zinc binding motif 
(HEXXHXXGXXH) in the catalytic domain, including a methionine eight 
residues after this forming a ‘met turn’, and a cysteine switch motif (PRCGXPD) 
in the pro-peptide, (except MMP-23) (Nagase et al, 2006; Rowan et al, 2008). 
These two motif regions are important in keeping pro-MMPs inactive (Nagase et 
al, 2006). There are however MMPs with a different structure, in particular the 
MT-MMPs, which include a membrane tethering region (Rowan et al, 2008). 
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 Figure 1.2 Domain structures of MMPs. Pre (pre domain); Pro (pro domain); Zn (zinc); Fu (furin 
recognition motif); F (fibronectin-like domains); V (vitronectin-like domain); TM (trans membrane domain); 
Cyt (cytoplasmic tail); GPI (glycosylphosphatidyl inositol); CA (cysteine array); Ig-like (immunoglobulin-like 
domain). Taken from Cawston and Young, 2010.  
 
1.3.2.2 The collagenases 
 
As mentioned, in terms of arthritis, the collagenases are perhaps the key 
enzymes, as they are known to degrade collagen type II, which is a key 
component of cartilage (Rowan et al, 2008), and when degraded cannot be 
replaced (Jubb et al, 1980). These collagenases include MMP-1, MMP-2, MMP-
8, MMP-13 and MMP-14. MMP-1, MMP-8 and MMP-13 are the most potent in 
this collagenolytic action (Rowan et al, 2008), with MMP-13 being the most 
potent in terms of collagen type II cleavage (Knauper et al, 1996). Cleavage of 
collagen occurs at a specific peptide bond which causes the production of what 
is known as the one quarter and three quarter length fragments (Rowan et al, 
2008). In terms of cartilage degradation in arthritis, it is thought that different 
collagenases have more predominant roles in OA and RA (Rowan et al, 2008). 
The fact that MMP-1 is produced by synovial fibroblasts as well as 
chondrocytes has led some to suggest that this may be the predominant 
collagenase in RA, and that MMP-13 maybe more predominant in OA which is 
thought to be a more chondrocyte-driven disease (Tetlow et al, 1998; 
Billinghurst et al, 1997). 
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1.3.2.3 The stromelysins 
 
The stromelysins include MMP-3, MMP-10 and MMP-11. MMP-3 and -10 are 
similar in structure, and are involved in the activation of a number of proMMPs, 
including MMP-1 and -13 (Nagase et al, 2006; Suzuki et al, 1990; Amalinei et 
al, 2007). MMP-11 is known to cleave serpins (Pei et al, 1994). MMP-11 also 
contains a furin recognition motif which allows it to be activated intracellularly 
(Pei et al, 1995). 
 
1.3.2.4 The gelatinases 
 
There are two known gelatinases, MMP-2 and MMP-9. As well as their ability to 
cleave gelatin, they can also cleave type IV, type V, type XI collagen, laminin, 
aggrecan core proteins and elastin. In addition, MMP-2 also has the ability to 
activate proMMP-13 (Nagase et al, 2006; Cawston et al, 2006). 
 
1.3.2.5 The matrilysins 
 
The matrilysins include MMP-7 and MMP-26; these MMPs do not contain the 
haemopexin domain that most other MMPs contain (Nagase et al, 2006). MMP-
7 can process a range of ECM components including fibronectin, laminin and 
proteoglycans (Amalinei et al, 2007). MMP-26 has the ability to undergo 
autocatalytic activation (Amalinei et al, 2007), and like MMP-7 can digest 
several different ECM molecules. 
 
1.3.2.6 The membrane-type MMPs 
 
The MT-MMPs include MMP-14 (MT-MMP-1), MMP-15 (MT-MMP-2), MMP-16 
(MT-MMP-3), MMP-17 (MT-MMP-4) MMP-24 (MT-MMP-5) and MMP-25 (MT-
MMP-6). These MT-MMPs are split into 2 groups; the type I transmembrane 
proteins (MMP-14, -15, -16 and -24) and the glycosylphophatidylinositol 
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anchored proteins (MMP-17 and -25) (Nagase et al, 2006). As with the 
stromelysin MMP-11, they contain a furin recognition motif allowing intracellular 
activation (Rowan et al, 2008). These MMPs (apart from MMP-17) have the 
ability to activate proMMP2 (Nagase et al, 2006; English et al, 2000). In 
addition, MMP-14 can activate proMMP-13 (Cawston et al, 2006), and also has 
collagenolytic activity, being able to cleave collagens type I, II and III yielding 
the characteristic one quarter and three quarter fragments (Ohuchi et al, 1997). 
 
1.3.2.7 Regulation of matrix metalloproteinases 
 
1.3.2.7.1 Synthesis 
 
MMPs are regulated at several levels; an important method of pro-MMP 
regulation is at the transcriptional level. This occurs through a number of 
transcription factors, including activating protein-1 (AP-1), NFκB and runt-
related transcription factor 2 (RUNX2) (Vincenti and Brinckerhoff, 2007), which 
will be discussed in detail later. 
 
1.3.2.7.2 Activation of proenzymes 
 
MMPs are regulated at the post-translational level through production as pro-
MMPs, which require cleavage of the pro-peptide. This occurs through a 
number of proteinases including serine proteinases, such as matriptase (Milner 
et al, 2010), MMPs including MMP-2 and MMP-3, as well as autocatalysis 
(Bellayr et al, 2009; Hadler-Olsen et al, 2011). The majority of MMPs are 
secreted from the cells as pro-MMPs (apart from those with a furin recognition 
domain and MT-MMPs), and activation usually occurs at the cell surface 
(Cawston et al, 2006). The pro-peptide contains an invariant cysteine residue, 
which allows it to bind to the zinc ion within the active site, preventing binding to 
its substrate (Clark et al, 2008). The pro region contains within it what is termed 
a ‘bait’ region which is susceptible to, and cleaved by, proteinases. However, 
cleavage of the bait region does not activate the MMP, which requires further 
cleavage for activation (Nagase et al, 2006). In some cases, cleavage of the 
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pro-peptide is not required for activation, all that is required is a physical 
delocalisation of the pro-peptide from the active site. This may be achieved by 
cleavage or by removal of the pro-peptide away from the catalytic region 
through binding of a binding partner (Hadler-Olsen et al, 2011). 
 
1.3.2.7.3 Inhibition 
 
Tissue inhibitor of metalloproteinases (TIMPs) consist of TIMPs 1-4. TIMPs 
inhibit the action of MMPs by blocking their active site, by forming a wedge 
shape that allows them to interact with the active site (Rowan et al, 2008; Clark 
et al, 2008; Vincenti and Brinckerhoff, 2007). TIMPs bind and inhibit MMPs in a 
1:1 ratio (Cawston et al, 2006). TIMPs consist of 2 domains, an N-terminal and 
C-terminal, with the N-terminal domain having the inhibitory activity (Rowan et 
al, 2008). The C-terminal domain may play a role in the rate of association 
between the TIMP and its MMP (Murphy et al, 2002). TIMPs have different 
modes of regulation, with TIMP-1 and -3 being inducible by factors such as 
transforming growth factor-β (TGF-β) and insulin like growth factor (IGF)-1 
(Cawston et al, 2006). TIMP-4 exhibits restricted expression, whilst TIMP-2 is 
constitutively expressed (Rowan et al, 2008). TIMPs vary in their affinity for 
MMPs, however they all have a fairly broad specificity and collectively have the 
ability to inhibit all MMPs (Rowan et al, 2008; Nagase and Murphy, 2008). 
TIMP-3 is thought to have the broadest range, and as well as inhibiting MMPs it 
also has the ability to inhibit ADAMs and ADAMTSs, whereas the other TIMPs 
are fairly limited in their ability to inhibit these enzymes (Nagase and Murphy, 
2008). TIMPs, although primarily inhibitors, can also in some cases play a role 
in activating MMPs. This occurs through co-localisation of different MMPs, 
through the ability of TIMPs to bind to more than one MMP at once. This is the 
case for the activation of MMP-2 by MT-MMP-1 through a ternary complex with 
TIMP-2 (Wang et al, 2000). 
TIMPs may be important in terms of inhibiting cartilage degradation to prevent 
arthritic disease. TIMP-3 gene depletion was shown to exacerbate arthritis in an 
aged mouse model (Sahebjam et al, 2007). However TIMP-1 and -2 silencing 
have not been shown to have any major phenotype (Rowan et al, 2008).  
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As well as TIMPs, α2-macroglobulin is able to inhibit MMPs by binding to them 
and causing them to be cleared through endocytosis (Strickland et al, 1990). 
 
1.3.3 A disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)  
 
The ADAMTS enzymes are members of the metalloproteinase family. As 
mentioned previously, along with MMPs the ADAMTSs are the most important 
proteinases in arthritis, as there is a subset which has the ability to degrade 
aggrecan, one of the major components of cartilage (Sandy et al, 1992). There 
are 19 different ADAMTSs, with the aggrecanases being composed of ADAMTS 
-1, -4, -5, -8, -9 and -15. The ADAMTSs consist of a signal peptide, a cysteine 
rich domain, a thrombospondin type I like repeat, a spacer region and C-
terminal TS repeats (Kuno et al, 2000; Tang et al 2001; Apte et al, 2004) (see 
Fig 1.3). The ADAMTSs contain a furin recognition motif in their pro-domain, 
which as stated by Rowan et al. (2008) would suggest they are secreted from 
the cell as active forms of the enzyme, much like those MMPs containing furin 
recognition motifs, however this does not always appear to be the case, as 
some are not. ADAMTSs also have C-terminal cleavage in the spacer region, 
this cleavage can occur through the action of MMPs and alters the specificity of 
ADAMTSs to their substrate (Rodriquez-Manzaneque et al, 2000; Flannery et 
al, 2002). ADAMTSs are activated through members of the enzyme family 
termed pro-protein convertases, which include furin (as mentioned), pro-protein 
convertase 5/6, pro-protein convertase 7 and Paired Basic Amino Acid Cleaving 
Enzyme 4 (PACE4) (Troeberg and Nagase, 2012). As previously mentioned, 
ADAMTSs can also be regulated through the action of TIMPs, in particular 
TIMP-3. In addition to arthritis, ADAMTSs play roles in a number of other 
diseases, for instance ADAMTS-1 has been linked with coronary artery disease 
(Sabatine et al, 2008), due to its ability to cleave versican (Sandy et al, 2001), 
which plays a role in heart disease. ADAMTS-8 has been associated with 
cancer of the brain (Dunn et al, 2006), whereby ADAMTS-8 is down regulated in 
brain tumours, and due to its anti-angiogenic properties this may play a role in 
cancer progression.  
ADAMTS-4 and -5 are the 2 most studied aggrecanases in terms of cartilage 
degradation (Tortorella and Malfait, 2008). ADAMTS-4 and -5 can cleave 
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aggrecan at 5 separate sites within the molecule (Lin and Liu, 2010). The most 
important cleavage site in terms of arthritic disease is Glu373-Ala374, since 
cleavage at this site leads to loss of the whole aggrecan molecule. Blocking 
cleavage at this site has shown to be protective against cartilage loss in a 
mouse model (Little et al, 2007). There is evidence that ADAMTS-5 is the most 
important aggrecanase of the two, as ADAMTS-4 deficient mice are not 
protected against aggrecan loss, however ADAMTS-5 deficient mice are 
(Stanton et al, 2005). Whether this is the case in human disease is still up for 
debate. 
TIMP-3 is able to inhibit both ADAMTS-4 and -5 (Kashiwagi et al, 2001). As well 
as this the proteoglycan syndecan-4 is thought to be important in ADAMTS-5 
regulation. Syndecan-4 deficient mice were seen to be protected against 
cartilage erosion, this was through a lack of ADAMTS-5 activity. Syndecan-4 
acts through direct interaction with ADAMTS-5, as well as through regulation of 
MMP-3 which can itself regulate ADAMTS-5 (Echtermeyer et al, 2009). 
 
Figure 1.3 Domain structures of MMPs. Pre (pre domain); Pro (pro domain); Zn (zinc); Fu (furin 
recognition motif); Dis (disintegrin); TSP-1 (thrombospondin type-1); Cys (cysteine domain); Sp (signal 
peptide); C-term (C-terminus). Taken crom Cawston and Young, 2010.  
 
1.3.4 Other proteinases involved in cartilage degradation 
 
Although the collagenases and aggrecanases are clearly key enzymes in terms 
of cartilage degradation during arthritis, a number of other enzymes have been 
shown to be up regulated in disease and play important roles.  
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1.3.4.1 Serine proteinases 
 
The serine proteinases are a group of enzymes, of which several are strongly 
implicated in arthritis. They are thought to play a major role in the activation of 
collagenases, and this activation may be a rate limiting step in arthritis 
development (Milner et al, 2001). Plasmin is thought to be important in MMP-1 
and -13 activation (Zhang et al, 2007; Morgan and Hill, 2005). Matriptase has 
been shown to activate MMP-1 and -13 in vitro, as well as enhancing 
collagenolysis, this effect on MMPs is thought to occur through PAR-2 
(discussed below) (Milner et al, 2010). Unlike those discussed so far, high 
temperature requirement A (Htra1) is thought to contribute to arthritis by direct 
action on the cartilage ECM, having been shown to act on a number of proteins 
including aggrecan, decorin and fibromodullin, as well as soluble type II 
collagen in vitro (Tsuchiya et al, 2005). 
 
1.3.4.2 Cysteine proteinases 
 
The cysteine proteinase cathepsin K is the only enzyme other than the MMPs 
which can cleave collagen type II (Kafienah et al, 1998). It is thought that 
cathepsin K may be important in arthritis, as overexpression in a mouse model 
demonstrated increased synovitis and cartilage degradation (Morko et al, 2005). 
Cathepsin K is also able to cleave aggrecan. This occurs at several sites within 
the aggrecan, and yields GAG fragments that cathepsin K must bind to in order 
to exhibit collagenolytic activity (Hou et al, 2003). Other cathepsins have been 
shown to be up regulated in arthritic cartilage. Cathepsins B, S and L have been 
implicated in cartilage degradation (Buttle and Saklatvala, 1992). However, the 
role of these enzymes in pathological cartilage degradation is still controversial 
(Hou et al, 2002; Bayliss and Ali, 1978; Sapolsky et al, 1973). As mentioned 
previously, an important feature of arthritic disease is chondrocyte death 
(Loeser et al, 2012). Caspases, members of the cysteine proteinase family, play 
a major role in cell apoptosis. It has been demonstrated that caspase-3 is up 
regulated in osteoarthritic chondrocytes, suggesting an important role in 
chondrocyte death and disease (Sharif et al, 2004). 
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1.4 Pro-inflammatory cytokines in arthritis 
 
Inflammation has been shown to be a major contributing factor in arthritis. 
Whilst the inflammatory aspect of RA has been known for many years, and 
studied greatly (Mcinnes and Schett, 2007), it is only relatively recently been 
accepted that OA also has inflammatory characteristics, wiith OA patients being 
shown to have inflamed synovium (Benito et al, 2005). As mentioned 
previously, this inflammation is driven by a number of pro-inflammatory 
cytokines including IL-1, TNF-α, IL-17 and IL-6 (Benito et al, 2005; Mcinnes and 
Schett, 2007). These cytokines, as well as causing inflammation, drive the 
degradation of cartilage by stimulating the production of proteinases by the cells 
present including chondrocytes, macrophage-like synoviocytes and synovial 
fibroblasts (Mcinnes and Schett, 2007). Knowledge of these pro-inflammatory 
cytokines is therefore of great interest in arthritis. 
 
1.4.1 Interleukin-1 (IL-1) 
 
IL-1 is an extracellular signalling cytokine family that plays a multitude of roles in 
many cellular pathways contributing to inflammation, IL-1 therefore plays a role 
in immunity and a great deal of diseases. IL-1 has been vastly studied due to its 
important role in cellular signalling, and it was the first interleukin to be 
discovered. It was identified in the mid 1980s, however, it had been studied long 
before this under different guises such as haematopoetin 1 and leukocyte 
endogenous mediator. The IL-1 family consists of 11 members, which are IL-1α, 
IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-18, IL-33, IL-1F5, IL-1F6, IL-1F7, IL-
1F8, IL-1F9 and IL-1F10 (Sims and Smith 2010). IL-1 signals through specific 
receptors which contain extracellular immunoglobulin domains and a Toll/IL-1 
receptor (TIR) domain in the cytoplasmic portion. IL-1 binds to the receptor 
subunit IL-1 receptor type 1 (IL-1R), this then leads to recruitment of a 
secondary subunit IL-1R accessory protein (IL-1RAP). The TIR domains in the 
cytoplasmic portion then recruit myeloid differentiation primary response protein 
88 (MYD88), IL-1R associated kinase 4 (IRAK4), TNF receptor-associated 
factor 6 (TRAF6) and other signalling intermediates. This then leads to the 
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activation of a number of signalling pathways (O’Neill, 2008). All members of 
the IL-1 family are conserved at the genetic level (Taylor et al, 2002).  
Two members of the IL-1 family termed IL-1α and IL-1β are potent pro-
inflammatory cytokines and play a major role in arthritis. Both of these cytokines 
are thought to have identical biological activities, however they are spatially 
separated with IL-1β being secreted and IL-1α associated with the plasma 
membrane (Kurt-Jones et al, 1995; Dinarello, 1996). In addition, IL-1β requires 
cleavage of its pro-domain in order to be activated (Martinon et al, 2009). These 
2 cytokines are also produced by different cells and are therefore differentially 
regulated (Dinarello, 1996; Rausch et al, 1994). IL-1α also has additional 
functions, as it has a nuclear localisation sequence allowing it to act within the 
nucleus, where it can play a role in epigenetic regulation, as it has been shown 
to interact with histone acetyltransferases (Buryskova et al, 2004). 
IL-1α and IL-1β due to their importance are tightly regulated. These 2 cytokines 
are regulated at the transcriptional level, and also through mRNA stability 
through various cytokines and stimuli (Rausch et al, 1994). There are also IL-1 
antagonists, which prevent IL-1 signalling. IL-1Ra can bind to the receptor 
subunit IL-1R to block IL-1 binding (Granowitz et al 1991). There is also a 
second IL-1R termed IL-1R2 which acts as a decoy receptor, IL-1R2 is able to 
bind IL-1, but does not transmit signalling (Colotta et al, 1993). 
 
1.4.1.1 IL-1 and arthritis 
 
As has been demonstrated many times, IL-1 is likely to play a major role in 
arthritis, since it is involved in the induction of various signalling cascades, such 
as mitogen activated protein kinase (MAPK) and NFκB. These signalling 
cascades lead to the regulation of MMPs and ADAMTSs and therefore cartilage 
degradation. In addition, IL-1 has been shown to reduce type II collagen 
production by chondrocytes in vitro (Goldring et al, 1994).  
IL-1 has been shown to be important in RA as anti-IL-1α and β treatment of a 
mouse collagen induced arthritis (CIA) model demonstrated reduced disease 
(Joosten et al, 1999). In confirmation of its important role in RA, treatment of RA 
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patients with recombinant IL-1Ra (Anakinra), although not universally 
successful, has been shown to be effective in many patients (Martens and 
Singh, 2009).  
 
1.4.2 Oncostatin M (OSM) 
 
OSM is a multifunctional cytokine, and is a member of the IL-6 family of 
cytokines (Heinrich et al, 2003). OSM signals through two different 
heterodimeric receptor complexes, both of which contain gp130, and either 
leukaemia inhibitory factor receptor (LIFR) or OSM receptor-β (OSMR-β) 
(Thoma et al, 1994). The binding of OSM to either of its receptor complexes 
then leads to the activation of various signalling pathways including janus 
kinase/signal transducers and activators of transcription (JAK/STAT) (Li et al, 
2001), MAPK and phosphoinositide-3 kinase (PI3K) (Godoy-Tunidor et al, 
2005). 
 
1.4.2.1 OSM and arthritis 
 
As mentioned, OSM can regulate a number of pathways involved in arthritis, it 
is therefore thought to play a role within arthritic disease. OSM has been shown 
to work synergistically with IL-1α to degrade bovine nasal cartilage in vitro 
(Cawston et al, 1995), as well as enhancing MMP-1 and -13 production in 
chondrocytes and human cartilage co-cultures (Cawston et al, 1998; Fearon et 
al, 2006). OSM has also been shown to work synergistically with TNF-α; it was 
shown to enhance bovine cartilage degradation as well as enhancing MMP-1, -
3 and -13 expression. OSM also worked synergistically with TNF-α to enhance 
joint damage when injected into the joint of a mouse, and showed increased 
MMP-13 expression (Hui et al, 2003). 
OSM has been found to be elevated in RA synovial fluid (Manicourt et al, 2000). 
As well as this, addition of OSM in mouse joints led to enhanced RA like 
symptoms including synovial cell proliferation and infiltration of mononuclear 
cells, in which the synovium took on characteristics of the pannus (Langdon et 
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al, 2000). In a mouse CIA model, treatment with anti OSM antibodies showed 
reduced RA (Plater-Zyberk et al, 2001). However, as much as OSM appears to 
be pro catabolic, it has also been shown to increase TIMP-1 expression in 
chondrocytes in vitro (Sanchez et al, 2004), possibly suggesting a role in 
protection of cartilage. Such contradictions may be dependent on the context of 
cytokine profile present. 
 
1.4.3 Tumour necrosis factor-α (TNF-α) 
 
TNF-α along with IL-1 has been shown to be extremely important in arthritis. It 
is a key regulator of pro-inflammatory stimuli, as mentioned above, as well as a 
number of signalling pathways, many of which are also regulated by IL-1, such 
as MAPK (Schett et al, 2000) and NFκB (Roman-Blas and Jimenez, 2006). Due 
to its importance in inflammation it is clearly important in RA, and this has been 
demonstrated most obviously by the success of anti TNF-α therapy in treating 
RA patients (Rankin et al, 1995). As well as this, blocking TNF-α in chondrocyte 
explant cultures demonstrated reduced cartilage degradation, as well as 
reduced MMP-1, -3 and -13 expression (Kobayashi et al, 2005). In addition, 
TNF-α addition also led to a decrease in collagen type II production by 
chondrocytes in vitro (Reginato et al, 1993). 
 
1.5 Anti-inflammatory cytokines in arthritis 
 
Anti-inflammatory cytokines are essential in normal homeostasis as a 
mechanism of dampening down the pro-inflammatory responses which occur. It 
is therefore thought that a major factor in arthritic disease, which has a very 
much pro-inflammatory feature, is the dysregulation of anti-inflammatory 
cytokine production (Boissier et al, 2008).  
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1.5.1 Interleukin-4 (IL-4) 
 
IL-4 is a potent anti-inflammatory cytokine, involved in the suppression of many 
pro-inflammatory pathways in a wide variety of cells. IL-4 signals through the 
JAK/STAT signalling pathway. The IL-4 receptor consists of two sub units, the 
IL-4 receptor α (IL-4Rα) chain, (Galizzi et al, 1990) and the γ common (γc) 
chain (Russel et al, 1993). These 2 subunits are associated with JAK1 and 
JAK3. In addition to this IL-4 signals through the same receptor as IL-13, which 
is made up of the 2 subunits IL-4Rα and IL-13Rα1 (Zurawski et al, 1995; Miloux 
et al, 1997); this also signals through the JAK/STAT pathway (Takeda et al, 
1996).  
IL-4 has been shown to inhibit the production of a number of pro-inflammatory 
cytokines, including IL-1, IL-6, TNF-α and IL-8 (Miossec et al, 1992; Morita et al, 
2001). IL-4 can inhibit IL-1 signalling by inducing IL-1R2 which, as mentioned, 
acts as a decoy receptor for IL-1 (Colotta et al, 1993). 
The anti-inflammatory effect of IL-4 may occur through a number of pathways in 
order to affect arthritis. It has been shown to reduce OSM-induced MMP-13 and 
ADAMTS-4 levels in bovine chondrocytes. IL-4 has also been shown to reduce 
IL-1-stimulated MMP-1 expression in synovial fibroblasts (Borghaei et al, 1998). 
As well as this, it was shown to reduce TGF-β-induced c-Jun N-terminal kinase 
(JNK) phosphorylation, which is a member of the MAPK family. However, 
somewhat contraindicative, the same stimulus was also shown to reduce TIMP-
3 (Mabrouk et al, 2008). In addition, adenoviral transfer of IL-4 into the joints of 
a mouse CIA model showed protection from cartilage destruction (Watanabe et 
al, 2000). 
 
1.5.2 Interleukin-10 (IL-10) 
 
IL-10 is a potent anti-inflammatory cytokine. IL-10 can work by blocking the 
expression of pro-inflammatory cytokine genes, as well as inducing other anti-
inflammatory cytokines (Moore et al, 2001). IL-10 signals through the JAK/STAT 
pathway; JAK1 and TYK2 are associated with the IL-10 receptor subunits IL-
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10R1 and IL-10R2 (Kotenko et al, 1997). On IL-10 binding the receptor, JAKs 
are then activated leading to activation of STAT1, 3 and 5 (Finbloom and 
Winestock, 1995; Wehinger et al, 1996). 
IL-10 has been shown to inhibit production of a vast array of pro-inflammatory 
cytokines, including IL-1, IL-6, IL-18 and TNF (de Waal Malefyt et al, 1991), as 
well as inhibiting NFκB (Lentsch et al, 1997). IL-10 has been shown to reduce 
the severity of arthritis in a mouse CIA model (Tanaka et al, 1996). As well as 
this, it has been shown that IL-10 leads to an increase in TIMP-1, demonstrating 
its ability to regulate MMP activation (Lacraz et al, 1995). IL-10 has also been 
shown to synergistically enhance the anti-inflammatory properties of IL-4; the 
addition of IL-10 to IL-4 enhances the release of IL-1Ra, hence increasing IL-1 
inhibition (Crepaldi et al, 2002). However, in contradiction to the anti-
inflammatory properties of IL-10, it has also been demonstrated that IL-10 can 
lead to AP-1 and NFκB activation (Hurme et al, 1994).  
 
1.5.3 Interleukin-13 (IL-13) 
 
IL-13 has also been shown to be an anti-inflammatory cytokine. IL-13 is very 
homologous to IL-4 and shares many functions with the cytokine. IL-13 signals 
through the JAK/STAT pathway, in particular through STAT6 much in the same 
way that IL-4 does (Takeda et al, 1996). IL-4 and IL-13 share the IL-4Rα subunit 
(Zurawski et al, 1995), this subunit in combination with IL-13Rα1, forms the IL-
13 receptor (Miloux et al, 1997). IL-13 is also able bind to another receptor IL-
13Rα2, however this is thought to possibly be a decoy receptor, as no IL-13 
signalling was seen when bound to IL-13Rα2 (Donaldson et al, 1998). In 
addition, IL-13Rα2 has been shown to inhibit IL-13 signalling (Kawakami et al, 
2001). 
IL-13 has been shown to reduce pro-inflammatory cytokine secretion including 
IL-1, TNF-α and IL-8 levels in synovial explant culture (Woods et al, 2000).  IL-
13 has also been shown to inhibit IL-1 by also increasing IL-1Ra (Chizzolini et 
al, 2009). In addition, IL-13 has also been shown to be anti-angiogenic in a rat 
model of RA, and angiogenesis has been shown to be important in the 
24 
 
development of RA and the synovial pannus (Haas et al, 2007). IL-13 has also 
been shown to supress NFκB activation through preservation of the NFκB 
inhibitor, inhibitor of kappa B (IκB)-α (Lentsch et al, 1997). 
 
1.6 Signalling pathways involved in arthritis/MMP regulation 
 
1.6.1 MAP kinases (MAPK) 
 
The MAPK pathway plays a role in a vast number of cellular processes, and is 
critical for cell growth, differentiation and survival (Pouyssegur et al, 2003). The 
MAPKs are ser/thr kinases (Loeser et al, 2008) involved in three signalling 
pathways, namely extracellular signal-regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK) and p38. Each pathway consists of 3 distinct levels, wherein 
MAPKs are activated through phosphorylation by MAP kinase kinases 
(MAP2K), which are activated by MAP kinase kinase kinases (MAP3Ks) 
through the same process (Thalhamer et al, 2008) (see Fig 1.4). MAPKs are 
activated by specific MAP2Ks (see Fig 1.4), and this occurs at a specific motif, 
which consists of T-X-Y. Each of the three MAPKs contain a different amino 
acid at the X region, with ERK containing glutamic acid, JNK a proline residue 
and p38 a glycine residue. This motif along with surrounding amino acids can 
influence the specificity of the MAPK for its substrate (Thalhamer et al, 2008). 
The MAPKs’ catalytic activity is enhanced over 5000 fold when activated 
through phosphorylation (Lew, 2003). Once activated the MAPKs can then 
subsequently translocate to the nucleus or remain in the cytoplasm and elicit a 
number of cellular events (Sacks, 2006).  
MAPKs are regulated by negative feedback through dual specificity 
phosphatases (DUSPs), threonine phosphatases, and tyrosine phosphatases. 
MAPKs themselves are able to regulate some such phosphatase activities and 
therefore contribute to their own regulation (Owens and Keyse, 2007). The JNK 
and p38 pathways are primarily activated by cellular stress, whilst ERK is 
primarily mitogen activated (Thalhamer et al, 2008). The MAPK pathways can 
be activated in conjunction, with a particular stimulus activating more than one 
MAPK pathway (Kiss-Toth et al, 2004), as is the case for TNF-α, IL-6 and IL-1, 
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which have been shown to activate all these MAPK pathways (Schett et al. 
2000). 
The MAPK pathways are important in terms of cartilage degradation and 
arthritis. These pathways are key mediators of cytokine signalling, which 
subsequently leads to regulation of a number of different proteins and 
transcription factors involved in cartilage degradation. All three of the MAPKs 
have been shown to be active in tissue of RA patients, each of these MAPKs 
were localised to different areas; JNK activation was localised around and 
within mononuclear cell infiltrates, ERK around synovial micro vessels, and p38 
in the synovial lining layer and synovial endothelial cells (Schett et al, 2000). 
Furthermore, all three MAPKs were increased in a dog OA model (Boileau et al, 
2006). 
The activation of the MAPKs has been shown to lead to MMP-1 and -13 up 
regulation in chondrocytes (Mengshol et al, 2000). ERK has been associated 
with OA, having been shown to effect progression in a rabbit OA model 
(Pelletier et al, 2003). ERK inhibition was shown to reduce MMP-1 and -13 
induction, with the inhibition of JNK shown to lead to a reduction in MMP-1 (Han 
et al, 2001). The inhibition of p38 was shown to reduce cartilage degeneration 
in an OA model in rats (Brown et al, 2008), as well as reducing both bone and 
cartilage degeneration in a CIA model in mice (Medicherla et al, 2006). Also, 
p38 has been shown to be involved in TNF-α and IL-1 production (Campbell et 
al, 2004; Baldassare and Bellone, 1999), which as mentioned are important in 
both OA and RA. In addition, p38 inhibition leads to a reduction in IL-6 
production through IL-1 and TNF in chondrocytes (Kumar et al, 2001). 
SAPK/p38 has been shown to contribute to MMP-1 and MMP-13 expression 
(Raymond et al 2006, Mengshol et al 2000), as well as stabilising MMP-1 
mRNA (Reunanen et al 2002).  
MAPKs can regulate MMPs through the regulation of transcription factors. A 
major transcription factor involved in the regulation of MMP-1 and -13 is AP-1. 
AP-1 can be a heterodimer consisting of c-Fos and c-Jun, Jun B or Jun D, as 
well as members of the fos-related antigen (Fra) and activating transcription 
factor (ATF) family (Eferl and Wagner, 2003). There is much evidence for the 
MAPK pathways playing a role in regulating MMPs through AP-1. The inhibition 
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of JNK has been shown to inhibit the phosphorylation of c-Jun, as well as 
inhibiting AP-1 activity, leading to a reduction in MMP-1 expression (Han et al, 
2001). JNK phosphorylation has been shown to increase transcription, protein 
stability and DNA binding of c-Jun (Minden et al, 1997). The inhibition of ERK 
has been shown to inhibit AP-1 activation (Han et al, 2001), whilst 
phosphorylation of ERK was shown to increase c-Jun expression and 
phosphorylation (Leppa et al, 1998). As well as this, ERK has also been shown 
to regulate E26 transformation specific sequence (Ets), which has been shown 
to be involved in MMP transcription by enhancing AP-1 activity (O’Hagan et al, 
1996). Mengshol et al. (2001) demonstrated evidence of p38 activating MMP-13 
through recruitment of AP-1, as well as the MMP-regulatory transcription factor 
runt related transcription factor (RUNX) 2 in chondrocytes. As with ERK, p38 
can enhance AP-1 activity by activating transcription factors such as Ets 
(Minden et al, 1997) and ATF2 (Davis et al, 2000). MAPKs may also regulate 
MMPs through regulating the production of ECM fragments, which as 
mentioned, can regulate enzyme activity. It was demonstrated that inhibition of 
the MAPKs led to inhibition of fibronectin fragment-mediated MMP-13 
production (Loeser et al, 2003).  
 
Figure 1.4. The different levels of the MAPK signalling pathway, demonstrating the specific 
regulation within each pathway. Adapted from Thalhamer et al, 2008. ASK, apoptosis signal-regulating 
kinase; ERK, extra-cellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MEK, MAPK kinase; 
MEKK, MEK kinase; MLK, mixed lineage kinase; MKK, MAPK kinase; TAK, TGFβ-activated kinase; RAF, 
rapidly accelerated fibrosarcoma; MMP matrix metalloproteinase; DUSP, Dual specificity phosphatase; P, 
phosphorylation. 
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1.6.2 Transforming Growth Factor-β/Sma and Mad related protein (TGF-
β/Smad) 
 
TGF-β is a family of growth factors involved in many different cellular pathways 
such as proliferation, differentiation and development (Van der Kraan et al, 
2009). TGF-β commonly signals through Smad proteins, which mediate this 
signalling (Van der Kraan et al, 2009). Smads are activated through TGF-β 
pathway activation, whereby TGF-β binds to its receptor TGF-β type II, this then 
forms a complex recruiting TGF-β type I receptor, activator receptor like kinase 
(ALK) 5, which then leads to phosphorylation of Smad 2 or 3. Alternatively, 
TGF-β type I receptor ALK1 can be recruited leading to phosphorylation of 
Smad 1, 5, or 8. Once activated the Smads form a complex with Smad 4 which 
subsequently translocates to the nucleus to regulate gene expression (Finsson 
et al, 2008).  
TGF-β may be important in OA as it has been shown to regulate chondrocyte 
hypertrophy (Blaney Davidson et al, 2007), which has been shown to be 
important in OA (Goldring, 2012). A paradox occurs with TGF-β as it has been 
shown to be both anabolic and catabolic. TGF-β has been shown to be 
chondroprotective (Blaney Davidson et al, 2005), and loss of TGF-β signalling in 
a mouse model resulted in enhanced cartilage degeneration (Serra et al, 1997), 
which was also the case for Smad 3 deficient mice (Yang et al, 2001). In 
addition, TGF-β has been shown to inhibit MMP-1 expression (Yuan and Varga, 
2001). As well as this, TGF-β has been shown to induce TIMP-3 (Su et al, 
1996). It has also been shown to both reduce the production of the pro-
inflammatory cytokine IL-1, and increase its inhibitor IL-1Ra (Chizzolini et al, 
2009). However, activation of the Smad 1/5/8 pathway has been shown to 
increase MMP-13 expression (Blaney Davison et al, 2009), and TGF-β itself has 
also been shown to promote MMP-13 gene expression (Uria et al, 1998). This 
apparent paradox may be due to different levels of TGF-β activity to give 
different effects, with high levels of TGF-β being catabolic and lower levels 
being anabolic. The ability of signalling pathways to be both catabolic and 
anabolic is common within signalling, and demonstrates the dynamism within 
signalling pathways. This allows both pro and anti-inflammatory cytokines to 
work through similar pathways giving different outcomes. This is often due to 
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the regulation of different transcription factors by these signalling pathways due 
to the specific cytokine stimulus. In addition, there is multiple cross talk between 
the different pathways. In this way these various pathways allow a diverse 
range of outcomes which in some cases can be pathological. 
 
1.6.3 Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) 
 
The JAK/STAT pathway is a key pathway in many cellular events including 
proliferation, migration and apoptosis (Rawlings et al, 2004). The JAKs are a 
family of intracellular kinases consisting of 4 members; JAK 1, 2, 3 and tyrosine 
kinase 2 (TYK2). The STATs are a family of transcription factors consisting of 7 
members; STAT 1, 2, 3, 4, 5A, 5B and 6 (Kisseleva et al, 2002). JAK activation 
occurs when a cytokine binds to its receptor leading to phosphorylation of the 
JAK, this then leads to recruitment and phosphorylation of STATs (Kisseleva et 
al, 2002). The activated STATs can then form dimers, both homo and 
heterodimers, and translocate from the cytoplasm to the nucleus, where they 
can then cause transcription of a number of genes (Kisseleva et al 2002; 
Korzus et al, 1997) (see Fig 1.5). In addition to being positive regulators of 
transcription, STATs can also be repressive, as is the case in the regulation of 
the immunoglobulin κ chain in B cells, where STAT5 can bind and recruit the 
histone methyltransferase enhancer of zeste homolog 2 (Ezh2), leading to 
repression of transcription at the epigenetic level (Mandal et al, 2011).   
The JAK/STAT pathway is regulated through a number of different 
mechanisms. JAKs have been shown to be regulated through 
dephosphorylation by phosphatases, in particular SH2 domain containing 
protein tyrosine phosphatase (SHP) 1 and SHP2 (Kisseleva et al, 2002). As well 
as this, the JAK/STAT pathway has been shown to be regulated through 
negative feedback by cytokine inducible SH2 protein/suppressors of cytokine 
signalling (CIS/SOCS), of which there are 8 (Nicola et al, 1999). This CIS/SOCS 
group of proteins has the ability to inhibit both JAK and STAT activation (Seki et 
al, 2002; Matsumoto et al, 1999; Ungureanu et al, 2002; Ram and Waxman 
1999). There are also a group of proteins termed protein inhibitor of activated 
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STATs (PIAS), which have been shown to bind STATs and prevent them from 
interacting with their target DNA (Liao et al, 2000). 
A number of cytokines acting through the JAK/STAT pathway, such as 
interferons, IL-6, IL-10, IL-4 and IL-12 (Walker and Smith, 2005), are thought to 
be important in terms of arthritis regulation, and inflammatory pathways. The 
JAK/STAT pathway has been shown to regulate MMP expression. STATs can 
cause transcription of c-fos which as previously stated is a key component of 
the AP-1 transcription factor, and a key regulator of MMPs. STAT3 gene 
silencing has been shown to reduce c-fos, MMP-1 and -13 expression in human 
chondrocytes (Litherland et al, 2010). STATs have also been shown to directly 
regulate MMPs by binding to their promoters (Zugowski et al, 2011). In addition, 
it has been shown that JAK/STAT signalling is involved in OSM-mediated MMP 
expression (Li et al, 2001) and is a major regulatory route for MMP expression 
(Li et al, 2001, Mabrouk et al, 2007).  
STAT1 was shown to be up regulated in synovial tissue from RA patients (van 
der Pouw Kraan et al, 2003). The silencing of STAT6 in a proteoglycan induced 
mouse model demonstrated a slower rate of cartilage erosion compared to wild 
type. In addition, STAT4 silencing in the same model led to protection against 
arthritis (Finnegan et al, 2002). As one would expect, the JAK proteins have 
also been shown to play a role in arthritis, with a strain of mouse which has a 
natural Tyk2 depletion being shown to be resistant to CIA (Ortmann et al, 2001; 
Shaw et al, 2003). Also, the use of a broad spectrum JAK inhibitor reduced the 
expression of inflammatory biomarkers in a CIA mouse model (Ghoreschi et al, 
2011). 
However, evidence for a role for STATs in RA is somewhat contradictory, as 
both STAT1 and STAT3 appear to be involved in both pro-inflammatory and 
anti-inflammatory pathways. STAT1 depletion in a zymosan-induced mouse 
model led to increased inflammation, suggesting STAT1 may be anti-
inflammatory and protective in arthritis (Hooge et al, 2004). STAT3 may be 
important in the survival of synovial cells, as a depletion of STAT3 led to an 
increase in synovial fibroblast apoptosis in vitro (Krause et al, 2002).  
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 Figure 1.5. The JAK/STAT signalling pathway. JAK; Janus kinase, STAT; signal transducer and 
activator of transcription, MMP; matrix metalloproteinase; AP, activating protein. 
 
1.6.4 Fibroblast growth factor (FGF)  
 
The FGF family is a family of proteins known to play a large variety of roles in 
cells, such as growth, differentiation and migration (Ellman et al, 2008).  These 
proteins bind heparin and heparin sulphate (Friedl et al 1997). In terms of 
cartilage homeostasis, FGF 2 is believed to be the most important. FGF 2 is 
thought to act as a mechanotransducer in cartilage. FGF 2 is bound to the 
heparin sulphate proteoglycan perlecan component of cartilage (Vincent et al, 
2007). During loading conditions, FGF 2 is released and activates signalling 
(Vincent and Saklatyala, 2006). The role of FGF 2 within cartilage is under 
debate, as it has been shown to be either catabolic or anabolic. FGF 2 has 
been shown to be protective in terms of cartilage degradation and arthritis. This 
may be via affecting aggrecanases, as it has been shown that the addition of 
FGF 2 to chondrocytes in vitro led to a decrease in IL-1-induced ADAMTS-4 
and -5 (Sawaji et al, 2008). In addition, FGF 2 deficient mice showed increased 
ADAMTS-5, and accelerated OA (Chia et al, 2009). In terms of catabolic effects, 
FGF 2 has been shown to increase MMP-13 expression in chondrocytes, and 
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this appears to occur through the MAPK and NFκB pathways (Muddasani et al, 
2007). As well as this, FGF 2 was shown to be increased in synovial tissue of 
patients with RA (Qu et al, 1995). 
 
1.6.5 Protease activated receptor-2 (PAR-2) 
 
PAR-2 is a G protein coupled receptor (Rothmeier and Ruf, 2012). As the name 
suggests PAR-2 is activated through proteolytic cleavage, more specifically, 
cleavage of its extracellular domain, by serine proteases (Troeberg and 
Nagase, 2012), one of which is matriptase (Milner et al, 2010). PAR-2 is 
considered to be important in arthritis, as PAR-2 deficient mice are protected 
against OA (Ferrell et al, 2010), as well as being protective in a CIA mouse 
model, which also showed lower levels of IL-6, TNF-α and IL-1β (Crilly et al, 
2012). PAR-2 has also been shown to lead to an increase in MMP-1 and -13 
expression in vitro (Boileau et al, 2007). 
 
1.6.6 Phosphoinositide 3-kinase (PI3K)/Akt 
 
The PI3K/Akt pathway plays many central roles in cellular signalling including 
that of cell survival, cell differentiation and cell cycle progression (Fayard et al, 
2005), as well as influencing the MAPK pathways (Ren et al, 2010). The 
PI3K/Akt pathway is initially activated through the binding of an extracellular 
factor to its membrane bound receptor, known as a receptor protein tyrosine 
kinase (RPTK), which subsequently results in autophosphorylation of tyrosine 
residues on the receptor. PI3K then translocates to the membrane and binds to 
the RPTK, which then leads to activation of PI3K and the conversion of 
phopshoinositol-4,5-biphosphate (PIP2) to phopshoinositol-3,4,5-triphosphate 
(PIP3). The production of PIP3 leads to recruitment of Akt and its subsequent 
activation. Once activated Akt then translocates to the nucleus and regulates 
various targets (Meier et al 2005) (see Fig 1.6).  
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 Figure 1.6. The PI3K/Akt pathway, demonstrating the various proteins involved in the signal 
transduction through the pathway. Taken from Meier et al. (2005). PI3K; phosphatidylinositol-3 kinase, 
RPTK; receptor protein tyrosine kinase, PIP2; phopshoinositol-4,5-biphosphate, PIP3; phopshoinositol-
3,4,5-triphosphate, PH; pleckstrin homology, PTEN; phosphatase and tensin homologue deleted from 
chromosome 10, PDK; phosphoinositide-dependent kinase, mTOR; mammalian target of rapamycin. 
 
The PI3K/Akt pathway has been shown to be up regulated by a number of pro-
inflammatory cytokines involved in arthritis such as OSM, TGF-β and IL-6 
(Godoy-Tundidor et al, 2005; Kim et al, 2002). As well as this, the PI3K/Akt 
pathway has been demonstrated to be involved in MMP-1 and -13 expression, 
as the inhibition of this pathway was shown to inhibit induction of these MMPs 
(Litherland et al, 2008). More specifically, it was demonstrated that the PI3K 
isoform p110α and the Akt isoform Akt1 were involved in MMP-1 and -13 
induction, as well as Akt3, p110δ and PDK1 being involved in MMP-13 
expression. In addition, inhibition of the PI3Kγ isoform was protective against 
cartilage degradation in an inflammatory mouse model (Hayer et al, 2009). 
As stated previously, TIMPs are involved in the inhibition of MMP activity, and it 
has been shown that the PI3K/Akt pathway is required for the up regulation of 
TIMP-3 by TGF-β (Qureshi et al, 2007).  As well as this the PI3K/Akt pathway 
has been shown to cooperate with other signalling pathways, such as the 
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MAPK pathway, which as previously demonstrated is important in arthritis 
signalling (Yart et al, 2002).  
As has been shown with other signalling pathways discussed, the PI3K/Akt 
pathway may have somewhat opposing roles, being both anabolic and 
catabolic. Akt may be important in preventing chondrocyte apoptosis, as 
inhibition of Akt resulted in an increase in apoptosis in a chondrocytic cell line 
(Chrysis et al, 2005). In addition, it was demonstrated by Starkman et al. (2005) 
that IGF-1-stimulated proteoglycan synthesis by chondrocytes required PI3K. 
 
1.7 Transcriptional control of MMPs 
 
1.7.1 Activating protein (AP) 1 
 
As mentioned earlier, AP-1 is a major transcription factor involved in the 
regulation of MMPs. The genes that encode the proteins of the AP-1 
heterodimer are termed immediate early response genes, since they are 
induced within minutes of stimulation, independent of protein synthesis (Clark et 
al, 2008). The regulation of AP-1 occurs through a number of pathways 
including the MAPK pathway (Whitmarsh et al, 1996) (by IL-1), and the 
JAK/STAT pathway (Korzus et al, 1997) (through OSM as well as IL-1) 
(Catterall et al, 2001), with the MAP kinase pathway being studied most (see 
above for details). The importance of AP-1 in MMP regulation is highlighted by 
the fact that the majority of MMPs contain AP-1 binding sites in their promoters 
(Chunghong et al, 2007). A great deal of work has looked to study the 
regulation of the collagenolytic MMPs, including their regulation by AP-1 (Clark 
et al, 2008). In terms of MMP-1 and -13, the heterodimer of c-Fos and c-Jun 
has been shown to be the most important transcription factor in their regulation 
(Hu et al 1994; Saez et al 1995). However, other combinations have also been 
shown to be important, for instance a Fra-1 containing AP-1 complex has been 
shown to regulate MMP-1 (Hao et al, 2008). As well as this, the effect of AP-1 is 
abrogated by other transcription factors such as Ets and polyoma enhancer 
activator 3 (PEA3) which can work in conjunction with AP-1 (Sharrocks et al 
1997; Benbow et al 1997). In many cases, AP-1 may be dependent on these 
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transcription factors for transcriptional activity, for instance an NFκB-like 
element was required for AP-1 to induce MMP-1 in rabbit fibroblasts during IL-1 
stimulation (Vincenti and Brinckerhoff, 1998). As well as direct transcriptional 
activation, AP-1 has also been shown to regulate MMP-1 through binding to its 
promoter and preventing PPAR-γ from binding, which is a known inhibitor of 
MMP-1 (Francois et al, 2004). In addition, AP-1 has been shown to be 
increased in RA synovium (Asahara et al, 1997). 
 
1.7.2 Activating transcription factor (ATF) 
 
The family of transcription factors known as ATF are thought to form 
heterodimers with a number of other transcription factors, including their family 
members, AP-1 and C/EBP. These transcription factors are both repressors and 
activators of transcription (Hai and Hartman, 2001). ATF transcription factors 
have been shown to play a role in MMP expression. ATF4 is one of the proteins 
capable of forming the AP-1 heterodimer which regulates MMPs (Fung and 
Demple, 2007). ATF3 has been shown to suppress MMP-1 expression, and this 
was shown to be STAT1 dependent (Hao et al, 2008), and ATF2 has been 
associated with up regulation of MMP-1 (Westermarck et al, 2000). Also, ATF1 
has been shown to increase expression of both MMP-2 and MT1-MMP 
(Melnikova et al, 2007).  Although ATF3 is thought to be a transcriptional 
repressor, silencing of ATF3 was shown to suppress MMP-13 expression (Kwok 
et al, 2009), suggesting a greater complexity in the transcriptional control of 
MMP-13. 
  
1.7.3 Hypoxia inducible factor (HIF) 
 
The HIF transcription factors are heterodimeric, and mediate the response to 
altered oxygen levels (Lim et al, 2013). The HIF-α subunits (HIF-1α and HIF-2α) 
respond to oxygen levels, whilst the HIF-β subunit is constitutively expressed 
(Weisner et al, 2003). Hypoxia has been shown to be increased in OA (Yudoh 
et al, 2005), and in these hypoxic conditions HIF is no longer degraded, which 
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allows the heterodimerization of these subunits and transcriptional up regulation 
of their targets. In particular HIF-2α is thought to be important in OA. HIF-2α 
may play a role in arthritis through regulation of collagenase and aggrecanase 
expression, including MMP-1 and -13 and ADAMTS4, as well as other genes 
involved in cartilage destruction (Yang et al, 2010). In a mouse model it was 
demonstrated that HIF-2α contributed to cartilage destruction (Yang et al, 
2010). As well as this, HIF-2α was shown to be increased in osteoarthritic tissue 
of both humans and mice (Saito et al, 2010). 
 
1.7.4 Sry high mobility group box (SOX) 9 
 
There are twenty SOX genes which have been identified, these are divided into 
eight groups, with SOX9 being a member of group E along with SOX8 and 
SOX10 (Akiyama, 2008). SOX9 is a major transcription factor important in 
cartilage development and chondrogenesis (Zhao et al, 1997). During this 
process it has been shown to be important in cartilage formation, including 
Col2a1 (Lefebvre et al, 1997) and aggrecan (Sekiya et al, 2000) expression. As 
well as this, it is thought that SOX9 is important in preventing chondrocyte 
hypertrophy during development (Bi et al, 2001). In addition, SOX9 depletion in 
mouse embryos demonstrated reduced chondrocyte proliferation, as well as 
reduced Indian hedgehog (Ihh) signalling (Akiyama et al, 2002). It is therefore 
thought that SOX9 may be important in normal cartilage homeostasis and 
preventing chondrocyte hypertrophy. Consistent with this, SOX9 has been 
shown to be down regulated in OA tissues (Brew et al, 2004). Chondrocyte 
hypertrophy occurs in development during the process of endochondral 
ossification, when cartilage which has been deposited is replaced by bone. 
During which the chondrocytes terminally differentiate and apoptose (Van der 
Kraan and Van den Berg, 2012). However, during arthritis chondrocytes have 
been shown to have characteristics of a hypertrophic phenotype, which include 
type X collagen (Nurminskya and Linsenmayer, 1996) and MMP-13 (Alvarez et 
al, 2000) expresssion. Proteins which regulate chondrocyte hypertrophy are 
therefore of great interest in arthritic disease. 
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1.7.5 Cytidine-Cytidine-Adenosine-Adenosine-Thymidine (CCAAT) enhanced-
binding protein (C/EBP) 
 
The C/EBP family are a group of transcription factors consisting of six proteins, 
C/EBP α, β, δ, ε, γ and ζ, which are involved in the differentiation of a number of 
tissues types (Yokoyama et al, 2011). C/EBPs are thought to play a role in 
arthritic disease, as they have been shown to be pro-inflammatory. C/EBP-β in 
particular has been shown to have binding motifs in the promoters of a number 
of pro-inflammatory cytokines including IL-6, IL-8 and TNF-α (Akira et al, 1990).   
C/EBP can form a heterodimer with AP-1 proteins c-Fos and c-Jun (Friedman, 
2007), as well as interacting with NFκB (Leclair et al, 1992). CEBP-β has been 
shown to regulate MMP-1, 3, 10 and 13 and ADAMTS-5 (Doyle et al, 1997; 
Armstrong et al, 2009; Hayashida et al, 2009; Tsushima et al, 2012). It has also 
been shown that C/EBP-β and the MAPKs combine within the same pathway to 
regulate MMPs. Raymond et al. (2006) demonstrated IL-1β induction of MMP-1 
in chondrocytes occurred through ERK-dependent activation of C/EBP-β. 
C/EBP-β was also shown to work cooperatively with RUNX2 to regulate MMP-
13 expression in chondrocytes, and this was thought to be induced by HIF-2α 
(Hirata et al, 2012). Whilst C/EBPδ depletion showed reduced arthritic damage 
in a mouse CIA model (Chang et al, 2012). 
 
1.7.6 Nuclear factor kappa B (NFκB) 
 
NFκB comprises a group of transcription factors, with five subunits identified 
consisting of NFκb1 (p50), NFκb2 (p52), Rel A (p65), Rel B and C Rel. They 
can form an array of homodimers and heterodimers, with the ability to regulate 
different genes. The most common dimer is p65:p50, which is involved in the 
canonical pathway (Chakraborty et al, 2010). NFκB is a major regulator in many 
cellular pathways, playing an important role in immune function and 
inflammation (Chakraborty et al, 2010). Due to its influence within the cell its 
activity is under tight control, most notably by IκB which binds and inhibits 
NFκB. Upon activation of the NFκB pathway, through cytokines such as IL-1β 
and TNF-α, inhibitor of IκB kinase (IKK) is activated, which subsequently 
37 
 
phosphorylates IκB, this leads to its proteasomal degradation and allows NFκB 
to translocate to the nucleus and have its effect (Roman-Blas and Jimenez, 
2006; Chakraborty et al, 2010). NFκB is also regulated through other 
mechanisms, such as the phosphorylation of the protein subunits themselves 
(Perkins, 2006). 
NFκB has been linked with arthritis as it is a key mediator of both IL-1 and TNF-
α expression, both of which are key pro-inflammatory cytokines in arthritis, as 
previously mentioned (Kapoor et al, 2011). As well as this, NFκB has been 
shown to be increased in RA and OA (Han et al, 1998). In addition, activation of 
the NFκB pathway resulted in enhanced inflammation and RA-like symptoms in 
rats (Takk et al, 2001). NFκB has also been associated with MMP-1 and -13 
expression (Vincenti and Brinckerhoff, 2002), and when NFκB is inhibited by 
constitutively expressing IκB, MMP-1 and -13 levels are reduced (Bondeson et 
al, 2000). It is also thought that NFκB can cooperate with AP-1 to regulate 
MMP-1 and -13 expression (Vincenti and Brinckerhoff, 2002). In addition, it has 
been demonstrated that NFκB can recruit B cell lymphoma-3 (Bcl-3), which 
serves to allow docking of transcriptional co-activators of MMPs – Tat 
interactive protein 60 (TIP60) and CREB binding protein (CBP)/p300 (Na et al 
1998; Dechend et al 1999). Data by Elliott et al. (2002), would suggest that 
recruitment of Bcl-3 is important in MMP-1 regulation, as it was shown that Bcl-
3 was required for MMP-1 gene expression in chondrocytes under IL-1β 
stimulation.  
 
1.7.7 Runt related transcription factor (RUNX2) 
 
RUNX2 is a transcription factor which has been shown to be important in 
development during endochondral ossification. It plays an important role in 
influencing chondrocyte hypertrophy (Takeda et al, 2001). It is therefore thought 
that RUNX2 may play a role in arthritis. RUNX2 is not expressed in normal 
cartilage, its expression is however enhanced in OA cartilage (Wang et al, 
2004). In addition, RUNX2 has been shown to be important in the regulation of 
both MMP-13 and ADAMTS-5 in vitro, where it is shown to be catabolic 
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(Tetsunaga et al, 2011). RUNX2 has been shown to cooperate with AP-1 to 
regulate MMP expression, in particular MMP-13 (Selvamurugan et al, 1998). 
 
1.8 Tribbles 1-3 
 
Mammalian Tribbles (Trb) are a group of three proteins named Trb 1, 2 and 3, 
discovered in the late 1990s (Kiss-Toth et al, 2011). They were originally shown 
to regulate a protein named string, an orthologue of cell division cycle (cdc) 25 
in Drosophila (Mata et al 2000). Trb1-3 have since been shown to play a role in 
many cellular pathways, including those involving diabetes, multiple sclerosis 
and cancer (Keeshan et al, 2006; Liu et al, 2010; Cavanillas et al, 2011). Trb1-3 
proteins are highly conserved, especially between mouse and humans, and 
within the human Trb1-3 family there are many sequence similarities 
(Yokoyama and Nakamura, 2011). 
 
1.8.1 Trb1-3 structure 
 
Trb1-3 consist of 3 domains; an N-terminal domain, which has a high serine and 
proline content (Hegedus et al, 2007); this is indicative of a protein with a high 
turnover (Rechsteiner and Rodgers 1996). The N-terminal domain has also 
been suggested to be a region of high phosphorylation (Hegedus et al, 2007), 
and has been shown to be required for the nuclear localisation of Trb1 and Trb3 
in Henrietta Lack (HeLa) cells (Kiss-Toth et al, 2006). Trb1-3 also consist of a 
central domain which contains a kinase-like domain (Hegedus et al, 2007). The 
kinase-like domain resembles a serine/threonine kinase and has many of the 
features of a kinase, however as yet no evidence has been shown that this 
domain functions as a kinase (Hegedus et al, 2007). This domain lacks certain 
common characteristics of a kinase, although lacking such characteristics does 
not necessarily make a kinase inactive (Hegedus et al, 2007). The kinase-like 
domain is highly conserved, suggesting that its function is important (Hegedus 
et al, 2007), and it has been shown to play a role in the binding of proteins 
(Eder et al, 2008). It has been suggested that Trb1-3 may act as decoy kinases 
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regulating other kinases (Hegedus et al, 2007). The C-terminus has also been 
shown to be involved in protein binding, including the MAP2K MEK1 (Yokoyama 
et al, 2010), and the E3 ubiquitin ligase constitutive photomorphogenic protein 
(COP) 1 (Qi et al, 2006). 
 
1.8.2 Trb1-3 location 
 
Trb1 and Trb3 have been shown to be predominantly present within the 
nucleus, with Trb2 localised to the cytoplasm (Kiss-Toth et al, 2006). Trb1-3 
have been shown to be expressed in most human tissues, with the highest 
expression of Trb1-3 mRNA being found in the bone marrow, pancreas, 
peripheral blood leukocytes, thyroid gland and muscle (Kiss-Toth et al, 2004).  
 
1.8.3 The regulation of Trb1-3 
 
It is unknown how Trb1-3 are regulated; however there are a number of 
possibilities. Perhaps one way in which Trb1-3 are regulated is at the 
transcriptional level through mRNA degradation. It has been shown that Trb1 
mRNA in particular has an extremely short half-life of less than 1 hour, with 
Trb2 and Trb3 having half-lives of 1.8 and 2.8 hours, respectively (Sharova et 
al, 2009). This study investigated the half-life of 19,977 genes and showed that 
less than 100 of these genes tested had a half-life of less than 1 hour, 
demonstrating the unusually rapid Trb1 mRNA turnover rate. 
Trb3 has been shown to be regulated through micro (mi)RNA. In vascular 
smooth muscle cells, platelet derived growth factor-BB (PDGF-BB) has been 
shown to induce miRNA-24 which in turn down regulates Trb3 (Chan et al, 
2010). In addition, miRNA-98 has been show to downregulate Trb2 (Xie et al, 
2012). As well as this Ord et al. (2009) describe the existence of several human 
Trb3 isoforms which differ in their 5’ untranslated region (UTR), and it is thought 
that this may be a way of regulating Trb3 expression, by affecting factors such 
as mRNA stability (Hughes et al, 2006). 
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Trb3 protein levels appear to be controlled through proteasomal degradation. It 
has been shown that Trb3 interacts with an E3 ubiquitin ligase called seven in 
absentia homolog (SIAH) 1, which has been shown to cause polyubiquitination 
of Trb3 and direct it to the proteasome for degradation (Zhou et al, 2008). Due 
to the fact that, as mentioned, Trb3 has been shown to be a nuclear protein 
(Kiss-Toth et al, 2006), its degradation through the proteasomal pathway may at 
first appear unusual. However, it has been demonstrated that the ubiquitin 
proteasome system is also present and active within the nucleus (Rockel et al, 
2005). Trb3 has also been shown to be regulated by PI3K during nutrient 
starvation in prostate cancer cells (Schwarzer et al, 2006). Inhibition of PI3K 
reduced Trb3 levels, and this was unique for Trb3 among the Trb1-3 proteins. A 
further level of complexity to the regulation of Trb1-3 is that they may respond to 
the same stimuli differently depending on the cell type. This has been shown 
through the regulation of Trb2 by IL-1; in THP-1 cells the addition of IL-1 leads 
to the up regulation of Trb2; in synoviocytes it is down regulated by the exact 
same stimulus (Sung et al, 2006). As well as these methods of Trb1-3 
regulation, interactions with other proteins may also stabilise Trb1-3 proteins, as 
it has been shown that interaction of Trb1 and Trb3 with MAP2Ks increases the 
levels of these Tribbles (Kiss-Toth et al, 2004). 
 
1.8.4 Trb1-3 regulation of signalling pathways 
 
1.8.4.1 Trb1-3 and the MAPK pathway 
 
Trb1-3 proteins have been shown to influence the MAP kinase pathways. They 
are thought to impact this pathway by binding to the MAP2Ks, as demonstrated 
by Kiss-Toth et al. (2004). Trb1 binds to MEK1 and MKK4, and it has been 
shown that the kinase-like domain is required for Trb1 interaction with MKK4 
(Sung et al, 2007). Both Trb2 and Trb3 were demonstrated to bind MEK1 and 
MKK7 (Kiss-Toth et al, 2004). As with Trb1, it has been shown that the kinase-
like domain is important in binding of Trb2 to these MAP2Ks (Eder et al, 2008).   
It is thought that the ratio of Trb1-3 to MAP2Ks influences whether the MAPK 
pathway is up regulated or down regulated. It has been shown by Kiss-Toth et 
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al. (2004) that low levels of Trb3 can up regulate ERK and JNK but inhibit p38, 
whilst higher levels inhibit all 3 MAPKs. This, perhaps, is consistent with Trb1-3 
acting as scaffolds, as it has previously been suggested by Sacks et al. (2006) 
that the ratio of the scaffold protein to its target proteins is essential in whether 
the pathway is activated or inhibited. Trb2 has been shown to inhibit both ERK 
and JNK activation via its interaction with MKK7 and MEK1 in monocytes (Eder 
et al, 2008). Interestingly, MAPKs may also play a role in Trb1-3 regulation, as it 
has recently been demonstrated that ERK could regulate Trb1 expression 
(Soubeyrand et al, 2013). 
 
1.8.4.2 Trb3 and the TGF-β/Smad pathway 
 
Trb3 has been shown to regulate TGF-β signalling and this may be through the 
stabilisation of Smad proteins (Park et al, 2009). It has been shown that Trb3 
interacts with BMP receptor II; upon activation of BMP, Trb3 dissociates from 
the receptor. Trb3 can then subsequently interact with Smurf1 and Smurf2, 
which are E3 ubiquitin ligases involved in the degradation of various proteins 
within the BMP pathway, including Smads (Park et al 2009; Fang et al, 2011). 
Interaction of Trb3 with Smurf causes the ubiquitination of Smurf and its 
degradation through the proteasomal pathway, leading to an increase in Smad 
proteins, and an enhancement in BMP signalling (Park et al 2009). It has also 
been demonstrated that Trb3 interacts directly with Smad3 and this has been 
shown to increase nuclear localisation and therefore signalling of Smad3 (Hua 
et al, 2011).  
In concordance with Trb3 regulating this pathway, depletion and overexpression 
of Trb3 resulted in a reduction and increase in TGF-β respectively (Chan, 2010; 
Chan et al 2007). Also, the overexpression of Smad3 and stimulation of TGF-β 
has been shown to increase Trb3 expression levels (Hua et al, 2011), which the 
authors suggest indicates Trb3 is involved in feedback control within this 
pathway. Interestingly, Trb3 may regulate TGF-β signalling through the JNK 
pathway, as previously mentioned, Trb3 can regulate the MAPKs, and JNK has 
been shown to regulate Smad4 (Giehl et al, 2007). 
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1.8.4.3 Trb2, Trb3 and the PI3K/Akt pathway 
 
Trb2 and Trb3 have been shown to interact with Akt. Both Trb2 and Trb3 have 
been shown to bind Akt and prevent its phosphorylation (Du et al, 2003), 
inhibiting this pathway, and therefore being implicated in a number of diseases. 
There is a great deal of evidence suggesting that Trb3 may play a role in insulin 
signalling and diabetes, and this is thought to be through the regulation of Akt 
(Du et al, 2003). It has been suggested that this interaction of Trb3 with Akt may 
influence the IGF-1 signalling pathway (Cravero et al, 2009). Cravero et al. 
(2009) demonstrated that Trb3 was up regulated in OA cartilage, with 
overexpression of Trb3 leading to a reduction in Akt phosphorylation and an 
increase in chondrocyte death by approximately 40%. They proposed that the 
effect of Trb3 on Akt phosphorylation could be a factor in reduced response of 
chondrocytes to IGF-1 in OA. It is possible that Trb3 may influence MMP 
signalling by disruption of the insulin/IGF-1 signalling pathway, as it has 
previously been shown that addition of IGF-1 can lead to an increase in both 
MMP-1 and -13 in cartilage (Wheeler et al, 2009). Contradictory to this, IGF-1 
was shown to reduce IL-1-induced MMP-1 and -13 expression in human 
articular chondrocytes (Hui et al 2001). It is also possible that the negative 
regulation of Akt by Trb2 and Trb3 may lead to regulation of MMPs by altering 
TIMP activity. As stated previously, TIMPs are involved in the inhibition of MMP 
activity, and it has been shown that the PI3K/Akt pathway is required for the up 
regulation of TIMP-3 by TGF-β (Qureshi et al, 2007). It is therefore possible that 
Trb2 and Trb3 prevent TIMP-3 induction by TGF-β. As well as this, Trb3 may 
regulate cartilage degradation through its interaction with Akt and disruption of 
insulin signalling (Du et al, 2003), as previous work has demonstrated that 
insulin prevents cartilage degradation in mice (Claassen et al, 2006). As 
mentioned previously, inhibition of PI3K reduced Trb3 levels, (Schwarzer et al, 
2006) and Akt is regulated by PI3K (Fayard et al, 2005); this may suggest that 
Trb3 may be acting as a negative feedback regulatory mechanism to control 
PI3K induced Akt activation. 
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1.8.4.4 Trb1-3 and C/EBP 
 
Trb1-3 have been shown to play a role in C/EBP regulation. Trb3 has been 
shown to interact with CCAAT/-enhancer-binding protein homologous protein 
(CHOP), which is a member of the C/EBP family (Ohoka et al, 2005). In 
addition, both CHOP and C/EBP-β bind to the Trb3 promoter, and are involved 
in Trb3 expression (Selim et al, 2007).  As well as this, Trb1 and Trb2 have 
been shown to negatively regulate both C/EBP-α and C/EBP-β, by reducing 
their levels (Keeshan et al, 2006; Naiki et al, 2007; Yamamoto et al, 2007). It 
has been shown that Trb2 reduces the levels of C/EBP-α by increasing its 
proteasomal degradation, and binds directly to C/EBP-α (Keeshan et al, 2006).  
 
1.8.4.5 Trb1, Trb3 and NFκB 
 
Work by Kiss-Toth et al. (2006) suggested that Trb1 was not involved in NFκB 
signalling, however in contrast Ostertag et al. (2010) suggested that Trb1 may 
have a pro-inflammatory role in adipocytes involving NFκB. This study stated 
that Trb1 is induced via pro-inflammatory pathways and plays a role in this pro-
inflammatory pathway through interaction with the p65 subunit of NFκB. Trb3 
has also been shown to interact with p65, with overexpression of Trb3 inhibiting 
NFκB activation (Duggan et al, 2010), which would suggest a possible anti-
inflammatory role for Trb3. In contrast to this, Kiss-Toth et al. (2004) 
demonstrated that both Trb3 overexpression and silencing showed no effect on 
NFκB. This work on Tribbles regulation of NFκB highlights an important feature 
of Tribbles, in that their effect on various signalling pathways, appears to be 
very cell type specific. 
 
1.8.4.6 Trb1-3 and cytokines  
 
Trb1-3 proteins have been shown to be involved in both pro-inflammatory and 
anti-inflammatory cytokine signalling. Trb2 has been shown to play a role in IL-8 
signalling, negatively regulating this cytokine, with the silencing and 
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overexpression of Trb2 increasing and decreasing IL-8 levels, respectively 
(Eder et al, 2008). This therefore suggests an anti-inflammatory role for Trb2, 
since IL-8, as previously mentioned, is a pro-inflammatory mediator and has 
been shown to be up-regulated in arthritis (Sakao et al, 2009). In contrast to 
this, it is suggested that Trb2 may have a pro-inflammatory role, as it has been 
shown to reduce levels of (anti-inflammatory) IL-10 in macrophages (Deng et al, 
2009; Woodell-May et al, 2011). Trb3 may have the ability to regulate a number 
of different cytokines, as Trb3 silencing in mast cells showed an increase in 
TNF-α, IL-4 and IL-6 (Kuo et al, 2012). 
 
1.8.4.7 Trb1-3 and AP-1 
 
It has previously been demonstrated that Trb1-3 proteins can regulate AP-1, 
therefore suggesting that they may play a role in MMP regulation through 
regulation of this transcription factor. It was shown in HeLa cells that Trb1, 2 
and 3 were involved in the regulation of AP-1 (Kiss-Toth et al, 2004; Eder et al, 
2008), where overexpression inhibited AP-1 activity. The kinase-like domain 
was required for this inhibition (Eder et al, 2008). Kiss-Toth et al. (2004) stated 
that both overexpression and silencing of Trb3 inhibited AP-1 activity. This 
possibly adds further evidence for Trb1-3 acting as scaffolds, as both 
overexpression and silencing of scaffolds has been shown to give similar effects 
(Morrison and Davis, 2003). It was also suggested that the regulation of AP-1 
by Trb1-3 may be due to their regulation of the MAPK pathways, as the MAP3K 
MEKK1 mediated activation of AP-1 was inhibited by Trb1-3 (Kiss-Toth et al, 
2004). However, in contrast to these findings, Hegedus et al. (2006) found that 
overexpression of Trb3 did not inhibit MEKK1 mediated activation of AP-1. This 
may demonstrate the cell type specificity of Trb1-3 action, as the work by 
Hegedus et al. (2006) was conducted in human embryonic kidney (HEK)-293 
cells whereas the work by Kiss-Toth et al. (2004) involved HeLa cells.  
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1.8.4.8 Trb3 and ATF 
 
It has been shown that Trb3 can interact with ATF4 (Bowers et al, 2003). Trb3 
is involved in the feedback control of ATF4, inhibiting ATF4; ATF4 initially 
causes the up regulation of Trb3, then through negative feedback it is inhibited 
by Trb3 (Jousse et al, 2007). In addition, ATF3 levels are sustained by TGF-β1, 
which has been shown to be regulated by Trb3 (as discussed previously) (Kwok 
et al, 2009).  
 
1.8.4.9 Trb3 and RUNX2 
 
It was demonstrated by Park et al. (2009) that Trb3 silencing led to a reduction 
in RUNX2 during stimulation with the amiloride derivative phenamil, suggesting 
that Trb3 may regulate MMP-13 through this pathway. 
 
1.8.4.10 Trb1-3 and disease 
 
Recent studies of Trb1-3 have suggested that they may play an important role 
in cellular signalling, and it has been proposed that they are involved in disease 
states. They have been suggested to play a role in cancer, with Trb1 and Trb2 
involved in acute myeloid leukaemia (AML). This role is thought to be due to the 
ability of Trb1 and Trb2 to influence C/EBPα (Keeshan et al, 2006; Gilby et al, 
2010). Trb3 has been implicated in breast cancer, and this is thought to be 
through possible regulation of the MAPK and TGF-β pathways (Izrailit et al, 
2013). In addition, Trb3 was shown to be up regulated in lung cancer, and 
depletion of Trb3 was shown to reduce the malignant behaviour of the cancer 
cells in vitro (Zhou et al, 2013).  
As previously stated, there is a great deal of evidence implying that Trb3 may 
play a key role in insulin signalling and diabetes, possibly through the regulation 
of Akt (Liu et al, 2010). Trb3 in has been shown to be up regulated in a diabetic 
mouse model, and overexpression of Trb3 led to diabetes in mice (Du et al, 
2003). Interestingly, it has been suggested that Trb2 may be an autoimmune 
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antigen; a genome wide association study has linked Trb2 with multiple 
sclerosis (Cavanillas et al, 2011), and anti Trb2 antibodies were seen in uveitis 
patients (Zhang et al, 2005), both of which are autoimmune diseases. This 
therefore possibly lends itself to Trb2 playing a role in rheumatoid arthritis by 
acting as an auto antigen.  
As previously described, Trb3 has been implicated in OA (Cravero et al, 2009). 
Trb3 has also been shown to be up regulated in stress conditions such as ER 
stress and hypoxia (Ohoka et al, 2005; Bowers et al, 2003). Trb3 is possibly a 
mediator of ER stress, as depletion of Trb3 reversed the effect of ER stress on 
insulin signalling in cardiac myocytes (Avery et al, 2010). This is linked with 
arthritis as both hypoxia and ER stress have been implicated in arthritis (Yudoh 
et al, 2005; Takada et al, 2011). 
 
1.9 Summary and aims of this study 
 
Arthritic diseases, in particular osteoarthritis (OA) and rheumatoid arthritis (RA) 
are a major cause of disability throughout the world, having an enormous cost 
to healthcare organisations. Both OA and RA can be caused by a number of 
factors, and in both cases can be considered as a number of diseases under 
the same umbrella. Ultimately however, the final outcome is the same with 
excessive cartilage degradation by proteases. 
Matrix metalloproteinases (MMPs) are a family of enzymes involved in cleavage 
of extracellular matrix proteins. They have many roles in both development and 
normal tissue homeostasis. As well as this they have been shown to be 
important in disease, one of which is arthritis. In terms of arthritis, the 
collagenases are perhaps the most important as they are known to degrade 
collagen type II, which is a key component of cartilage (Rowan et al, 2008), and 
when degraded cannot be replaced (Jubb et al, 1980). The two major 
collagenases are MMP-1 and -13. A greater understanding of the regulatory 
mechanisms of these MMPs could lead to the potential for new therapeutic 
arthritis treatments. 
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Trb1-3 are a group of proteins linked with diseases including diabetes, multiple 
sclerosis and cancer. Trb1-3 are reported to play a role in regulating many 
cellular signalling pathways, such as mitogen-activated protein kinase (MAPK), 
phosphoinositide-3-kinase/Akt (PI3K/Akt) and nuclear factor kappa B (NFκB). 
These pathways are considered important in mediating gene expression 
changes, including MMPs. In addition to this, Trb3 has also been shown to be 
up regulated in OA (Cravero et al, 2009). It is therefore hypothesised that Trb1-
3 may regulate various signalling pathways within chondrocytes, in order to 
regulate MMPs, and control cartilage degradation. 
 
1.9.1 Overall aim 
 
• To assess whether Trb1 and Trb3 impact on cytokine-induced MMP 
expression in human chondrocytes. 
 
1.9.2 Specific aims 
 
• Gain a greater understanding of the regulation of Trb1 and Trb3 within 
the chondrocyte. 
• Determine whether Trb1 and Trb3 regulate MMP-1 and MMP-13 within 
chondrocytes, and determine if this regulation was through known MMP 
transcription factors. 
• Determine whether Trb1 and Trb3 interact with MAP2Ks, and in doing so 
regulate the MAPK pathway in chondrocytes. 
• Determine whether Trb1 and Trb3 regulate other signalling pathways 
known to regulate MMPs, such as NFκB, PI3K/Akt and JAK/STAT in 
chondrocytes. 
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Chapter 2: Materials and methods 
 
2.1 Materials 
 
2.1.1 Antibodies 
 
All antibodies are rabbit polyclonal, and were used at a concentration of 1:2000 
in 5% BSA, unless otherwise stated. Phospho-Akt (Ser473) (#4060), phospho-
STAT1 (ser727) (#8826), phospho-STAT1 (tyr701) (#9167), phospho-STAT3 
(ser727) (#9134), phospho-STAT3 (tyr705) (#9145), phospho-ERK (thr202, 
tyr204) (#4370), phospho-p38 (thr180, tyr 182) (#4511), p65 (#8242), phospho-
p65 (ser536) (#3033), c-Fos (#2250), Histone H3 (#9717B), Lamin A/C (#2032) 
and Caveolin 1 (#3267B) were from Cell Signalling Technology (Danvers, MA, 
USA). Trb1, made up in 5% milk, (#09-126) and mouse glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) monoclonal antibody, (1:50000 dilution) 
(#MAB374) were from Millipore (MA, USA). Trb3 (#2488-1), c-Jun (#1254-1), 
phospho-JNK (Tyr 185, Tyr 223) (#2155-1) and MEK2 (#04-377) monoclonal 
antibodies and β-tubulin (#1799-1) were from Epitomics (Insight Biotech, 
Wembley). Mouse Ubiquitin antibody was from Enzo Life Sciences (Exeter, UK) 
Mouse c-Myc monoclonal antibody, (1:500 dilution), (#sc-40), phospho-c-JUN 
(thr93), (1:500 dilution) (#sc-101722) and ATF3, (1:500 dilution) (#sc-188) were 
from Santa Cruz (California, USA).  
 
2.1.2 Cells 
 
The human chondrosarcoma cell line, SW1353, and the human embryonic 
kidney cell line HEK 293T were from the American Type Culture Collection 
(ATCC) (Middlesex, UK). Mach1TM-T1® chemically competent E.coli were from 
Invitrogen (Paisley, UK). 
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2.1.3 Cell culture reagents 
 
Dulbecco’s Modified Eagle’s Medium (DMEM), DMEM-F12, and foetal bovine 
serum (FBS) were from Invitrogen. Phosphate buffered saline (PBS) was from 
Lonza (Wokingham, UK). Penicillin-streptomycin solution (10,000 U/ml and 10 
mg/ml, respectively), L-glutamine solution (200 mM), Nystatin suspension 
(10,000 U/ml), trypsin-ethylenediaminetetraacetic acid (EDTA) solution (0.5 g 
porcine trypsin and 0.2 g/L EDTA), hyaluronidase (from bovine testes, 439 
U/mg), trypsin (from porcine pancreas, 1020 U/mg) and collagenase (from 
Clostridium histolyticum type I) were from Sigma-Aldrich (Poole, UK). Tryptone, 
yeast extract and bacto-agar were from Difco Laboratories (Detroit, MI, USA). 
Syringe filters (0.2 μm) were from Pall Life Sciences (Portsmouth, UK). Cell 
strainers (100 micron) were from Scientific Laboratory Supplies (Hessle, UK). 
Tissue culture plates and chamber slides were from Nunc, Fisher Scientific 
(Loughborough, UK). 
 
2.1.4 Commercially available kits 
 
Qiaprep Spin Midi/Maxi Kit was from Qiagen (Crawley, UK). Subcellular Protein 
Fractionation Kit, Nuclear Fractionation kit and c-Myc immunoprecipitation kit 
were from ThermoScientific (Loughborough, UK).  Lenti-x-concentrator kit was 
from Clontech (Saint-Germain-en-Laye, France). 
 
2.1.5 Molecular Biology Reagents 
 
DharmafectTM 1 lipid reagent and SMARTpool® small interfering RNA (siRNA) 
negative control (D-001810), Trb1 siRNA SMARTpool® (smartpool 1) (L-
003633-00) and Trb3 siRNA SMARTpool® (L-003754-00) were from 
Dharmacon (Cramlington, UK), Trb1 # 1-6 (SI00138425, SI03032358, 
SI03054800, SI03100223, SI05066817, SI05066824) and AllStars negative 
control (#1027280) were from Qiagen. Trb1 siRNA smartpool 2 (SC-77704) was 
from Santa Cruz. TRIPZ inducible lentiviral shRNA negative control (RHS4743), 
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TRIPZ Trb1 shRNA # 1-3 (V2THS_137339, V2THS_137340, V2THS_137343), 
GIPZ non-silencing lentiviral shRNA control (RHS4346) and GIPZ Trb1 shRNA 
# A-D (V2LHS_405278, V2LHS_234767, V2LHS_137339, V2LHS_337823) 
were from ThermoScientific. JetPEI Transfection Reagent was from Polyplus 
transfection (Illkirch, France). Trb1 and Trb3 over-expression plasmids (see 
appendix A for plasmid maps) and GFP protein complementation assay (PCA) 
constructs Trb1V1, Trb1V2, Trb3V1, Trb3V2, NFκBV1, MEKV1, MKK4V1, 
MKK6V1 and MKK7V1 were a kind gift from Dr Endre Kiss-Toth (Sheffield 
University, UK). SidestepTM Lysis and Stabilization Buffer was from Agilent 
Technologies, Stratagene Product Division (CA, USA) Cells-to-cDNA lysis 
buffer was from Ambion, (Huntington, UK). Real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) primers were from Sigma-Aldrich. 18S 
rRNA, Trb1, Trb3, MMP-1 and MMP-13 probes were from Sigma-Aldrich. IL-8, 
c-jun, ATF3, IKKβ, MEK1, MKK4, MKK6 and MKK7 probes were from Roche 
(Burgess Hill, UK). c-fos gene expression assay on-demand was from Life 
Technologies (Paisley, UK). First strand buffer, Moloney Murine Leukaemia 
Virus (M-MLV) reverse transcriptase, Dithiothreitol (DTT) and RNaseOut 
Recombinant Ribonuclease inhibitor were from Invitrogen. VECTASHIELD 
mounting medium with DAPI was from Vector Labs (Peterborough, UK). 
DNase-free H2O was from Sigma-Aldrich.  
 
2.1.6 Immunoblotting reagents  
 
Bradford Ultra was from Expendeon (Cambridgeshire, UK), Ammonium 
peroxodisulphate (APS) was obtained from BDH (Leicestershire, England). 
Bovine serum albumin (BSA), β-mercaptoethanol, N,N,N’N’-
tetramethylenediamine (TEMED), 1,10-phenanthroline and 
polyoxyethylenesorbitan monolaurate (Tween 20) were obtained from Sigma-
Aldrich. 40% (w/v) acrylamide/bis-acrylamide (37.5:1) solution was obtained 
from Severn Biotech (Worcestershire, UK). PageRulerTM prestained protein 
ladder was from ThermoScientific. Enhanced chemiluminescence (ECL) 
western blot detection reagents were from Amersham Biosciences (Little 
Chalfont, UK).  
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2.1.7 Inhibitors 
 
UO126 (MEK inhibitor) was from Calbiochem (Nottingham, UK), MG132 
(proteasome inhibitor) was from Sigma-Aldrich. All inhibitors were reconstituted 
in sterile filtered Dimethyl sulphoxide (DMSO) (Sigma-Aldrich).  
 
2.1.8 Cytokines 
 
Recombinant human IL-1α was a kind gift from GlaxoSmithKline (Stevenage, 
UK) and was stored at -20oC prior to formulation at the appropriate 
concentration in the relevant culture medium. Recombinant OSM was prepared 
in-house (method described in Uddin et al, 2002) and stored at a stock 
concentration of 85 μg/ml at -80oC prior to formulation at the appropriate 
concentration in the relevant culture medium. 
 
All other standard laboratory chemicals and reagents, unless otherwise 
indicated, were commercially available from Sigma-Aldrich, Invitrogen or BDH 
Chemicals. 
 
2.2 Methods 
 
2.2.1 Isolation of Human Articular Chondrocytes (HACs) 
 
Human cartilage from OA patients was observed macroscopically for normal 
cartilage and dissected. Cartilage pieces were then enzymatically digested, 
firstly in hyaluronidase (1 mg/ml, 4 ml/g of cartilage) at 37°C for 15 minutes, 
then trypsin (2.5 mg/ml, 4 ml/g) at 37°C for 30 minutes, and finally bacterial 
collagenase (2 mg/ml, 3 ml/g) overnight at 35°C. HAC were subsequently 
obtained by centrifugation of the digested material at 112 x g for 10 minutes 
after filtering debris through a 100 micron Nylon cell strainer. HAC were 
maintained in DMEM containing 10% (w/v) FBS, 400 IU penicillin, 400 µg/ml 
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streptomycin, 40 IU/ml nystatin and 2 mM L-glutamine. Consent was obtained 
from all patients, and the study was approved by the Newcastle and North 
Tyneside Joint Ethics Committee, REC reference 09/H00906/72. 
Approximately one joint out of four per week was obtained which had sufficient 
normal cartilage for cell culture. An average of 8 million cells would be obtained 
from each viable joint, allowing for 2-3 HAC experiments per week. 
  
2.2.2 Cell culture 
 
Reagents: 
• HAC were cultured in DMEM culture medium containing 10% (w/v) FBS, 
2 mM L-glutamine, 400 IU/ml penicillin, 400 μg/ml streptomycin and 40 
IU/ml Nystatin. 
• SW1353 cells were cultured in DMEM in a 1:1 ratio with Ham’s F-12 
medium (DMEM:F12) containing 10% (w/v) FBS, 2 mM L-glutamine, 200 
IU/ml penicillin and 200 μg/ml streptomycin. 
• HEK293T cells were cultured in DMEM culture medium containing 10% 
(w/v) FBS, 2 mM L-glutamine, 200 IU/ml penicillin and 200 μg/ml 
streptomycin. 
 
Method: 
Cells were counted and seeded at a density of 20,000 cells/cm2 for SW1353 
cells and HEK293T cells and 40,000 cells/cm2 for HAC into 96 well plates, 
chamber slides, 6-well plates, 6 cm dishes, 10 cm dishes or 500 cm2 dishes. 
Cells were grown to the confluency required for the individual experiment, at 
37°C in 5% (v/v) CO2/humidified air.   
 
2.2.3 Lentivirus production 
 
HEK 293T cells were plated at the seeding density above into 500cm2 dishes. 
Cells were grown to approximately 70-80% confluency. Cells were 
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subsequently transfected with the DNA plasmids; pCMV packaging plasmid, D2 
envelope plasmid and lentivirus transfer vector plasmid, using jetPEI 
transfection reagent, 1:2 ratio (DNA:jetPEI) (see overexpression method for 
details). Medium was changed after 24 hours and then removed 72 hours after 
this. The medium was subsequently filtered through a 0.45 µm filter, aliquoted 
and frozen at -80°C. This was performed in medium containing heat inactivated 
serum, achieved through 56°C treatment for 30 minutes. Reproducibility of 
batches produced was assessed through comparison of transduction efficiency 
of each virus batch. 
  
2.2.4 Lentivirus concentration 
 
Lentiviral medium was removed and filtered as above. Lentivirus was then 
concentrated as per manufacturer’s instructions. Briefly lentivirus medium was 
added to lentivirus-x-concentrator, 1:3 ratio (virus:concentrator). This was then 
incubated at 4°C for 30 minutes, and subsequently spun at 1500 x g for 45 
minutes at 4°C. The lentivirus pellet was then resuspended in the desired 
volume of PBS, aliquoted and frozen at -80°C. 
 
2.2.5 siRNA transfection of cells 
 
Cells were seeded into 96 well plates, 6 well plates or 6 cm dishes at a seeding 
density above. Cells were grown to approximately 60% confluency. Medium 
was then removed and replaced with fresh medium (50 µl-96 well plate, 500 µl-
6 well plate, 1.25 ml-6cm dish) then subsequently treated with siRNA diluted in 
serum-free medium to give a final concentration of 100 nM siRNA. siRNA had 
been mixed with DharmafectTM transfection reagent (0.26 µl/well for a 96 well 
plate, 3.25 µl/well for a 6 well plate and 8.125 µl/dish for a 6cm dish) for 20 
minutes at room temperature prior to addition to cells for 48 hours. Cells were 
then serum-starved overnight before addition of IL-1α (0.5 ng/ml for SW1353 
cells, 0.05 ng/ml for HAC) + OSM (10 ng/ml) or serum-free medium alone for a 
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designate time. Cells were then lysed or a nuclear fractionation performed for 
either immunoblotting or RT-PCR. 
 
2.2.6 shRNA transfection of cells 
 
Cells were seeded into 96 well plates or 6 well plates at a seeding density 
above. Cells were grown to approximately 60% confluency, then subsequently 
treated with shRNA at stated concentrations, in addition to 8 µg/ml polybrene in 
serum-free medium for 6 hours, then 20% (w/v) FBS medium added for 24 
hours. Medium was then changed with 10% (w/v) FBS medium, and in the case 
of the inducible TRIPZ shRNA, 3 µg/ml doxycycline was also added. The cells 
were then incubated for 48 hours before visualisation by fluorescence 
microscopy. Cells were then lysed for either immunoblotting or RT-PCR. 
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Gene Sequence 
Trb1 smartpool 1 ACAACATAGACACTATGTA 
AGCGTGATTGCGAGAGCAC 
GAAACTCTTCTCCCTCCTG 
TACCGGCAAAGACTGAACA 
Trb1 smartpool 2 ACACTTACTAATAACCGTT 
CGTTTGATGATTGTACGTA 
CGAGAGCACCAACGAGCTG 
TCCACCCTTAGGTCGGAGA 
Trb1 #1 CATGACACATGAAACATGA 
Trb1 #2 GACATAAACTCTTTACCGA 
Trb1 #3 TAGTCATTGACAGAGAACC 
Trb1 #4 GAAAACATCCACCCTTAGG 
Trb1 #5 AGACAATCTATACAGGTCT 
Trb1 #6 CGGAGACAATCAATACAGG 
Trb3 smartpool GATGCACCCTGGACTCTAT 
GTTGAATCTATGGCTCGCA 
CTTTGCTCGAGCTTCACCC 
CGTGACTCATATGGTCGTT 
Table 2.1. siRNA sequences. 
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Gene Sequence 
Trb1 #1 AAGGGAAACAAATTTGCAG 
Trb1 #2 TATTGGCCCAATTTGTCAC 
Trb1 #3 TTCTCTACAAGTCAGAAAC 
Trb1 #A ATTACACACTTGACCACCG 
Trb1 #B TTATTACACACTTGACCAC 
Trb1 #C AAGGGAAACAAATTTGCAG 
Trb1 #D TTCTGAGTCGATGTACCCG 
Table 2.2. shRNA sequences. 
 
2.2.7 Addition of MG132 proteasomal inhibitor or UO126 MEK inhibitor to cells 
 
Cells were seeded into 6 well plates at a seeding density above. Cells were 
grown to approximately 70-80% confluency. Cells were then serum-starved 
overnight before addition of 5 µM MG132 for 3 hours or 10µM UO126 for 1 
hour. For UO126 treatment cells were then stimulated with IL-1α (0.05 ng/ml) + 
OSM (10 ng/ml) or serum-free medium for 20 minutes. Cells were then lysed for 
immunoblotting. 
 
2.2.8 Overexpression plasmid transfection 
 
Cells were seeded into 96 well plates, 6 well plates and chamber slides at a 
seeding density above. Cells were grown to 70-80% confluency. Plasmid DNA 
was then added (0.01 ng/cell for HAC and 0.005 ng/cell for SW1353 cells for 
standard overexpression and 0.01 ng/cell for protein complementation assay 
(PCA)). All plasmids were pcDNA3.1 vector. Control was pcDNA3.1 for 
standard overexpression, and venus 1 and venus 2 empty vectors for PCA. 
Cells were transfected using jetPEI transfection reagent in a 1:2 ratio 
(DNA:jetPEI) in 150mM NaCl in a volume of 10% of the final medium volume 
following the manufacturer’s instructions. Briefly, jetPEI was vortexed and 
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added to 150mM NaCl, plasmid DNA was then added to an equal volume of 
NaCl. JetPEI NaCl solution was then vortexed and added to the DNA NaCl 
solution, vortexed and left for 20 minutes before addition to the cells. Medium 
was then changed after 6 hours. Cells were then incubated for 48 hours. Cells 
were then serum-starved overnight before addition of IL-1α (0.5 ng/ml for 
SW1353 cells, 0.05 ng/ml for HAC) + OSM (10 ng/ml) or serum-free medium 
alone. Cells were then lysed for either immunoblotting or RT-PCR. 
 
For PCA; after 48 hours transfection, cells were starved for 6 hours, then 
washed twice in PBS and fixed using 4% (w/v) paraformaldehyde for 10 
minutes. Cells were then washed a further 2 times in PBS and visualised using 
VECTASHIELD with DAPI mounting medium under a fluorescence microscope 
(Leica DMLB) (Leica, Milton Keynes UK), with SPOT ADVANCED software 
(Michigan, USA). 
 
2.2.9 Preparation of plasmid DNA 
 
Reagents: 
• Luria broth (LB) containing 10 g NaCl, 10 g tryptone and 5 g yeast 
extract per litre dH2O. 
• LB Agar containing 10 g NaCl, 10 g tryptone, 5 g yeast extract and 15 g 
agar per litre dH2O. 
• Qiaprep Spin Midi/Maxi Kit. 
 
Reagents were autoclaved prior to use and ampicillin added at a final 
concentration of 100 μg/ml in filter-sterilised water for selection. Standard 
aseptic technique was used throughout the procedure. 
 
Mach1TM-T1® chemically competent E.coli (30 μl) and 0.5 μl plasmid (see 
appendix A for plasmid maps) was added to a 1.5 ml Eppendorf tube and 
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swirled to mix. The tube was then incubated on ice for 30 minutes and 
subjected to heat shock at 42°C for 30 seconds. The tube was incubated on ice 
for 2 minutes before the addition of 500 μl pre-warmed Super Optimal Broth 
with Catabolite Repression (SOC) medium (37°C). Tubes were incubated for 1 
hour in a 37°C water bath. On pre-warmed agar plates containing 100 µg/ml 
ampicillin, 50 μl volumes were streaked out. Plates were allowed to dry for 5 
minutes and then incubated at 37°C overnight. A single colony for each plasmid 
was picked and placed into a universal with 5 ml LB containing 100 μg/ml 
ampicillin. This was shaken at 37°C for 8 hours at 250 rpm before transferring 
the culture to a conical flask containing 250 ml LB containing 100 μg/ml 
ampicillin. The conical flasks were shaken at 37°C overnight at 250 rpm.  
Overnight cultures were centrifuged at 6000 x g for 15 minutes at 4°C to pellet 
cells. Plasmid DNA was then isolated using the Qiaprep Spin Midi/Maxi Kit as 
follows:- 
The pellet was resuspended in 10 ml of buffer P1 containing RNase A. 10 ml of 
buffer P2 was then added, mixed by inverting 4-6 times and incubated at room 
temperature for 5 minutes. 10 ml of chilled buffer P3 was added, mixed by 
inverting 4-6 times and incubated on ice for 20 minutes. This was then 
centrifuged at 20,000 x g for 30 minutes at 4°C. The supernatant was then 
removed and centrifuged again at 20,000 x g for 15 minutes at 4°C. A QIAGEN-
tip 500 was equilibrated by applying 10 ml buffer QBT and allowing the column 
to empty by gravity flow. The supernatant was then applied to the QIAGEN-tip, 
and allowed to enter through gravity flow. The QIAGEN-tip was then washed 
with 2 x 30 ml buffer QC. DNA was then eluted with 15 ml buffer QF, and the 
DNA precipitated with 10.5 ml room temperature isopropanol. This was then 
mixed and centrifuged at 15,000 x g for 30 minutes at 4°C. The supernatant 
was then removed and the DNA pellet washed with 5 ml room temperature 70% 
ethanol, and centrifuged at 15,000 x g for 10 minutes. The supernatant was 
removed, and the pellet air dried for 10 minutes, then re-dissolved in 250 µl 
dH2O. DNA concentration was quantified by spectrophotometry (Nanodrop ND 
1000 spectrophotometer, ThermoScientific) and stored at -20°C until required.   
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2.2.10 RT-PCR 
 
Culture medium was removed and cells were washed once with ice-cold PBS. 
For HAC 20 μl SideStepTM Lysis and Stabilization Buffer was added to each 
well and the plate was then vortexed for 2 minutes to ensure complete cell lysis. 
5 μl cell lysate was transferred to a new 96 well plate and diluted with 15 μl 
dH20. 4 μl of the diluted cell lysate was transferred to a new 96 well plate for 
reverse transcription. To each well of the 96 well plate 1 μl random hexamers 
(0.2 μg/ml) 4µl of dH20 and 3 μl dNTPs (2.5 mM) were added and the plate 
heated at 70°C for 5 minutes. For SW1353 cells 30 µl Cells-2-cDNA lysis buffer 
was added to each well, and the cells lysed by tip and transferred to a separate 
96 well plate. The plate was then heated at 75°C for 10 minutes. 8 µl cell lysate 
was transferred to a new 96 well plate for reverse transcription. To each well of 
the 96 well plate 1 µl random hexamers (0.2 µg/ml) and 3 µl dNTPs (2.5 mM) 
were added and the plate heated at 70°C for 5 minutes. For both cell types the 
plate was immediately placed on ice where 4 μl 5x First Strand Synthesis 
Buffer, 2 μl DTT (0.1 M), 0.125 μl RNaseOut (40 U/μl), 1.375 µl dH20 and 0.5 μl 
MMLV (200 U/μl) were added to each well. The plate was incubated at 37°C for 
50 minutes, followed by 70°C for 15 minutes. 30 µl dH2O was then added to 
each well prior to first use. SW1353 cDNA was diluted 1:100 and HAC cDNA 
was diluted 1:20 for housekeeping gene quantification. 5 µl cDNA was added to 
a 96 well PCR plate, along with 4.5 µl taqman gene expression master mix, 0.2 
µl forward and reverse primers (30 µM) and 0.1 µl probe (15 µM).  Relative 
quantification of genes was performed using the 7900HT system (Applied 
Biosystems, Foster City, CA). Cycling conditions were 10 minutes at 95°C, then 
40 cycles of 15 seconds at 95°C, and 1 minute at 60°C. The 18S ribosomal 
RNA gene was used as a housekeeping gene control to normalise for 
differences in RNA in each sample. Primers and probe sequences are shown in 
Table 1. 
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Gene Forward primer Reverse primer Probe  
18S 
rRNA 
CGAATGGCTCAT
TAAATCAGTTAT
GG 
TATTAGCTCTAGAA
TTACCACAGTTATC
C 
TCCTTTGGTCGCTCGCT
CCTCTCCC 
TRB1 CCCCAAAGCGA
GGTGCCT 
TACCCGGGTTCCAA
GACG 
CAGCCTCTTGAGAGGGG
A 
TRB3 CTGGCCGCTGT
CTGGTTC 
GGGCATCGGGTCC
TGTCG 
TGCCTCCTTCGTCGGGA
G 
MMP-1 AAGATGAAAGGT
GGACCAACAATT 
CCAAGAGAATGGC
CGAGTTC 
CAGAGAGTACAACTTAC
ATCGTGTTGCGGCTC 
MMP-13 AAATTATGGAGG
AGATGCCCATT 
TCCTTGGAGTGGTC
AAGACCTAA 
CTACAACTTGTTTCTTGT
TGCTGCGCATGA 
c-fos ABI assay on 
demand 
#Hs00170630_m1 
 
 
c-jun CCAAAGGATAGT
GCGATGTTT 
CTGTCCCTCTCCAC
TGCAAC 
Universal probe library 19 
ATF3 TTTGCCATCCAG
AACAAGC 
CATCTTCTTCAGGG
GCTACCT 
Universal probe library 53 
IL-8 AGACAGCAGAG
CACACACAAGC 
AGGAAGGCTGCCA
AGAGAG 
Universal probe library 72 
IKKβ CTGAGCCAGCAA
GAAGAGT 
TGTGCCTCTTCTAG
CAA 
Universal probe library 83 
MEK1 TCCAGCTTTCTT
CAGGACTTG 
TTCTACAGCGATGG
CGAGAT 
Universal probe library 58 
MKK4 CAGCGATATCAA
TCGACATAC 
GGCCAAAGTATAAA
GAGCTTC 
Universal probe library 33 
MKK6 CCAGTTCCATTA
TAGGCTCCA 
CAAGGCTTGCATTT
CTATTGG 
Universal probe library 8 
MKK7 GGAGCTCTCTGA
GGATGG 
CGCAGGATCGACC
TCAAC 
Universal probe library 24 
Table 2.3. Primers and probe sequences used for RT-PCR. TaqMan chemistry was used for analysis. 
Universal probe library probes were FAM labelled, all other probes were FAM-TAMRA labelled. 
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2.2.11 Western Blotting 
 
Culture medium was removed, and cells washed with ice-cold PBS. Cells were 
then lysed with ice-cold lysis buffer (50 mM Tris-Cl, pH 7.5, 1.2 M glycerol, 1 
mM EGTA, 1 mM EDTA, 1 mM Na3VO4, 10 mM 2-glycerophosphate, 50 mM 
NaF, 5 mM sodium pyrophosphate, 1% (v/v) Triton X-100, 1 μM microcystin-LR; 
0.1% (v/v) 2-mercaptoethanol, protease inhibitor cocktail. Cells were then 
scraped into the lysis buffer, vortexed thoroughly, incubated on ice for 20 
minutes, before removal of particulate material by centrifugation at 13,000 x g 
for 5 minutes at 4°C. The supernatant was then removed and stored at -80ºC. 
For subcellular and nuclear fractionation, cells were isolated in PBS and 
pelleted at 500 x g for 5 minutes prior to the procedures described below.  
Cell lysate samples had their protein content quantified through the Bradford 
assay, using BSA as a standard and Bradford Ultra reagent, which was 
subsequently measured using a Tecan Sunrise microplate reader (Tecan, 
Reading UK) at a wavelength of 495 nm to assess the colourimetric change. 
Samples were then made up in water to give equal amounts of protein per 
sample. 5 x Sample buffer (0.625 mM Tris HCl pH 6.8, 40% (v/v) glycerol, 10% 
(w/v) SDS, 0.5% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol) was 
then added to 20 μl of each cell lysate sample and heated to 105°C for 5 
minutes to denature the protein. Lysates/fractions were electrophoresed on 
10% sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE). Molecular 
weight markers were PageRuler pre-stained protein standards. Protein was 
transferred to polyvinilydene fluoride (PVDF) membranes using an iBlot gel 
transfer device (Invitrogen) according to manufacturer’s instructions. Following 
transfer, the blot was blocked with TBS with 0.2% Tween 20 (TBS-T) containing 
5% (w/v) non-fat dried milk (blocking buffer) for 1 hour at room temperature. 
The blot was then washed three times in 20 ml TBS-T for 5 minutes, and then 
incubated overnight at 4ºC with primary antibody diluted in TBS-T (containing 
5% BSA or non-fat dried milk). The blot was then washed three times in 20 ml 
TBS-T for 10 minutes. The blot was incubated for 1 hour with either mouse or 
rabbit secondary antibody conjugated with horseradish peroxidase (HRP), and 
then washed three times in TBS-T for 10 minutes. Proteins were detected with 
enhanced chemiluminescent (ECL) reagent according to the manufacturer‘s 
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instructions, using the GeneGnome chemiluminescent detection machine 
(Syngene, Cambridge, UK). 
 
2.2.12 Subcellular fractionation  
 
Packed 
cell 
volume 
(μl) 
CEB (μl) MEB (μl) NEB (μl) NEB (μl) + 
CaCl2, 
MNase* 
PEB (μl) 
10 100 100 50 50 50 
20 200 200 100 100 100 
50 500 500 250 250 250 
* MNase = Micrococcal nuclease 
Table 2.4. Subcellular protein fractionation reagent volumes for different packed cell volumes. 
 
Cytoplasmic extraction buffer (CEB), was added to the cell pellet, incubated on 
ice for 10 minutes with gentle mixing, then centrifuged at 500 x g for 5 minutes 
at 4°C. The supernatant was then removed and frozen at -80°C (cytoplasmic 
extract). Ice cold membrane extraction buffer (MEB) was added to the cell 
pellet, vortexed and incubated at 4°C for 10 minutes with gentle mixing, then 
centrifuged at 3000 x g for 5 minutes at 4°C. The supernatant was then 
removed and frozen at -80°C (membrane extract). Ice cold nuclear extraction 
buffer (NEB) was then added to the cell pellet, vortexed, and incubated at 4°C 
for 30 minutes with gentle mixing, then centrifuged at 5000 x g for 5 minutes at 
4°C. The supernatant was then removed and frozen at -80°C (soluble nuclear 
extract). Chromatin bound extraction buffer was then prepared by adding 5 µl of 
100 mM CaCl2 and 3 µl of Micrococcal Nuclease per 100 µl NEB. Room 
temperature chromatin bound extraction buffer was then added to the pellet, 
vortexed, and incubated at room temperature for 15 minutes. After incubation 
the solution was then vortexed and centrifuged at 16,000 x g for 5 minutes at 
4°C. The supernatant was then removed and frozen at -80°C (chromatin bound 
nuclear extract). Room temperature cytoskeletal extraction buffer (PEB) was 
then added to the cell pellet, vortexed and incubated for 10 minutes at room 
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temperature, then centrifuged at 16,000 x g for 5 minutes at 4°C. The 
supernatant was then removed and frozen at -80°C (cytoskeletal extract). 
 
2.2.13 Nuclear fractionation 
  
Packed 
cell 
volume (μl) 
CERI (μl) CERII (μl) NER (μl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
 
Table 2.5. Nuclear protein fractionation reagent volumes for different packed cell volumes. 
 
Cytoplasmic extraction reagent I (CERI) was added to the pellet, vortexed, and 
incubated on ice for 10 minutes. Cytoplasmic extraction reagent II (CERII) was 
then added, vortexed, incubated on ice for 1 minute, vortexed again, then 
centrifuged for 5 minutes at 16,000 x g at 4°C. The supernatant was then 
removed and frozen at -80°C (cytoplasmic extract). The cell pellet was then 
resuspended in nuclear extraction reagent (NER), vortexed every 10 minutes 
for 40 minutes, whilst on ice, then centrifuged for 10 minutes at 16,000 x g at 
4°C. The supernatant was then removed and frozen at -80˚C (nuclear extract). 
 
2.2.14 Immunoprecpitiation 
 
Immunoprecipitation was carried out as per manufcaturers instructions. Briefly. 
cells were initially lysed. Lysates were then added to Pierce spin columns, 
followed by anit-c-Myc agarose slurry. Columns were then incubated with gentle 
end-over-end mixing overnight at 4ºC. Columns were then pulse centrifuged for 
10 seconds and the flow through discarded. TBS-T wash solution was then 
added to each column and pulse centrifuged for 10 seconds, and the wash 
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discarded, this was repeated twice. Conditioning buffer was then added to the 
column and pulse centrifuged for 10 seconds and the flow through discarded. 
Non-reducing sample buffer was then added to each column, the column 
heated at 100ºC for 5 minutes, and pulse centrifuged for 10 seconds to obtain 
the sample. 
 
2.3 Statistical analysis 
 
Statistical analysis of data was performed by a Student’s unpaired 2 sample t-
test (Microsoft  EXCEL) on standard error of the mean, *p<0.05, **p<0.01, 
***p<0.001. 
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Chapter 3: RNA inhibition and overexpression optimisation 
 
3.1 Introduction 
 
In order to establish the effect that a specific protein has on various pathways it 
is common practice to alter these levels, whether in vitro or in vivo, and assess 
the effect of this change on the pathway. Therefore, in order to assess the effect 
of Trb1 and Trb3 on various signaling pathways it was first required to optimize 
the ability to both inhibit and overexpress Trb1 and Trb3 protein expression. 
In order to inhibit Trb1 and Trb3 expression, two methods were assessed; this 
was small interfering RNA (siRNA) inhibition and short hairpin (shRNA) 
inhibition. These two methods essentially work on the same principle, which is 
inhibition of expression of specific genes through binding to RNA and 
preventing translation. The difference between siRNA and shRNA is that siRNA 
is simply transfected into a cell and is present only transiently. shRNA has an 
expression vector, often bacterial or viral, which integrates into the host 
genome, and the shRNA is constitutively expressed, meaning continued 
silencing of the gene. The shRNA is processed within the cell where one of the 
double strands is degraded. This shRNA then binds to a complementary 
sequence of mRNA. If there is complete complementarity then the mRNA is 
degraded, if there is only partial complementarity then mRNA translation is 
repressed. 
Overexpression of Trb1 and Trb3 was achieved through transfection of plasmid 
DNA containing the sequence for the protein of interest into the cell. This 
plasmid DNA is then expressed using the cells expression machinery. 
Throughout these results chapters only Trb1 and Trb3 were assessed. Trb2 
was not assessed as it had previously been demonstrated within our lab that 
Trb2 had no effect on MMP-1 or -13 mRNA expression following pro-
inflammatory stimulation (Duncan, 2010), therefore it was determined that Trb1 
and Trb3 would be the sole focus of this thesis. 
Both primary Human Articular Chondrocytes (HAC) and a human 
chondrosarcoma cell line (SW1353 cells) were used throughout this study. Both 
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cell types were used as it was not always possible to use primary cells, the 
reasons for which will be discussed later, therefore SW1353 cells were used as 
a model cell type for HAC. 
 
The aims of this chapter were to:- 
 
• Assess and optimise the ability to silence Trb1 and Trb3 using siRNA in 
SW1353 cells and HAC. 
• Assess and optimise the ability to silence Trb1 using shRNA in SW1353 
cells and HAC. 
• Assess and optimise the ability to overexpress Trb1 and Trb3 in SW1353 
cells and HAC. 
 
3.2 Results 
 
3.2.1 Trb1 gene silencing using siRNA in SW1353 cells and HAC 
 
It was initially investigated whether it was possible to silence Trb1 gene 
expression using siRNA. A number of different siRNAs were tested. This 
included pooled siRNA of 3 different siRNAs (Trb1 smartpool 1 and 2), as well 
as individual siRNA (Trb1 # 1-6). Trb1 siRNA gene silencing was tested in both 
SW1353 cells and HAC. Trb1 smartpool 1 and 2 were compared to the siCon 
smartpool control, and Trb1 # 1-6 individual siRNAs were compared to the 
AllStars individual siRNA control. It was not possible to reproducibly silence 
Trb1 to a sufficient level in either SW1353 cells (Fig 3.1A) or HAC (Fig 3.1B) 
using siRNA. Figures 3.1A and 3.1B demonstrate silencing after 24 hours, this 
was also attempted at a number of other time points (data not shown). 100 nmol 
siRNA was used as this was previously shown to be the optimum concentration 
to use for SW1353 cells and HAC without becoming toxic to the cells. 
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A 
 
B 
                                                                                             
Figure 3.1. Trb1 gene silencing optimisation using siRNA in SW1353 cells and HAC. mRNA 
expression analysis of Trb1 after transfection with Trb1 siRNA of SW1353 cells (A) and HAC (B). Cells 
were transfected with siRNA in 96 well plates (100 nmol/well) for 24 hours and then serum-starved for 6 
hours before lysis. Total RNA was isolated, reverse transcribed to cDNA and Trb1 expression assessed by 
real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value 
plotted. Results are measured in hextuplicate (+/-standard error of the mean). Trb1 smartpool 1 and 2 refer 
to two different pools of three different Trb1 siRNA. Trb1 # 1-6 refer to 6 different individual Trb1 siRNA. 
Results are representative of 2 independent experiments, from 2 separate donors in regard to HAC. Ct 
values for siCon were 10.14 +/- 0.39 for 18S and 27.42 +/- 0.35 for Trb1 for SW1353, and 17.38 +/- 0.19 
for 18S and 32.77 +/- 0.10 for Trb1 for HAC (+/- = standard error of the mean).  
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3.2.2 Trb3 gene silencing using siRNA in SW1353 cells and HAC 
 
It was demonstrated that Trb3 mRNA expression could be successfully silenced 
in SW1353 cells (Fig 3.2). 100 nmol siRNA was used, for the reason discussed 
above. 
 
Figure 3.2. Trb3 gene silencing using siRNA in SW1353 cells. mRNA expression analysis of Trb3 after 
transfection with Trb3 siRNA in SW1353 cells. Cells were transfected with Trb3 siRNA in 96 well plates 
(100 nmol/well) for 24 hours and serum-starved for 6 hours before lysis. Total RNA was isolated, reverse 
transcribed to cDNA and Trb3 expression assessed by real-time RT-PCR. Values were normalised to the 
housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, (+/-
standard error of the mean), ***p<0.001. Results are representative of 2 independent experiments. Ct 
values for siCon were 14.48 +/- 0.08 for 18S and 26.96 +/- 0.18 for Trb3 (+/- = standard error of the mean). 
 
Trb3 protein expression was also depleted when Trb3 was silenced using 
siRNA in SW1353 cells (Fig 3.3). 
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Figure 3.3. Trb3 gene silencing using siRNA effect on Trb3 protein expression in SW1353 cells. A. 
Trb3 and GAPDH abundance after transfection with Trb3 siRNA in SW1353 cells. Cells were transfected 
with Trb3 siRNA in 6 well plates  (100 nmol/well) for 48 hours and serum-starved for 6 hours. Cells were 
then lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated 
proteins. Lanes were extracted from the same membrane. Results are representative of approximately 30 
independent experiments. B. Combined densitometric scans from 4 separate blots representative of 
approximately 30 blots performed. Values were normalised to GAPDH. Results are +/-standard deviation 
of the mean, ***p<0.001.  
 
It was then demonstrated that Trb3 mRNA expression was successfully 
silenced using Trb3 siRNA in HAC (Fig 3.4). 100 nmol siRNA was again used. 
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 Figure 3.4. Trb3 gene silencing using siRNA in HAC. mRNA expression analysis of Trb3 after 
transfection with Trb3 siRNA in HAC. Cells were transfected with Trb3 siRNA in 96 well plates (100 
nmol/well) for 24 hours and serum-starved for 6 hours before lysis. Total RNA was isolated, reverse 
transcribed to cDNA and Trb3 expression assessed by real-time RT-PCR. Values were normalised to the 
housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, (+/-
standard error of the mean). ***p<0.001. Results are representative of 2 independent experiments, from 2 
separate donors. Ct values for siCon were 17.01 +/- 0.10 for 18S and 35.53 +/- 0.24 for Trb3 (+/- = 
standard error of the mean). 
 
Trb3 protein expression was also depleted when Trb3 was silenced using 
siRNA in HAC (Fig 3.5). 
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Figure 3.5. Trb3 gene silencing using siRNA effect on Trb3 protein expression in HAC. A. Trb3 and 
GAPDH abundance after transfection with Trb3 siRNA in HAC. Cells were transfected with Trb3 siRNA in 
6 well plates (100 nmol/well) for 48 hours and serum-starved for 6 hours. Cells were then lysed and 
proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Lanes were 
extracted from the same membrane. Results are representative of approximately 30 independent 
experiments, from 30 separate donors. B. Combined densitometric scans from 4 separate blots 
representative of approximately 30 blots performed. Values were normalised to GAPDH. Results are +/-
standard deviation of the mean, ***p<0.001.  
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3.2.3 Trb1 overexpression optimisation in SW1353 cells and HAC 
 
It was assessed whether Trb1 protein could be overexpressed in SW1353 cells. 
Trb1 was successfully overexpressed, as shown by the overexpressed Trb1 
above the native Trb1 (Fig 3.6). It was decided not to go above 0.9 µg of 
plasmid DNA as this amount gave good overexpression, and the transfection 
reagent used can be toxic to the cells, therefore as low an amount as possible 
to get good overexpression was used. Overexpressed Trb1 gave a larger than 
expected band (55kDa) compared to the native Trb1 (40kDa).  
 
Figure 3.6. Trb1 overexpression optimisation in SW1353 cells. Trb1 and GAPDH abundance after 
transfection with Trb1 overexpression plasmid in SW1353 cells. Cells were transfected with Trb1 
overexpression plasmid in 6 well plates, as indicated, for 48 hours and then serum-starved for 6 hours. 
Cells were then lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the 
indicated proteins. Results are representative of 2 independent experiments. 
 
It was then assessed whether Trb1 could be overexpressed in HAC. Trb1 was 
successfully overexpressed, as can be seen by the overexpressed Trb1 protein 
above the native Trb1 (Fig 3.7). The amount of overexpressed protein 
increased with the amount of plasmid added up to 4 µg, whilst 6 µg did not 
generate any more overexpressed protein (Fig 3.7). As seen for SW1353 cells, 
overexpressed Trb1 gave a larger than expected band (55kDa) compared to the 
native Trb1 (40kDa). 
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 Figure 3.7. Trb1 overexpression optimisation in HAC. Trb1 and GAPDH abundance after transfection 
with Trb1 overexpression plasmid in HAC. Cells were transfected with Trb1 overexpression plasmid in 6 
well plates, as indicated, for 48 hours and then serum-starved for 6 hours. Cells were then lysed and 
proteins were separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. 
Results are representative of 2 independent experiments, from 2 separate donors.. 
 
3.2.4 Trb1 immunoprecipitation in SW1353 cells 
 
Trb1 was also immunoprecipitated in SW1353 cells. Overexpressed Trb1 was 
immunoprecipitated through its c-Myc tag. Immunoprecipitated overexpressed 
Trb1 also gave a larger than expected band (55kDa) compared to the native 
Trb1 (40kDa) (Fig 3.8). 
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 Figure 3.8. Trb1 immunoprecipitation in SW1353 cells. Trb1, c-Myc and GAPDH abundance after 
transfection with Trb1 overexpression plasmid in SW1353 cells. Cells were transfected with Trb1 
overexpression plasmid in 6 well plates, as indicated, for 48 hours and then serum-starved for 6 hours. 
Cells were then lysed, and immunoprecipitation performed. and proteins separated by SDS-PAGE and 
analysed by immunoblotting for the indicated proteins. Results are representative of 2 independent 
experiments. 
 
3.2.5 Trb3 overexpression optimisation in SW1353 cells and HAC 
 
It was assessed whether Trb3 could be overexpressed at the protein level in 
SW1353 cells. Trb3 was successfully overexpressed as observed by the c-Myc 
tag on the overexpression plasmid (Fig 3.9). For reasons unknown, 
overexpressed Trb3 was not detected by the Trb3 antibody in SW1353 cells. 
Both the c-Myc tagged Trb3 protein and the endogenous Trb3 were 
approximately the same size of 45 kDa, providing further evidence that the c-
Myc antibody was in fact detecting the overexpressed Trb3. The amount of 
overexpressed protein increased with the amount of plasmid DNA used; 1.2 µg 
gave the highest overexpression (Fig 3.9). As before for Trb1 optimisation in 
SW1353 cells, it was decided not to go above 1.2 µg as this amount gave good 
overexpression, and the transfection reagent used can be toxic to the cells, 
therefore as low an amount as possible to get good overexpression was used.  
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 Figure 3.9. Trb3 overexpression optimisation in SW1353 cells. Trb3, c-Myc-tagged Trb3 and GAPDH 
abundance after transfection with Trb3 overexpression plasmid in SW1353 cells. Cells were transfected 
with Trb3 overexpression plasmid in 6 well plates, as indicated, for 48 hours and then serum-starved for 6 
hours. Cells were then lysed and proteins were separated by SDS-PAGE and analysed by immunoblotting 
for the indicated proteins. Results are representative of 2 independent experiments. 
 
It was then assessed whether Trb3 could be overexpressed in HAC. Trb3 was 
successfully overexpressed, as can be seen by the c-Myc tag on the 
overexpression plasmid (Fig 3.10). Interestingly it appeared that the Trb3 
antibody could also detect the overexpressed c-Myc-tagged Trb3 in HAC, which 
mimicked the increase in protein expression seen with the c-Myc antibody.  The 
amount of overexpressed protein increased with the amount of plasmid added 
up to 4µg, whilst 6µg did not give any more overexpressed protein (Fig 3.10). 
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 Figure 3.10. Trb3 overexpression optimisation in HAC. Trb3, c-Myc-tagged Trb3 and GAPDH 
abundance after transfection with Trb3 overexpression plasmid in HAC. Cells were transfected with Trb3 
overexpression plasmid in 6 well plates, as indicated, for 48 hours and then serum-starved for 6 hours. 
Cells were then lysed and proteins were separated by SDS-PAGE and analysed by immunoblotting for the 
indicated proteins. Results are representative of 2 independent experiments, from 2 separate donors. 
 
3.2.6 Trb1 gene silencing optimisation using shRNA in SW1353 cells and HAC 
 
3.2.6.1 Optimisation of GFP lentiviral shRNA in HAC and SW1353 cells 
 
Due to the inability to silence Trb1 using siRNA, silencing using shRNA was 
then attempted. In order to initially assess the feasibility of lentiviral transduction 
in both SW1353 cells and HAC, as well as optimising the technique, a lentiviral 
GFP was used. SW1353 cells were initially assessed due to ease of 
transduction. Specific volumes of virus were used, and transfection efficiency 
assessed. The volumes used were a percentage of the total volume, for 
instance 100% virus was pure virus-containing supernatant added to the cells, 
50% virus was half virus-containing supernatant and half medium. It was 
demonstrated that virus production was successful, and the method of 
transduction was successful, as fluorescence from the GFP lentiviral empty 
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vector shRNA was detected within the cells (Fig 3.11). The best transduction 
efficiency was with 100% virus, which gave approximately 50% transduction, 
with transduction efficiency decreasing with lower concentrations (all 
transduction efficiencies were approximated by eye). 
 
 
Figure 3.11. Optimisation of GFP lentiviral shRNA using different concentrations of shRNA in 
SW1353 cells. Fluorescent images of lentiviral GFP shRNA expression in SW1353 cells. Cells were 
transduced with lentivirus shRNA in 8 well chamber slides (12.5%, 25%, 50% and 100%) with 8 µg/ml 
polybrene for 24 hours, medium was then changed and the cells incubated for a further 48 hours, as 
detailed in the Materials and Methods, then fixed and visualised. Results are representative of a single 
experiment. 
 
The same experiment as above was then performed on HAC, in order to test 
transduction efficiency. This was performed using live imaging, rather than 
fixing the cells, which was used from then on. It was observed that it was 
possible to transduce HAC with lentivirus. 100% lentivirus gave the best 
transduction efficiency with efficiency reducing with lower concentrations (Fig 
3.12). Transduction efficiency was lower than that in SW1353 cells, with 
approximately 20% efficiency for 100% lentivirus. 
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 Figure 3.12. Optimisation of GFP lentiviral shRNA using different concentrations of shRNA in HAC. 
Fluorescent images of lentiviral GFP shRNA expression in HAC. Cells were transduced with lentivirus 
shRNA in 96 well plates (12.5%, 25%, 50% and 100%) with 8 µg/ml polybrene for 24 hours, medium was 
then changed and the cells incubated for a further 48 hours, as detailed in the Materials and Methods, then 
visualised. Results are representative of a single experiment. 
 
3.2.6.2 Optimisation of polybrene concentration in HAC 
 
Different concentrations of polybrene were tested in order to increase 
transduction efficiency in HAC. Polybrene is a cationic polymer which acts 
through “charge shielding” by neutralising the electrostatic repulsion forces 
between the lentivirus and sialic acid on the cell surface (Davis et al, 2004), 
therefore increasing transduction efficiency. The best concentration appeared to 
be 6-8 µg/ml of polybrene, concentrations above or below this range showed a 
decrease in transduction (Fig 3.13), therefore 8 µg/ml was continued to be 
used. 
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 Figure 3.13. Optimisation of polybrene concentration in HAC. Fluorescent images of lentiviral GFP 
shRNA expression in HAC. Cells were transduced with lentivirus shRNA in 96 well plates with 100% virus 
and different concentrations of polybrene for 24 hours, medium was then changed and the cells incubated 
for a further 48 hours, as detailed in the Materials and Methods, then visualised. Results are 
representative of a single experiment. 
 
3.2.6.3 Centrifugation of cells in order to increase transduction of shRNA in 
HAC 
 
In order to further optimise transduction efficiency in HAC, centrifugation was 
performed after the lentivirus was added, and compared to non-centrifuged 
cells. This is thought to enhance transduction efficiency by enhancing the 
density of the virus at the cell surface. However, centrifugation did not enhance 
transduction efficiency, and appeared to give reduced transduction, compared 
to non-centrifuged cells, with non-centrifuged showing approximately 25% 
efficiency and centrifuged approximately 15% efficiency (Fig 3.14).  
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 Figure 3.14. Centrifugation of cells in order to increase transduction of shRNA in HAC. Fluorescent 
images of lentiviral GFP shRNA expression in HAC. Cells were transduced with lentivirus shRNA in 96 well 
plates with 100% virus and 8 µg/ml polybrene, as detailed in the Materials and Methods, then spun at 1200 
x g for 90 minutes at room temperature, and incubated for 24 hours, medium was then changed and the 
cells incubated for a further 48 hours, then visualised. Results are representative of a single experiment. 
 
3.2.6.5 Optimisation of inducible TRIPZ Trb1 lentiviral shRNA in HAC and 
SW1353 cells 
 
After it was confirmed lentiviral shRNA could successfully be produced and 
transduced into both SW1353 cells and HAC, Trb1 lentiviral shRNA was then 
tested. The Trb1 lentivirus used initially was TRIPZ inducible shRNA, whereby 
the expression of the shRNA was induced in the presence of doxycycline; this 
was through a tetracycline response element. In addition to this, the tetracycline 
response element also drives expression of the turbo red fluorescence protein 
(RFP) promoter which allows the fluorescence visualisation of transduction 
efficiency, and promoter activity.  
Three separate Trb1 shRNA (Trb1 # 1-3) were assessed, in order to give a 
better probability of identifying one which could silence Trb1. This was initially 
assessed in SW1353 cells. The lentivirus was concentrated in order to allow a 
greater amount of lentivirus to be added to maximise transduction efficiency. 
The lentivirus was concentrated through centrifugation, using a commercial kit, 
and concentrated 50-fold. In addition to this, transduction was also carried out 
three different ways: 1. As above; 2. Transducing in serum-free medium for 6 
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hours, then addition of 20% FBS medium; 3. Replenishing the doxycycline 
every day. The 300% virus gave the best transduction efficiency for all groups 
compared to the 200% (Fig 3.15). It also appeared that transduction in serum-
free medium gave better transduction compared to the other methods (Fig 
3.15), achieving almost 100% transduction for Trb1 # 1 and Trb1 # 3; Trb1 # 2 
gave slightly lower transduction efficiency. 
It was also assessed from these cells whether Trb1 shRNA led to gene 
silencing of Trb1. From the mRNA data Trb1 # 3 shRNA appeared to be the 
only shRNA which silenced Trb1 (Fig 3.16). Interestingly, this silencing occurred 
at 200% virus rather than the 300% which had given a higher transduction 
efficiency. Both serum-free (Fig 3.16B) and replenished (Fig 3.16C) conditions 
gave silencing of Trb1. However, Trb3 mRNA expression was also assessed for 
the 200% virus in serum-free medium, and it was shown that the shRNA also 
silenced this gene (Fig 3.17), therefore it was not specific for Trb1. 
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 Figure 3.15. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA through alteration of serum 
content and doxycycline in SW1353 cells. Fluorescent images of inducible lentiviral TRIPZ Trb1 shRNA 
expression in SW1353 cells. Cells were transduced with lentivirus shRNA in 96 well plates (200% or 
300%) with 8 µg/ml polybrene in either 10% FBS medium or serum-free medium for 6 hours then 20% 
FBS medium added (SFM group). Medium was then changed after 24 hours and 3 µg/ml doxycycline was 
added, and the cells incubated for a further 48 hours, or medium changed and doxycycline added again 
after 24 hours (replenished group), as detailed in the Materials and Methods, then visualised. Three 
different Trb1 shRNA were tested (Trb1 # 1-3). Results are representative of 2 independent experiments. 
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 Figure 3.16. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA through alteration of serum 
content and doxycycline in SW1353 cells: Assessment of Trb1 gene silencing. mRNA expression 
analysis of Trb1 after transduction with inducible lentiviral TRIPZ Trb1 shRNA in SW1353 cells. Cells were 
transduced with lentivirus shRNA in 96 well plates (200% and 300%) with 8 µg/ml polybrene in either 10% 
FBS medium or serum-free medium for 6 hours then 20% FBS medium (B). Medium was then changed 
after 24 hours and 3 µg/ml doxycycline was added, and the cells incubated for a further 48 hours, or 
medium changed and doxycycline added again after 24 hours (C), as detailed in the Materials and 
Methods, before lysis. Total RNA was isolated, reverse transcribed to cDNA and Trb1 expression 
assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the 
mean values plotted. Results are measured in hextuplicate, (+/-standard error of the mean), *p<0.05. 
Results are representative of 2 independent experiments. Ct values for siCon werey 11.91 +/- 0.11 for 18S 
and 24.43 +/- 0.64 for Trb1 for Normal,11.41 +/- 0.66 for 18S and 23.83 +/- 0.42 for Trb1 for SFM, and 
12.97 +/- 0.18 for 18S and 23.23 +/- 0.69 for Trb1 for replenished (+/- = standard error of the mean). 
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 Figure 3.17. Assessment of Trb3 gene silencing during TRIPZ Trb1 lentiviral shRNA transduction in 
SW1353 cells. mRNA expression analysis of Trb3 after transduction with inducible lentiviral TRIPZ Trb1 
shRNA in SW1353 cells. Cells were transduced with lentivirus shRNA in 96 well plates (200%) with 8 
µg/ml polybrene in serum-free medium for 6 hours then 20% FBS medium. Medium was then changed 
after 24 hours and 3 µg/ml doxycycline was added, and the cells incubated for a further 48 hours, as 
detailed in the Materials and Methods, before lysis. Total RNA was isolated, reverse transcribed to cDNA 
and Trb3 expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 
18S rRNA and the mean value plotted. Results are measured in hextuplicate, (+/-standard error of the 
mean), *p<0.05. Results are representative of 2 independent experiments. Ct values for siCon were 12.23 
+/- 0.25 for 18S and 25.39 +/- 0.48 for Trb3 (+/- = standard error of the mean). 
 
It was then assessed whether the TRIPZ Trb1 shRNA could be transduced into 
HAC. Taking into account the results from SW1353 experiments, the serum-free 
medium technique was used for all future experiments. In addition, due to the 
known difficulty in transducing HAC, as demonstrated by the GFP lentiviral 
shRNA data (see Fig 3.12, 3.13, 3.14), a higher concentration of virus was 
used. It was not possible to transduce HAC to a high efficiency using the Trib1 
TRIPZ shRNA. It was only possible to transduce a few cells with 600% virus for 
the Trb1 # 3 shRNA (Fig 3.18). 
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 Figure 3.18. Optimisation of inducible TRIPZ Trb1 lentiviral shRNA using different concentrations 
of shRNA in HAC.  Fluorescent images of inducible lentiviral TRIPZ Trb1 shRNA expression in HAC. 
Cells were transduced with lentivirus shRNA in 96 well plates (300% and 600%) with 8 µg/ml polybrene in 
serum-free medium for 6 hours then 20% FBS medium. Medium was then changed after 24 hours and 3 
µg/ml doxycycline was added, and the cells incubated for a further 48 hours, as detailed in the Materials 
and Methods, then visualised. Three different Trb1 shRNA were tested (Trb1 # 1-3). Results are 
representative of 2 independent experiments, from 2 separate donors. 
 
Due to the apparent lack of transduction of HAC, it was then tested whether it 
was the ability to induce the lentivirus which was the reason why there was 
such a low apparent transduction efficiency, rather than the ability to transduce 
the HAC per se. Therefore, non-inducible GIPZ and inducible TRIPZ controls 
were compared within the same HAC population. Three different concentrations 
of virus were compared; 250%, 500% and 750%. It was demonstrated that the 
GIPZ controls had a much higher percentage of fluorescent cells, compared to 
the TRIPZ controls (Fig 3.19), suggesting that the cells were being transduced 
but the doxycycline was not inducing the shRNA. It was therefore decided to 
use GIPZ Trb1 shRNA. 
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 Figure 3.19. Assessment of the ability of doxycycline to induce lentivirus in HAC. Fluorescent 
images of inducible lentiviral TRIPZ control, non-inducible GIPZ control and GFP shRNA expression in 
HAC. Cells were transduced with lentivirus shRNA in 96 well plates (250%, 500% and 750%) with 8 µg/ml 
polybrene in serum-free medium for 6 hours then 20% FBS medium. Medium was then changed after 24 
hours and 3 µg/ml doxycycline was added, and the cells incubated for a further 48 hours, as detailed in the 
materials and methods, then visualised. Results are representative of a single experiment.  
 
3.2.6.6 Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA in HAC 
 
Four different Trb1 shRNA were tested (Trb1 # A-D) in order to increase the 
probability that one might silence Trb1. It was initially assessed if it was possible 
to transduce HAC with the GIPZ lentivirus, in addition to assessing the 
transduction efficiency. Through fluorescence microscopy, it was demonstrated 
that transduction of the virus was successful for all of the lentiviral constructs 
(Fig 3.20). Transduction efficiency appeared similar for all of the constructs at 
approximately 50-60%, with Trb1 # C being slightly lower. The increase in 
concentration from 750% to 1000% appeared to have little effect on 
transduction efficiency. 
As transduction efficiency appeared sufficient, Trb1 silencing was measured at 
both the mRNA and protein levels. None of the four Trb1 shRNA had any 
apparent reproducible effect on either Trb1 mRNA or protein depletion (Fig 3.21 
and 3.22). For measurement of protein depletion the 1000% concentration was 
used, as there appeared little difference in transduction efficiency between the 
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two different concentrations. Due to time constraints no further work was 
performed in order to silence Trb1 in either HAC or SW1353 cells. 
 
Figure 3.20. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different 
concentrations of shRNA in HAC. Fluorescent images of non-inducible lentiviral GIPZ Trb1 shRNA 
expression in HAC. Cells were transduced with lentivirus shRNA in 96 well plates (750% and 1000%) with 
8 µg/ml polybrene in serum-free medium for 6 hours then 20% FBS medium added. Medium was then 
changed after 24 hours, and the cells incubated for a further 48 hours, as detailed in the Materials and 
Methods, then visualised. Four different Trb1 shRNA were tested (Trb1 # A-D). Results are representative 
of 2 independent experiments, from 2 separate donors. 
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 Figure 3.21. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different 
concentrations of shRNA in HAC: Assessment of Trb1 gene silencing. mRNA expression analysis of 
Trb1 after transduction with non-inducible lentiviral GIPZ Trb1 shRNA in HAC. Cells were transduced with 
lentivirus shRNA in 96 well plates (750% and 1000%) with 8 µg/ml polybrene in serum-free medium for 6 
hours then 20% FBS medium added. Medium was then changed after 24 hours, and the cells incubated 
for a further 48 hours, as detailed in the Materials and Methods, before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and Trb1 expression assessed by real-time RT-PCR. Values were normalised 
to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, 
(+/-standard error of the mean). Four different Trb1 shRNA were tested (Trb1 # A-D). Results are 
representative of 2 independent experiments, from 2 separate donors. Ct values for siCon were 20.51 +/- 
0.54 for 18S and 35.78 +/- 0.61 for Trb1 (+/- = standard error of the mean). 
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 Figure 3.22. Optimisation of non-inducible GIPZ Trb1 lentiviral shRNA using different 
concentrations of shRNA in HAC: Assessment of Trb1 protein expression.  Trb1 and GAPDH 
abundance after transfection with non-inducible lentiviral GIPZ Trb1 shRNA in HAC. Cells were transduced 
with lentivirus shRNA in 6 well plates (1000%) with 8 µg/ml polybrene in serum-free medium for 6 hours 
then 20% FBS medium added. Medium was then changed after 24 hours, and the cells incubated for a 
further 48 hours, as detailed in the Materials and Methods. Cells were then lysed and proteins were 
separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are 
representative of 2 independent experiments, from 2 separate donors. 
 
3.3 Discussion 
 
The ability to control and alter the expression of genes is critical in order to 
understand their roles within the cell. Therefore, initially it was essential to 
determine whether it was possible to control the genetic expression of the Trb1 
and Trb3 in order to study them; by decreasing or increasing their expression. 
This was attempted through both siRNA and shRNA gene silencing, and 
plasmid overexpression.  
It was initially investigated whether Trb1 could be successfully depleted using 
siRNA. It was not possible to deplete Trb1 in either HAC or SW1353 cells. Trb1 
mRNA has been shown to have a very short half-life of less than 1 hour 
(Sharova et al, 2009). This is fairly unique, as demonstrated by the study which 
tested 20,000 genes, and showed less than 100 had a half-life of less than 1 
hour. Therefore, it may not have been possible to silence Trb1 as the mRNA 
was being degraded too quickly and re-synthesised. This would prevent 
silencing of Trb1, as any of the mRNA that was being silenced would quickly be 
degraded along with the siRNA, and new functional mRNA synthesised before 
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an effect could be seen. This theory is consistent with Trb3 having a longer half-
life of 2.8 hours (Sharova et al, 2009) and successfully being silenced in 
SW1353 cells and HAC at both the mRNA and protein level. In order to 
demonstrate that Trb1 mRNA levels were in fact being measured, and that what 
was being seen was not simply background, a negative control well of no 
template and water should have been performed. In addition, in order to verify 
that the correct amplicons were being produced a melt curve should have been 
performed. 
Throughout this thesis 18S ribosomal RNA was used as the housekeeping 
gene. This is commonly used as a housekeeping gene for RT-PCR, as it is 
quite consistent in many cell types, however it does have limitations. 18S rRNA 
may not always represent the total cellular RNA. In addition, it has a high 
abundance, constituting 85-90% of total cellular RNA, meaning this may be 
problematic for medium and low expressing target genes. 
Both Trb1 and Trb3 were successfully overexpressed in both HAC and SW1353 
cells. It was not possible to visualise overexpressed Trb3 in SW1353 cells, 
however the c-Myc tag encoded within the plasmid was used to show that Trb3 
was indeed being overexpressed. The reason for the lack of visualisation of 
overexpressed Trb3 was unknown. However, it was possible that the 
overexpressed Trb3 protein was not exposing the primary antibody binding site 
for the particular antibody used. Overexpressed Trb1 gave a larger than 
expected band (55kDa) compared to the native Trb1 (40kDa). The reason for 
this was unkown, however, there are a number of possible reason; the 
overexpressed Trb1 may be glycosylated, phosphorylated or sumoylated. Also, 
the overexpressed Trb1 may be polyubiquitinated, and an accumulation is seen 
due to the degradation machinery being saturated. This ability to overexpress 
both Trb1 and Trb3 therefore allows the effect of an increase in these proteins 
on the various signalling pathways to be investigated. In addition, it also allows 
a number of possible techniques to be performed, such as protein 
complementation assays (as seen in chapters 4, 6 and 7), and co-
immunoprecipitation.  
Due to the inability to silence Trb1 using siRNA, shRNA was used in order to 
attempt to silence Trb1, as shRNA would provide constitutive silencing of the 
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gene. Initially, GFP was used in order test production of the lentivirus, scale up 
the lentiviral production, as well as optimising transduction efficiency of the 
lentivirus in both HAC and SW1353 cells. Production and transduction of the 
GFP lentivirus proved to be possible in both SW1353 cells and HAC. A number 
of different lentivirus concentrations were tested, as well as different polybrene 
concentrations.  
The initial Trb1 shRNA tested was doxycycline inducible, which allowed the 
ability to induce expression of shRNA and therefore silence the gene of interest 
at the time point required. In addition, a red fluorescence protein promoter was 
also induced which allowed transduction efficiency to be assessed. Three 
different Trb1 shRNA were tested. In order to further improve transduction 
efficiency the lentivirus was concentrated through a centrifugation technique. 
This allowed a greater amount of virus to be added. Transduction in serum-free 
medium was tested as this has been shown to enhance transduction efficiency; 
as complement within the serum can inactivate the viral vector particles (Depolo 
et al, 2000). Replenishing of doxycycline was also tested as it has been shown 
that in culture conditions the half-life of doxycycline was 24 hours; and the cells 
were incubated for a further 48 hours after addition of doxycycline. It was 
demonstrated that concentrating the lentivirus was effective with the best 
transduction efficiency in SW1353 cells being 300% virus. In addition serum-
free medium was also effective as this showed increased transduction in 
SW1353 cells. Replenishing doxycycline also proved to give greater induction of 
the shRNA compared to standard induction. This demonstrated that many 
factors can control the level of shRNA expression; and complete optimisation of 
expression can be complex. The depletion of Trb1 was also tested. One 
shRNA, Trb1 # 3, showed Trb1 depletion at the mRNA level, however, this was 
not specific and showed depletion of Trb3 also. This was not entirely surprising, 
as it has been shown that Trb1 and Trb3 share common sequences (Yokoyama 
and Nakamura, 2011). Interestingly, however, the silencing at the mRNA level 
appeared to be greatest at 200% virus which showed lower transduction 
efficiency, the reason for this was unknown. 
I was unable to observe apparent transduction of HAC to a sufficient level using 
the TRIPZ Trb1 lentivirus. It is thought that this was due to the inability of the 
doxycycline to either penetrate the HAC or have an effect once inside the cells. 
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The reason for this assumption was that when comparing the percentage of 
fluorescent cells of both the GIPZ and TRIPZ control, GIPZ gave a much higher 
percentage. This suggested that it was the induction of the shRNA that was not 
working, rather than the transduction. 
Due to the inability to induce TRIPZ, GIPZ Trb1 was then tested. Four different 
Trb1 shRNA were used, which had different sequences to the TRIPZ shRNA. 
Transduction efficiency in HAC was good at approximately 50-60%, suggesting 
that it was in fact induction and not transduction of the TRIPZ shRNA which was 
the problem. However, mRNA and protein expression analysis showed no 
substantial depletion of Trb1 with any of the shRNA. The reason for this may 
possibly be the same reason why Trb1 siRNA did not work, in that Trb1 mRNA 
is being turned over too quickly within the HAC, therefore the lentiviral shRNA is 
not being generated rapidly enough in order to bind sufficient Trb1 mRNA to 
deplete it. Alternatively, it may be that the four sequences tested were not 
specific enough to bind and silence the mRNA. 
 
3.4 Synopsis 
 
It was not possible to specifically silence Trb1 using either siRNA or shRNA. 
Two methods of shRNA were used, both inducible and non-inducible. Inducible 
shRNA was unable to be induced in HAC due to the inducible factor doxycycline 
having little effect in these cells. However, non-inducible shRNA gave high 
transduction efficiency in HAC, but as mentioned Trb1 was not silenced. It is 
possible Trb1 could not be silenced in HAC due to the high degradation rate of 
this gene. Trb1 was silenced in SW1353 using inducible shRNA, however this 
was not specific and also led to the silencing of Trb3. Trb1 was successfully 
overexpressed using plasmid overexpression, therefore its function within the 
cell can still be investigated. However, this result was not ideal, as in order to 
truly investigate the effects of a protein on signalling pathways both 
overexpression and silencing is required. In addition, silencing is more 
biologically relevant than overexpression, as overexpression produces 
expression levels not physiologically seen within the cell, and can therefore 
produce cellular anomalies. It was possible to silence Trb3 using siRNA and 
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overexpress Trb3 using plasmid overexpression, therefore its role within the cell 
can be more fully investigated. 
 
3.5 Summary 
 
• Trb1 gene expression could not be silenced using siRNA in either 
SW1353 cells or HAC. 
 
• Trb3 gene expression was silenced using siRNA in both SW1353 cells 
and HAC. 
 
• Trb1 gene expression was silenced using shRNA in SW1353 cells; 
however it was not specific for Trb1, and also silenced Trb3. 
 
• Trb1 gene expression could not be silenced using shRNA in HAC. 
 
• Trb1 and Trb3 were successfully overexpressed and optimised in both 
SW1353 cells and HAC using plasmid overexpression. 
 
 
 
 
 
 
 
 
95 
 
Chapter 4: The regulation of Trb1 and Trb3 
 
4.1 Introduction 
 
The method of regulation of Trb1 and Trb3 proteins is largely unknown. They 
may be regulated through a number of pathways, such as mRNA stability 
(Sharova et al, 2009), whilst Trb3 has been shown to be regulated through 
proteasomal degradation by SIAH1 (Zhou et al, 2008). Trb1 and Trb3 have 
been shown to be upregulated by IL-1β in a number of different cell types (Sung 
et al, 2006). In addition, Trb3 has been shown to be downregulated through 
miRNA, in particular miRNA 24 (Chan et al, 2010). Both Trb1 and Trb3 have 
been demonstrated to be predominantly nuclear (Kiss-Toth et al, 2006), and this 
subcellular distribution may give indications of their modes of regulation. Trb1 
and Trb3 have also been shown to respond to stress conditions, being up 
regulated during endoplasmic reticulum (ER) stress and hypoxia (Ohoka et al, 
2005; Bowers et al, 2003). An added level of complexity of Trb1 and Trb3 is that 
they appear to be somewhat cell type specific in many cases, whereby they 
appear to have an effect on a pathway in one cell type but not in another 
(Duggan et al, 2010, Kiss-Toth et al, 2004 Hegedus et al, 2006). 
Trb1 and Trb3 have been shown to regulate many pathways involved in arthritis 
and MMP regulation including the MAPK (Kiss-Toth et al, 2004), PI3K/Akt (Du 
et al, 2003) and NFκB (Duggan et al, 2010) pathways. In addition, Trb3 has 
been shown to be up-regulated in OA and it has been suggested that it may 
play a role in OA progression (Cravero et al, 2009).  
It is therefore hypothesised that Trb1 and Trb3 may be regulated in both HAC 
and SW1353 cells in similar manners to which they have previously been 
demonstrated within the literature. This regulation includes through cellular 
stress, cytokine stimulation and proteasomal degradation, as well as through 
their cellular distribution. A greater understanding in the way in which Trb1 and 
Trb3 are regulated may provide insights into how they may be involved in the 
signalling pathways involved in arthritis. 
Cytokines play a major role in arthritic disease, with IL-1 playing a predominant 
role (Feldman et al, 1996; Scott et al, 2010; McInnes and Schett, 2007; Goldring 
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et al, 1994). In addition, OSM has also been shown to have a role in arthritis 
(Plater-Zyberk et al, 2001). IL-1 and OSM have been shown to work 
synergistically in terms of cartilage degradation in vitro (Cawston et al, 1995). 
OSM has also been shown to synergistically enhance IL-1 mediated MMP 
expression (Cawston et al, 1998; Rowan et al 2003; Fearon et al, 2006), 
confirming that IL-1 and OSM in combination is a potent pro-inflammatory 
cytokine stimulus. Therefore, throughout this thesis in order to mimic a pro-
inflammatory environment in vitro, IL-1+OSM stimulation will be used.  
 
The aims of this chapter were to:-  
 
• Determine the subcellular distribution of Trb1 and Trb3, and investigate 
whether IL-1+OSM stimulation alters this distribution. 
• Determine the effect of cellular stress on Trb1 and Trb3 over time, 
through a serum-starvation time course.  
• Determine the effect of IL-1+OSM stimulation on Trb1 and Trb3 over 
time. 
• Determine whether Trb1 and Trb3 are degraded through the 
proteasome. This was performed through proteasomal inhibition and 
determining Trb1 and Trb3 protein abundance. 
• Investigate if Trb1 and Trb3 interact together, and therefore possibly 
regulate one another through this interaction.  
 
4.2 Results 
 
4.2.1 Trb1 and Trb3 subcellular localisation and the effect of IL-1+OSM 
stimulation in SW1353 cells 
 
Whilst it has previously been demonstrated that Trb1 and Trb3 are 
predominantly present within the nucleus, this study was conducted in HeLa 
cells and not in a chondrocyte context (Kiss-Toth et al, 2006). In addition, the 
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effect of pro-inflammatory stimulation on Trb1 and Trb3 cellular localisation has 
not been studied previously. In order to assess subcellular distribution, 
experiments were performed in SW1353 cells, as due to the number of cells 
required, the amount of cartilage needed in order to perform the experiment 
was not available. 
Trb1 protein was present within the cytoplasmic, membrane and soluble nuclear 
fractions, with the highest amounts appearing to be in the cytoplasm and 
nucleus (Fig 4.1). However, the fractionation was not completely successful as 
demonstrated by the fractionation markers (Caveolin, Lamin A/C, and MEK2). In 
particular the cytoplasmic fractionation marker MEK2 demonstrated similar 
abundance between the cytoplasm and membrane as that for Trb1 protein 
abundance. 
IL-1+OSM stimulation appeared to have no effect on membrane bound and 
nuclear Trb1, however, it did appear to increase abundance of cytoplasmic Trb1 
(Fig 4.1), stimulation did not appear to affect localization of the protein though. 
Trb3 protein expression appeared to be mainly within the cytoplasm and soluble 
nuclear fractions (Fig 4.1). There was, however, protein present in the other 
fractions (membrane, chromatin nuclear and cytoskeletal). It is possible that this 
expression may be due to an inefficient fractionation process, as shown by the 
fractionation markers. As with Trb1; IL-1+OSM stimulation appeared to increase 
abundance of cytoplasmic Trb3 (Fig 4.1), but did not affect its localisation. 
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 Figure 4.1. Trb1 and Trb3 localise predominantly within the nucleus and cytoplasm, as well as 
increasing in protein abundance within the cytoplasm during IL-1+OSM stimulation in SW1353 
cells. Trb1, Trb3, Caveolin, Lamin A/C and MEK2 abundance within different subcellular compartments +/- 
IL-1+OSM stimulation in SW1353 cells. Cells were serum-starved overnight, then stimulated with IL-1 (0.5 
ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were subjected to subcellular fractionation after stimulation. 
Proteins were separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. 
Caveolin, Lamin A/C and MEK2 providing controls for Membrane, Nuclear and Cytoplasmic extracts, 
respectively. Results are representative of 2 independent experiments. 
 
4.2.2 Trb1 and Trb3 protein abundance during 24 hour serum-starvation in HAC 
 
Cellular stress is thought to be important in terms of arthritis (Yudoh et al, 2005; 
Takada et al, 2011), as it has been shown to activate a number of pro-
inflammatory pathways, such as the MAPK pathway (Thalhamer et al, 2008). It 
was therefore investigated whether Trb1 and Trb3 may be up regulated during 
stress conditions.  
HAC were serum-starved over time points up to 24 hours, in order to determine 
Trb1 and Trb3 protein abundance over this time period during cellular stress. 
Trb1 protein abundance appeared to increase slightly after 2 hours of 
starvation, and continued to increase up to 6 hours (Fig 4.2). By 12 hours Trb1 
protein levels had reduced below the basal level which continued up to 24 
hours. 
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Trb3 protein abundance gradually increased over time during serum-starvation 
(Fig 4.2). Protein abundance was shown to be increased by 2 hours, which then 
continued up to 12 hours. By 24 hours Trb3 protein levels had reduced slightly, 
but were still above basal level. 
 
Figure 4.2. Trb1 and Trb3 respond to serum-starvation in HAC. Trb1, Trb3 and GAPDH abundance 
after serum-starvation treatment of HAC. Cells were serum-starved for the indicated time points. Cells 
were then lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated 
proteins. Results are representative of 2 individual experiments, from 2 separate donors. 
 
4.2.3 Trb1 and Trb3 mRNA expression and protein abundance during IL-
1+OSM stimulation in HAC 
 
In order to determine whether Trb1 and Trb3 were up regulated within a pro-
inflammatory environment, HAC were stimulated with the potent pro-
inflammatory cytokine combination of IL-1+OSM over a period of 24 hours.  
IL-1+OSM stimulation led to a gradual increase in Trb1 mRNA expression up to 
4 hours which proved to be significant. An increase in Trb1 mRNA expression 
appeared as early as 20 minutes, however this was not statistically significant 
(Fig 4.3 A). By 8 hours the mRNA expression had reduced and continued at this 
level at 24 hours. 
IL-1+OSM stimulation showed a trend of a gradual increase in Trb3 mRNA 
expression up to 24 hours (Fig 4.3 B), however, this was not significant. 
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Figure 4.3. IL-1+OSM stimulation leads to an increase in Trb1 and Trb3 mRNA expression in HAC. 
mRNA expression analysis of Trb1 (A) and Trb3 (B) after IL-1+OSM stimulation of HAC. Cells were serum-
starved overnight before stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for the indicated time points 
before lysis. Total RNA was isolated, reverse transcribed to cDNA and Trb1 and Trb3 expression 
assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the 
mean value plotted. Results are measured in hextuplicate, (+/-standard error of the mean). Results are 
combined data from 3 separate donors. *p<0.05. Ct values for siCon were 18.68 +/- 0.19 for 18S and 
34.50 +/- 0.64 for Trb1 and 35.21 +/- 0.21 for Trb3 (+/- = standard error of the mean). 
. 
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 In addition to mRNA expression, protein abundance was also investigated 
during IL-1+OSM stimulation, over the same time course. Trb1 protein 
abundance appeared to increase at 1 hour, and subsequently decrease by 2 
hours and remain constant (Fig 4.4). This increase then subsequent decrease 
was similar to that for Trb1 mRNA, however the increase in protein abundance 
was much less prolonged. 
Trb3 protein abundance showed an increase with IL-1+OSM stimulation, 
increasing by 4 hours and continuing up to 8 hours, then subsequently 
decreasing by 24 hours back to basal (Fig 4.4). This was slightly different from 
the mRNA data which showed a trend for a continued increase up to 24 hours. 
The increase then decrease in protein abundance with IL-1+OSM stimulation 
was similar to that seen with Trb1, however this occurred more rapidly with 
Trb1. 
 
Figure 4.4. IL-1+OSM stimulation increases Trb1 and Trb3 protein abundance in HAC. Trb1, Trb3 
and GAPDH abundance after IL-1+OSM stimulation of HAC. Cells were serum-starved overnight before 
stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for the indicated time points before lysis. Cells were 
then lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated 
proteins. Results are representative of 3 independent experiments, from 3 separate donors. 
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4.2.4 Assessment of proteasomal degradation of Trb1 and Trb3 in HAC 
 
Since Trb3 has been shown to be degraded through the proteasomal pathway 
in HEK 293T cells (Zhou et al, 2008), it was hypothesised that Trb1 may also be 
regulated in a similar manner, as this is a common cellular method of controlling 
levels of protein expression. Proteasomal degradation of Trb1 and Trb3 in HAC 
was therefore investigated using MG132. MG132 inhibits 20S proteasome 
activity by binding to the active site of the β subunits, and blocks the proteolytic 
activity of the 26S proteasome complex (Guo and Peng, 2013).  
It was initially demonstrated that MG132 was inhibiting the proteasome by 
analyzing ubiquitinated protein levels. Proteins are first ubiquitinated in order to 
be recognized and degraded by the proteasome (Chen et al, 2008). Therefore, 
inhibition of the proteasome should show an increase in ubiquitinated proteins.  
It was observed that MG132 caused an increase in ubiquitinated proteins (Fig 
4.5). The addition of MG132 had no effect on Trb1 protein abundance (Fig 4.6), 
suggesting that it was not degraded through the proteasome. 
The addition of MG132 led to a considerable increase in Trb3 protein 
abundance (Fig 4.6). This suggested that Trb3 protein levels may be regulated 
through proteasomal degradation in HAC. 
  
Figure 4.5. Ubiquitinated protein levels increase with the addition of MG132 in HAC. Ubiquitin and 
GAPDH abundance after MG132 treatment of HAC. Cells were serum-starved overnight, then treated with 
MG132 (5µM for 3 hours). Cells were then lysed and proteins separated by SDS-PAGE and analysed by 
immunoblotting for the indicated proteins. Lanes were extracted from the same membrane. 
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i                                                                ii            
Figure 4.6. The addition of MG132 leads to an increase in Trb3 protein abundance but has no effect 
on Trb1 in HAC. A. Trb1, Trb3 and GAPDH abundance after MG132 treatment in HAC. Cells were serum-
starved overnight, then treated with MG132 (5µM for 3 hours). Cells were then lysed and proteins 
separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Lanes were extracted 
from the same membrane. Results are representative of 3 independent experiments, from 3 separate 
donors. B. Combined densitometric scans from 3 separate blots, from 3 separate donors for Trb1 (i) and 
Trb3 (ii). Values were normalised to GAPDH. Results are +/-standard deviation of the mean, **p<0.01. 
 
 
 
104 
 
4.2.5 Trb1 and Trb3 interaction 
 
The potential for interaction between Trb1 and Trb3 was investigated as it was 
hypothesised that they may form heterodimers in order to regulate signaling 
pathways. This interaction was investigated using a technique called protein 
complementation assay (PCA). In this assay, two complementary Venus 
reporter fragments, V1 and V2, are fused to the protein(s) of interest. Upon 
direct interaction of the fusion proteins, the Venus fluorescent reporter activity is 
reconstituted and generates fluorescence. 
The interaction was investigated in SW1353 cells, as the technique required 
transfection of two plasmid constructs into the same cell, which has a low 
efficiency. Since HAC are difficult to transfect, it was not possible to transfect 
two plasmid constructs at a high enough efficiency. 
Trb1 and Trb3 did not appear to interact in SW1353 cells, as no fluorescence 
was observed when microscopically visualised (Fig 4.7), both Trb1V1-Trb3V2 
and Trb1V2-Trb3V1 were tested (Trb1V2-Trb3V1 data not shown). Trb1-MEK1 
was included as a positive control. 
 
 
Figure 4.7. Fluorescent images of Trb1 (V1) and Trb3 (V2), as well as MEK1 (V1) and Trb1 (V2) 
overexpression constructs in SW1353 cells. Cells were transfected with each construct in 8 well 
chamber slides (0.2 µg per construct) for 48 hours, as detailed in the Materials and Methods, then serum 
starved for 6 hours, fixed and visualised. Results are representative of 2 independent experiments. 
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4.3 Discussion 
 
In order to gain a better understanding of the context of their role within arthritis, 
a greater knowledge of the Trb1 and Trb3 proteins, and ways in which they may 
be regulated was sought. It was initially determined where Trb1 and Trb3 
proteins were localised in SW1353 cells, and also whether this localisation 
changed following a pro-inflammatory stimulus.  
Pro-inflammatory stimuli were used throughout in order to mimic the 
inflammatory environment in arthritis. RA in particular has been shown to be 
very much an inflammatory disease, with a number of pro-inflammatory 
cytokines involved including, IL-1, TNF-α, IL-6, OSM and IL-8 (Feldman et al, 
1996; Scott et al, 2010; McInnes and Schett, 2007; Manicourt et al 2000). OA 
has also now been accepted to have an inflammatory aspect to its progression, 
with synovial inflammation being a characteristic, and IL-1 and TNF-α shown to 
be up-regulated in OA (Benito et al, 2005). In addition, it has been shown that 
MMPs are up-regulated by pro-inflammatory stimulation (Clark et al, 2008). 
Therefore in order to attempt to mimic this pro-inflammatory catabolic 
environment, the stimulus of IL-1+OSM was used.  
In order to study cellular localisation, SW1353 cells were used instead of HAC, 
as discussed. SW1353 cells are a chondrocytic cell line that are often used as a 
model for primary human chondrocytes. However, they are just a model and as 
such there are differences within signalling pathways between primary human 
chondrocytes and SW1353 cells (Borden et al, 1996; Mengshol et al, 2000) 
which must be taken into account when interpreting results. 
Trb1 and Trb3 were shown to be present predominantly in the cytoplasm and 
nucleus of SW1353 cells, suggesting that they have the ability to move between 
different cellular compartments. This is somewhat contradictory to Kiss-Toth et 
al. (2006), who showed Trb1 and Trb3 to be predominantly present in the 
nucleus. This may be due to cell type specificity, as that study was in HeLa 
cells. Both Trb1 and Trb3 contain a nuclear localisation sequence in their N-
terminus (Kiss-Toth et al, 2006), and therefore their ability to move between the 
cytoplasm and nucleus was not unexpected. The presence of Trb1 and Trb3 
both within the nucleus and cytoplasm suggests that they may be able to 
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regulate the transport of proteins to and from the nucleus, possibly regulating 
the ability of proteins to control transcription. The movement of proteins to and 
from the nucleus in order to regulate signalling pathways is a common 
occurrence within cellular signalling, including many proteins shown to be 
involved in arthritis such as NFκB, Akt and the MAPKs (Roman-Blas and 
Jimenez, 2006; Meier et al, 2005 and Sacks, 2006). 
Stimulation with IL-1+OSM did appear to alter the cellular abundance of Trb1 
and Trb3. Trb1 and Trb3 abundance increased within the cytoplasm during 
stimulation, suggesting that they were responsive to pro-inflammatory stimuli. It 
is unknown whether this response to IL-1+OSM stimulation is in a pro-
inflammatory or anti-inflammatory context, as they may be increasing to 
propagate the pro-inflammatory response, or to dampen the response. 
However, stimulation did not appear to affect localisation of either Trb1 or Trb3. 
These similarities between Trb1 and Trb3 in terms of subcellular localisation, 
and response to IL-1+OSM, possibly suggests that Trb1 and Trb3 may work in 
a similar manner within a pro-inflammatory environment. 
The effect of cellular stress on Trb1 and Trb3 expression was assessed in HAC; 
this was performed through serum-starvation. Trb1 increased during serum-
starvation, suggesting that it was responsive to stress stimuli. This would be in 
concordance with data from Ostertag et al. (2010) who stated that Trb1 was 
increased during stress conditions in adipocytes. Trb1 was increased by 2 
hours of starvation suggesting that its up regulation is fairly rapid, and the 
expression of Trb1 is under tight control, due to this rapid increase. By 12 hours 
serum-starvation Trb1 protein expression had reduced, suggesting that Trb1 
may be involved in the initial response of HAC to stress conditions. 
Trb3 was shown to be up regulated during serum-starvation. This was 
expected, as Trb3 has been shown to be a stress response protein, being up-
regulated during both ER stress and hypoxia (Ohoka et al, 2005, Bowers et al, 
2003). As with Trb1, Trb3 appeared to have a rapid response to cellular stress, 
and this response continued up to the final 24 hour time point, suggesting that 
Trb3 was involved in continued stress responses within the cell. A longer time 
course would be required to fully investigate the effects of starvation stress on 
Trb3.  
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The effect of the pro-inflammatory stimuli of IL-1+OSM on Trb1 and Trb3 was 
further investigated with a timecourse study. Trb1 appeared to respond to pro-
inflammatory stimulation showing an increase in both mRNA and protein 
expression. The mRNA levels showed a more prolonged response than the 
protein levels, which were much more transient showing a rapid increase and 
subsequent decrease. This suggested that Trb1 protein levels are not directly 
controlled through transcriptional activation, and there is a greater complexity to 
their regulation such as degradative regulation. The fact that protein abundance 
is reduced in such a rapid fashion possibly indicates that Trb1 is not regulated 
through activation such as phosphorylation, as if this were the case one may 
not expect the level of the protein to be so tightly regulated, however, this is not 
always true. Trb1 has previously been shown to be up-regulated during 
inflammation; as previously stated it has been shown to be involved in pro-
inflammatory signalling in adipocytes (Ostertag et al, 2010). Trb1 was also 
shown to be up regulated by the pro-inflammatory stimulus TNF-α, and was 
also shown to be up regulated during chronic antibody-mediated allograft failure 
(Ashton-Chess et al, 2008).  
As with Trb1, Trb3 responded to a pro-inflammatory stimulus, showing an 
increase. The mRNA increase was not significant, however it showed a trend of 
a continuous increase up to 24 hours, suggesting a more prolonged response 
than Trb1. The increase in protein abundance was also more prolonged, 
however the initial response was less rapid. In addition, as with Trb1, the Trb3 
mRNA levels showed a more prolonged response than the protein levels. 
Suggesting that Trb3 protein levels are also not directly controlled through 
transcriptional activation, and there is a greater complexity to their regulation 
such as degradative regulation. Trb3 has previously been suggested to be 
involved in inflammatory signalling, as it has been shown to be involved in the 
survival and activity of mast cells which release pro-inflammatory mediators 
when activated (Ord et al, 2012). This role of Trb3 is thought to be through the 
action of IL-3 which regulates Trb3 mRNA expression. In addition, Trb3 
silencing has also been shown to reduce inflammation in diabetic mice, showing 
a decrease in IL-6 and TNF-α (Ti et al, 2011). These studies along with the 
results above suggest Trb3 may be involved in pro-inflammatory signalling. 
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The regulation of Trb1 and Trb3 through the proteasomal degradation pathway 
was assessed using the proteasome inhibitor MG132. MG132 had no effect on 
Trb1 protein abundance. It is possible that no effect was seen due to full 
inhibition of the proteasomal pathway not being achieved. The level of 
ubiquitinated proteins present during MG132 treatment did not appear to be 
elevated to the extent one would expect from full proteasomal inhibition. 
Alternatively, it is possible that Trb1 protein levels are regulated through a 
different pathway, such as degradation through the lysosomal pathway. 
Trb3 protein abundance was shown to increase with addition of MG132, 
suggesting that it was indeed degraded through the proteasomal pathway in 
HAC, and would suggest that Trb1 and Trb3 may be regulated differently. 
Proteasomal degradation would be a way of tightly regulating Trb3 protein 
levels within the cell. This result would concur with the IL-1+OSM timecourse 
data where mRNA and protein expression did not correlate. This regulation of 
Trb3 through proteasomal degradation has been reported previously, as it has 
been shown that Trb3 interacts with an E3 ubiquitin ligase called SIAH1. SIAH1 
has been shown to cause polyubiquitination of Trb3 and direct it to the 
proteasome for degradation (Zhou et al, 2008). Due to the effect of cytokine 
stimulation on both Trb1 and Trb3 protein abundance, it is possible that 
cytokine stimulation may also have an effect on the proteasomal degradation of 
both Trb1 and Trb3, and should be investigated. 
As mentioned, both Trb1 and Trb3 appeared to be present within the same 
cellular compartments, and in addition to this during IL-1+OSM stimulation they 
both appeared to increase within the cytoplasm. One possible explanation for 
this would be that Trb1 and Trb3 can in fact form a heterodimer within the cell. 
However, the protein complementation assay showed no signs of Trb1 and 
Trb3 interacting together in SW1353 cells. This study was performed in non-
stimulatory conditions, therefore it is possible that they could in fact interact 
during stimulation, which should be investigated. In addition, it is possible that 
they do not interact but co-localise in order to modulate the consequences of 
signalling pathways following inflammatory stimuli. 
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4.4 Synopsis 
 
Both Trb1 and Trb3 appear to be regulated similarly in some respects. They 
have similar localisation within SW1353 cells, and their translocation during pro-
inflammatory stimulation is similar. In addition, they both appear to be up 
regulated under stress conditions and during pro-inflammatory stimulation in 
HAC. This suggests that they both may play a role within arthritic disease; as 
mentioned both cellular stress and inflammation are key characteristics of 
arthritis. They do however vary in the duration of this up regulation, suggesting 
that they may play differing roles. In addition to this, it appears that they are 
down regulated differently, further suggesting that Trb1 and Trb3 may play 
varying roles within the cell. 
 
4.5 Summary 
 
• Both Trb1 and Trb3 appeared to be predominantly nuclear and 
cytoplasmic in SW1353 cells, and IL-1+OSM stimulation led to an 
increase in both Trb1 and Trb3 within the cytoplasm. 
 
• Serum starvation of HAC led to a rapid but transient increase in Trb1 
protein expression, with an increase up to 6 hours, followed by a 
decrease. Trb3 also showed a rapid increase, but had a more prolonged 
increase in protein expression. 
 
• IL-1+OSM stimulation showed a rapid and transient increase in Trb1 
mRNA and protein expression, with protein abundance reducing earlier 
than mRNA expression. Trb3 showed a trend in the increase in mRNA 
expression, which was not significant, and protein abundance showed an 
increase which was less rapid and transient compared to Trb1. 
 
• Proteasomal inhibition by MG132 had no effect on Trb1 but showed an 
increase in Trb3 protein abundance. 
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• Trb1 and Trb3 did not interact in SW1353 cells. 
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Chapter 5: The effect of Trb1 and Trb3 on MMPs and 
transcription factors which regulate these MMPs 
 
5.1 Introduction 
 
MMPs are a group of enzymes which cleave ECM components, and have been 
shown to be important in degrading cartilage ECM (Clark et al, 2008, Rowan et 
al, 2008). MMPs are important in terms of normal development and 
homeostasis (Cawston et al, 2005), but it is when their regulation is not under 
control that excessive ECM degradation occurs and a disease state arises.  
In terms of arthritis, the collagenases are perhaps the most important 
proteinases as they are known to degrade collagen type II, which is a key 
component of cartilage (Rowan et al, 2008), and when degraded cannot be 
replaced (Jubb et al, 1980). MMP-1, MMP-8 and MMP-13 are the most potent in 
this collagenolytic action (Rowan et al, 2008), with MMP-13 being the most 
potent in terms of collagen type II cleavage (Knauper et al, 1996). There is 
therefore a great deal of research underway, in order to understand MMP 
regulation. 
As mentioned, Trb1 and Trb3 are reported to play a role in regulating many 
cellular signalling pathways, such as MAPK (Kiss-Toth et al, 2004), PI3K/Akt 
(Du et al, 2003) and NFκB (Duggan et al, 2010). These pathways are 
considered important in mediating gene expression changes, including MMPs. 
In addition, it has been demonstrated that Trb3 is upregulated in OA (Cravero et 
al, 2009), and that Trb1 and Trb3 are induced during cellular stress (Ostertag et 
al, 2010; Ohoka et al, 2005; Bowers et al, 2003), which is a characterisitic of 
arthritis and MMP production. Trb1 and Trb3 have also been shown to regulate 
transcription factors known to regulate MMPs such as AP-1 (Kiss-Toth et al, 
2004) and C/EBP (Ohoka et al, 2005; Gilby et al, 2010). It is therefore 
hypothesised that Trb1 and Trb3 may work through one or more of the 
pathways discussed, in order to regulate various transcription factors to regulate 
MMPs. It was initially assessed whether Trb1 and Trb3 could indeed regulate 
collagenolytic MMPs within a chondrocytic pro-inflammatory environment, and if 
this was through regulation at the transcriptional level.  
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The aims of this chapter were:- 
 
• Determine whether Trb1 and Trb3 regulate MMP-1 and MMP-13 
expression. 
• Determine whether Trb1 and Trb3 regulate the expression and activation 
of the individual subunits of the transcription factor AP-1; c-Fos and c-
Jun. 
• Determine whether Trb1 and Trb3 regulate the transcription factor ATF3. 
 
5.2 Results 
 
5.2.1 Effect of Trb1 overexpression on MMP-1 and MMP-13 mRNA expression 
during IL-1+OSM stimulation in HAC and SW1353 cells 
 
It was initially assessed whether Trb1 could regulate the collagenases MMP-1 
and -13 within a pro-inflammatory chondrocytic environment. MMP-1 and -13 
were chosen as they are thought to be the major collagenases in OA and RA 
(Tetlow et al, 1998; Billinghurst et al, 1997).  
As demonstrated in Chapter 3, it was not possible to silence Trb1. Trb1 was 
therefore overexpressed in SW1353 cells, and the mRNA expression of MMP-1 
and -13 investigated, following stimulation with the pro-inflammatory stimulus IL-
1+OSM. Trb1 overexpression resulted in a significant decrease in both MMP-1 
and -13 mRNA expression during stimulation with IL-1+OSM (Fig 5.1). 
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Figure 5.1. Trb1 overexpression leads to a reduction in MMP-1 and MMP-13 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells. mRNA expression analysis of MMP-1 (A) and MMP-13 
(B) after transfection with Trb1 overexpression plasmid +/-  IL-1+OSM stimulation of SW1353 cells. Cells 
were transfected with Trb1 overexpression plasmid in 96 well plates (0.04 μg DNA/well) for 48 hours and 
serum-starved overnight before addition of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 6 hours before lysis. Total 
RNA was isolated, reverse transcribed to cDNA and MMP-1 and MMP-13 expression assessed by real-
time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value plotted. 
Results are measured in hextuplicate (+/-standard error of the mean). Results are combined data from 3 
separate experiments, **p<0.01. Ct values for siCon were 13.99 +/- 0.27 for 18S, 29.73 +/- 0.29 for MMP-1 
and 31.03 +/- 0.08 for MMP-13. (+/- = standard error of the mean). 
 
Overexpression of Trb1 in HAC also led to a significant reduction in MMP-13 
mRNA expression during IL-1+OSM stimulation, and the expression was 
reduced to non-stimulated basal levels (Fig 5.2B). However, overexpression of 
Trb1 had no significant effect on MMP-1 expression (Fig 5.2A), unlike in 
SW1353 cells. 
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Figure 5.2. Trb1 overexpression leads to a reduction in MMP-13 mRNA expression but has no effect 
on MMP-1 during IL-1+OSM stimulation in HAC. mRNA expression analysis of MMP-1 (A) and MMP-13 
(B) after transfection with Trb1 overexpression plasmid +/- IL-1+OSM stimulation of HAC. Cells were 
transfected with Trb1 overexpression plasmid in 96 well plates (0.2 μg DNA/well) for 48 hours and serum-
starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 24 hours before lysis. Total 
RNA was isolated, reverse transcribed to cDNA and MMP-1 and MMP-13 expression assessed by real-
time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value plotted. 
Results are measured in hextuplicate, (+/- standard error of the mean). Results are combined data from 3 
separate donors, *p<0.05. Ct values for siCon were 17.48 +/- 0.33 for 18S, 25.49 +/- 0.49 for MMP-1 and 
30.59 +/- 0.37 for MMP-13 (+/- = standard error of the mean). 
 
5.2.2 Effect of Trb1 overexpression on c-fos and c-jun mRNA expression during 
IL-1+OSM stimulation in HAC 
 
Due to the apparent effect of Trb1 on MMP-13 mRNA expression, it was 
investigated whether Trb1 could regulate the AP-1 heterodimer subunits c-fos 
and c-jun. AP-1, as described previously, has been shown to be a major 
transcription factor involved in MMP regulation (Clark et al, 2008). The 
heterodimer of c-Fos and c-Jun has been shown to be the most important 
transcription factor in terms of MMP-1 and -13 regulation (Hu et al 1994, Saez 
et al 1995). In addition Litherland et al, (2010) demonstrated that silencing of c-
fos and c-jun caused a reduction in IL-1+OSM induced MMP-1 and -13 
expression. It has also been shown that Trb1 and Trb3 can regulate AP-1 
transcription factor activation (Kiss-Toth et al, 2004). 
The effect of Trb1 on c-fos and c-jun mRNA expression was not assessed in 
SW1353 cells, as work performed previously within the lab did not detect 
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expression of either of these 2 genes in this cell type, with the methods 
available.  Trb1 overexpression led to a significant reduction in both c-fos and c-
jun mRNA expression during IL-1+OSM stimulation in HAC (Fig 5.3). In 
addition, in non-stimulated conditions Trb1 overexpression showed a trend 
towards a reduction in c-jun expression (p=0.08), however this was not 
significant. 
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Figure 5.3. Trb1 overexpression leads to a reduction in c-fos and c-jun  mRNA expression during 
IL-1+OSM stimulation in HAC. mRNA expression analysis of c-fos (A) and c-jun (B) after transfection 
with Trb1 overexpression plasmid +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb1 
overexpression plasmid in 96 well plates (0.2 μg DNA/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 1 hour before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and c-jun and c-fos expression assessed by real-time RT-PCR. Values were 
normalised to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in 
hextuplicate, (+/- standard error of the mean). Results are combined data from 3 separate donors, 
*p<0.05. Ct values for siCon were 20.68 +/- 0.81 for 18S, 33.53 +/- 1.20 for c-jun and 34.39 +/- 0.68 for c-
fos (+/- = standard error of the mean). 
 
5.2.3 Effect of Trb1 overexpression on ATF3 mRNA expression during IL-
1+OSM stimulation in HAC  
 
In addition to investigating the effect of Trb1 on AP-1, the effect of Trb1 
overexpression on ATF3 mRNA expression was investigated in HAC. ATF are a 
family of transcription factors that have been shown to regulate MMPs (Kwok et 
al, 2009, Melnikova et al, 2007, Fung and Demple, 2007). In addition, it had 
previously been demonstrated within our lab that ATF3 silencing led to a 
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reduction in MMP-13 mRNA expression (Macdonald, 2013). As well as this, 
Trb1 and Trb3 may regulate the ATF pathway, as it was shown that Trb3 can 
regulate ATF4 (Jousse et al, 2007). It was therefore hypothesised that Trb1 
may regulate ATF3 and therefore regulate MMP-13. Trb1 overexpression led to 
a significant reduction in ATF3 mRNA expression in the presence of IL-1+OSM 
stimulation (Fig 5.4). 
 
 
Figure 5.4. Trb1 overexpression leads to a reduction in ATF3 mRNA expression during IL-1+OSM 
stimulation in HAC. mRNA expression analysis of ATF3 after transfection with Trb1 overexpression 
plasmid +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb1 overexpression plasmid in 96 
well plates (0.2 μg DNA/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) 
+ OSM (10 ng/ml) for 80 minutes before lysis. Total RNA was isolated, reverse transcribed to cDNA and 
ATF3 expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S 
rRNA and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). 
Results are combined data from 3 separate donors, *p<0.05. Ct values for siCon were 19.85 +/- 0.75 for 
18S and 36.31 +/- 0.40 for ATF3 (+/- = standard error of the mean). 
 
5.2.4 Effect of Trb3 siRNA gene silencing on MMP-1 and MMP-13 mRNA 
expression during IL-1+OSM stimulation in HAC and SW1353 cells 
 
It was then assessed whether Trb3 could regulate the collagenases MMP-1 and 
-13 within a pro-inflammatory chondrocytic environment. The effect of Trb3 
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silencing on MMP-1 and -13 was initially investigated in SW1353 cells. Trb3 
silencing showed a significant reduction in both MMP-1 and -13 in the presence 
of IL-1+OSM stimulation (Fig 5.5). 
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Figure 5.5. Trb3 gene silencing leads to a reduction in MMP-1 and MMP-13 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells. mRNA expression analysis of MMP-1 (A) and MMP-13 
(B) after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected 
with Trb3 siRNA in 96 well plates (100 nmol/well) for 48 hours and serum-starved overnight before addition 
of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 6 hours before lysis. Total RNA was isolated, reverse transcribed 
to cDNA and MMP-1 and MMP-13 expression assessed by real-time RT-PCR. Values were normalised to 
the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, (+/- 
standard error of the mean). Results are combined data from 2 separate experiments, ***p<0.001. Ct 
values for siCon were 14.39 +/- 0.11 for 18S, 29.20 +/- 0.49 for MMP-1 and 28.47 +/- 0.19 for MMP-13 (+/- 
= standard error of the mean). 
 
Trb3 silencing in HAC led to a significant reduction in MMP-13 mRNA 
expression during IL-1+OSM stimulation (Fig 5.6B). Silencing however, had no 
effect on MMP-1 mRNA expression (Fig 5.6A). This varied from that seen in 
SW1353 cells where both MMP-1 and -13 appeared to be regulated by Trb3. 
This is in concordance with Trb1 which also demonstrated the same cell type 
specific differences.  
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Figure 5.6. Trb3 gene silencing leads to a reduction in MMP-13 mRNA expression but has no effect 
on MMP-1 during IL-1+OSM stimulation in HAC. mRNA expression analysis of MMP-1 (A) and MMP-13 
(B) after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 
siRNA in 96 well plates (100 nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 
(0.05 ng/ml) + OSM (10 ng/ml) for 24 hours before lysis. Total RNA was isolated, reverse transcribed to 
cDNA and MMP-1 and MMP-13 expression assessed by real-time RT-PCR. Values were normalised to the 
housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, (+/-
standard error of the mean). Results are combined data from 3 separate donors, **p<0.01. Ct values for 
siCon were 17.79 +/- 0.05 for 18S, 23.22 +- 0.07 for MMP-1, and 27.25 +/- 0.12 for MMP-13 (+/- = 
standard error of the mean). 
 
5.2.5 Effect of Trb3 overexpression on MMP-1 and MMP-13 mRNA expression 
during IL-1+OSM stimulation in HAC and SW1353 cells 
 
Due to Trb3 silencing appearing to affect MMP mRNA expression, the effect of 
Trb3 overexpression on MMP-1 and -13 mRNA expression was also 
investigated. This was initially studied in SW1353 cells. Overexpression of Trb3 
led to a significant reduction in MMP-13 (Fig 5.7A), but had no effect on MMP-1 
(Fig 5.7B) following IL-1+OSM stimulation. This differed to the observed effects 
of Trb3 silencing, where Trb3 appeared to reduce both MMP-1 and -13 
expression.  
Both silencing and overexpression of Trb3 led to a reduction in MMP-13. This 
would appear to be somewhat counterintuitive, as one would generally expect 
opposing effects for silencing and overexpression. 
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Figure 5.7. Trb3 overexpression leads to a reduction in MMP-13 mRNA expression, but has no 
effect on MMP-1 during IL-1+OSM stimulation in SW1353 cells. mRNA expression analysis of MMP-1 
(A) and MMP-13 (B) after transfection with Trb3 overexpression plasmid +/- IL-1+OSM stimulation of 
SW1353 cells. Cells were transfected with Trb3 overexpression plasmid in 96 well plates (0.04 μg 
DNA/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) 
for 6 hours before lysis. Total RNA was isolated, reverse transcribed to cDNA and MMP-1 and MMP-13 
expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA 
and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). 
Results are combined data from 2 separate experiments, *p<0.05. Ct values for siCon were 13.06 +/- 0.22 
for 18S, 31.59 +/- 0.30 for MMP-1 and 31.65 +/- 0.41 for MMP-13 (+/- = standard error of the mean). 
 
Trb3 overexpression in HAC showed a significant reduction in MMP-13 during 
IL-1+OSM stimulation (Fig 8B), but had no effect on MMP-1 mRNA expression 
(Fig 8A). This result was similar to that seen with Trb3 silencing in HAC, 
whereby Trb3 had no effect on MMP-1 but led to a reduction in MMP-13.  
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Figure 5.8. Trb3 overexpression leads to a reduction in MMP-13 mRNA expression, but has no 
effect on MMP-1 during IL-1+OSM stimulation in HAC. mRNA expression analysis of MMP-1 (A) and 
MMP-13 (B) after transfection with Trb3 overexpression plasmid +/- IL-1+OSM stimulation of HAC. Cells 
were transfected with Trb3 overexpression plasmid in 96 well plates (0.2 μg DNA/well) for 48 hours and 
serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 24 hours before lysis. 
Total RNA was isolated, reverse transcribed to cDNA and MMP-1 and MMP-13 expression assessed by 
real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value 
plotted. Results are measured in hextuplicate, (+/- standard error of the mean). Results are combined data 
from 3 separate donors, *p<0.05. Ct values for siCon were 13 +/- 0.36 for 18S, 31.66 +/- 0.38 for MMP-1 
and 32.57 +/- 0.06 for MMP-13 (+/- = standard error of the mean). 
 
5.2.6 Effect of Trb3 siRNA gene silencing on c-fos and c-jun mRNA expression 
and protein abundance, as well as c-Jun activation during IL-1+OSM stimulation 
in HAC 
 
Due to the observed effect of Trb3 on MMP-13 mRNA expression, it was 
investigated whether Trb3 could regulate the MMP transcription factor AP-1, 
specifically its subunits c-fos and c-jun, the importance of which on MMP 
transcription is described above.  
Trb3 silencing did not appear to have any effect on c-fos or c-jun mRNA 
expression in HAC, either at the basal level, or during IL-1+OSM stimulation 
(Fig 5.9). This suggested that Trb3 does not regulate the AP-1 transcription 
factor at the mRNA level. 
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A                                                        B 
 
Figure 5.9. Trb3 siRNA gene silencing has no effect on c-fos and c-jun mRNA expression during IL-
1+OSM stimulation in HAC. mRNA expression analysis of c-fos (A) and c-jun (B) after transfection with 
Trb3 siRNA +/-  IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 96 well plates 
(100 nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 
ng/ml) for 1 hour before lysis. Total RNA was isolated, reverse transcribed to cDNA and c-fos and c-jun 
expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA 
and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). 
Results are combined data from 3 separate donors. Ct values for siCon were 19.33 +/- 0.07 for 18S, 31.28 
+/- 0.19 for c-jun and 29.87 +/- 0.24 for c-fos (+/- = standard error of the mean). 
 
The effect of Trb3 silencing on c-Fos and c-Jun protein abundance as well as c-
Jun activation was also investigated. It was hypothesised that although Trb3 
silencing did not appear to regulate c-fos and c-jun at the mRNA level it may be 
involved in regulation at the protein level, as has been shown previously for 
Trb1 and Trb3 with other proteins.  
In order to detect c-Fos and c-Jun, nuclear fractions were analysed, as they 
have a relatively low overall abundance within the cell. It was initially 
demonstrated that Trb3 was silenced at the protein level. Trb3 silencing led to a 
reduction in c-Fos protein abundance within the nucleus during IL-1+OSM 
stimulation. In addition, Trb3 silencing also led to a reduction in c-Jun activation 
(Fig 5.10). This suggested that Trb3 regulates the AP-1 transcription factor by 
regulating both c-Fos and c-Jun; c-Fos through its protein abundance within the 
nucleus, and c-Jun through activation by phosphorylation. There was no effect 
on native c-Jun expression during Trb3 silencing, both basally or in the 
presence of IL-1+OSM, c-Jun was therefore used as a loading control. 
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 Figure 5.10. Trb3 siRNA gene silencing regulates both c-Jun and c-Fos at the protein level during 
IL-1+OSM stimulation in HAC. Trb3, c-Fos, p-c-Jun and c-Jun protein abundance after transfection with 
Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 6 cm dishes (100 
nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) 
for 1 hour. Nuclear fractionation was then performed and proteins separated by SDS-PAGE and analysed 
by immunoblotting for the indicated proteins. Results are representative of 3 independent experiments, 
from 3 separate donors. 
 
5.2.7 Effect of Trb3 siRNA gene silencing on ATF3 mRNA expression and 
protein abundance during IL-1+OSM stimulation in HAC 
 
As previously mentioned, it had been demonstrated within the lab that ATF3 
silencing led to a reduction in MMP-13 mRNA expression, but had no effect on 
MMP-1 (Macdondald, 2013), much in the same way that Trb3 silencing in HAC 
was specific for MMP-13. It was therefore thought that Trb3 may regulate ATF3 
in order to regulate MMP-13. Trb3 silencing led to a significant reduction in 
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ATF3 mRNA expression in the presence of IL-1+OSM stimulation in HAC (Fig 
5.11).  
 
Figure 5.11. Trb3 siRNA gene silencing leads to a reduction in ATF3 mRNA expression during IL-
1+OSM stimulation in HAC. mRNA expression analysis of ATF3 after transfection with Trb3 siRNA +/- IL-
1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 96 well plates (100 nmol/well) for 48 
hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 80 minutes 
before lysis. Total RNA was isolated, reverse transcribed to cDNA and ATF3 expression assessed by real-
time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value plotted. 
Results are measured in hextuplicate, (+/- standard error of the mean). Results are combined data from 3 
separate donors, *p<0.05. Ct values for siCon were 19.83 +/- 0.05 for 18S and 34.95 +/- 0.37 for ATF3 (+/- 
= standard error of the mean). 
 
Due to the effect of Trb3 on ATF3 mRNA expression in HAC, the effect of Trb3 
silencing on ATF3 nuclear protein abundance was also investigated. Trb3 
protein expression was successfully silenced. Trb3 silencing showed a 
reduction in ATF3 protein abundance within the nucleus during IL-1+OSM 
stimulation (Fig 5.12). This would correlate with that seen at the mRNA level, 
where Trb3 silencing showed a reduction in ATF3 mRNA expression.  
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 Figure 5.12. Trb3 siRNA gene silencing leads to a reduction in ATF3 nuclear protein abundance 
during IL-1+OSM stimulation in HAC. Trb3, ATF3 and Histone H3 protein abundance after transfection 
with Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 6 cm dishes 
(100 nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 
ng/ml) for 80 minutes. Nuclear fractionation was then performed and proteins separated by SDS-PAGE 
and analysed by immunoblotting for the indicated proteins. Results are representative of 3 independent 
experiments, from 3 separate donors. 
 
5.2.8 Effect of Trb3 overexpression on ATF3 mRNA expression during IL-
1+OSM stimulation in HAC 
 
Due to Trb3 silencing appearing to effect ATF3 mRNA expression, Trb3 was 
also overexpressed and ATF3 mRNA expression investigated in HAC. As with 
Trb3 silencing overexpression of Trb3 also showed a significant reduction in 
ATF3 during IL-1+OSM stimulation (Fig 5.13). This result is in agreement with 
that seen for Trb3 regulation of MMP-13 in HAC, where both silencing and 
overexpression demonstrated a reduction in MMP-13. 
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 Figure 5.13. Trb3 overexpression leads to a reduction in ATF3 mRNA expression during IL-1+OSM 
stimulation in HAC. mRNA expression analysis of ATF3 after transfection with Trb3 overexpression 
plasmid +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 overexpression plasmid in 96 
well plates (0.2 μg DNA/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) 
+ OSM (10 ng/ml) for 80 minutes before lysis. Total RNA was isolated, reverse transcribed to cDNA and 
ATF3 expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S 
rRNA and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). 
Results are combined data from 3 separate donors. *p<0.05. Ct values for siCon were approximately 22 
+/- 0.23 for 18S and 38.1 +/- 0.08 for ATF3 (+/- = standard error of the mean). 
 
5.3 Discussion 
 
MMPs have been shown to be extremely important in terms of cartilage 
degradation. Understanding the proteins and pathways involved in their 
regulation is therefore of great interest. MMP-1 and -13 mRNA expression was 
investigated in both HAC and SW1353 cells, as in some experiments in other 
chapters it was not always possible to investigate the signaling in HAC for 
various reasons. Therefore, it was necessary to establish whether Trb1 and 
Trb3 could indeed regulate these MMPs in both cell types, and also investigate 
the differences between HAC and SW1353 cells in the way in which Trb1 and 
Trb3 regulate MMP-1 and -13 expression. As mentioned previously, it has been 
shown that there are differences in MMP signalling pathways between primary 
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human chondrocytes and SW1353 cells (Borden et al, 1996, Mengshol et al, 
2000). 
Trb1 overexpression led to a reduction in both MMP-1 and -13 mRNA 
expression during IL-1+OSM stimulation in SW1353 cells, however in HAC only 
MMP-13 was affected. This may suggest that in SW1353 cells Trb1 regulates 
pathways which affect both MMP-1 and -13, whereas in HAC Trb1 regulates 
pathways more specific to MMP-13, suggesting cell type specificity. In addition, 
in HAC Trb1 overexpression reduced MMP-13 expression levels down to the 
basal control levels, suggesting that it completely abolished the IL-1+OSM 
stimulatory affect.  
This result, in both cell types, suggests that Trb1 may be involved in anti-
inflammatory pathways which reduce pro-inflammatory stimuli and catabolic 
signaling including MMP expression and cartilage degradation. In agreement 
with this, previous work within our lab has suggested that Trb1 may be involved 
in the IL-4 pathway (Duncan, 2010), which is a known anti-inflammatory 
cytokine pathway that has been shown to inhibit IL-1 signaling (Colotta et al, 
1993). IL-4 has also been shown to reduce OSM induced MMP-13 levels and 
IL-1 stimulated MMP-1 expression (Borghaei et al, 1998). Trb1 may therefore 
work through this pathway in order to reduce MMP expression. However, 
without the ability to silence Trb1 expression this cannot be confirmed. 
Trb1 overexpression also resulted in a reduction in both c-fos and c-jun mRNA 
expression during IL-1+OSM stimulation in HAC. c-Fos and c-Jun are the two 
subunits which form the major AP-1 heterodimer involved in the transcriptional 
regulation of both MMP-1 and -13 (Hu et al 1994, Saez et al 1995). It has 
previously been demonstrated that Trb1 overexpression led to a reduction in 
AP-1 in HeLa cells (Kiss-Toth et al, 2004). However, this study did not state the 
specific AP-1 subunits which Trb1 regulated as regulation was demonstrated 
through an AP-1 luciferase construct. Regulation was only investigated in HAC 
as previous work within our lab could not detect c-fos or c-jun mRNA expression 
in SW1353 cells, highlighting a further difference between HAC and SW1353 
cells in terms of MMP regulation. However, it has been previously demonstrated 
that c-fos and c-jun are expressed in SW1353 cells (Lim et al, 2011). The AP-1 
result is consistent with that seen for the MMP data, suggesting that Trb1 may 
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be anti-inflammatory and protective to cartilage degradation. This may be 
through inhibition of AP-1 which subsequently leads to an inhibition of MMP 
expression. Also, in non-stimulated conditions Trb1 overexpression showed a 
strong trend towards a reduction in c-jun expression. This suggests that Trb1 
may also regulate AP-1 in a non-inflammatory environment, perhaps implying 
that Trb1 may have a greater impact in OA rather than RA, which is more 
inflammation driven. The fact that Trb1 appears to regulate AP-1 would suggest 
it has the ability to regulate both MMP-1 and -13. The difference seen between 
MMP-1 and -13 expression during Trb1 overexpression in HAC may be due to 
additional transcription factors which Trb1 can regulate. It has been shown that 
the effect of AP-1 is abrogated by other transcription factors (Sharrocks et al 
1997, Benbow et al 1997), and the modulation of AP-1 through these various 
transcription factors is only just being elucidated. These specific transcription 
factors may underlie the observation that Trb1 has a greater impact on MMP-13 
than MMP-1.  
ATF3 is one of those transcription factors mentioned which may abrogate AP-1 
transcriptional activation of MMPs. As mentioned, work within our lab had 
shown ATF3 to regulate MMP-13 but not MMP-1. In addition, AP-1 was shown 
to regulate IL-1+OSM mediated ATF3 expression (Macdonald, 2013). It has 
also been previously demonstrated that silencing of ATF3 suppresses MMP-13 
expression (Kwok et al, 2009). ATF3 has also been shown to work 
synergistically with c-jun in order to increase its activity (Pearson et al, 2003). 
Trb1 overexpression showed a reduction in ATF3 mRNA expression during IL-
1+OSM stimulation in HAC. This result would therefore correlate with the 
previous data for both MMP-13 and AP-1 suggesting that Trb1 is anti-
inflammatory, whereby Trb1 can inhibit both AP-1 and ATF3 which leads to an 
inhibition in MMP expression. The effect of Trb1 on the AP-1 subunits c-jun and 
c-fos may subsequently lead to a reduction in ATF3 mRNA expression; 
alternatively Trb1 may act directly on ATF3. 
As with Trb1, the effect of Trb3 on MMPs appeared to be cell type specific, 
differing between HAC and SW1353 cells. Trb3 silencing in SW1353 cells 
showed a reduction in both MMP-1 and -13 mRNA expression, whilst only 
affecting MMP-13 in HAC. This result suggested that Trb3 regulates pathways 
in HAC which ultimately lead to specifically regulating transcription factors 
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involved in MMP-13 expression, whereas in SW1353 cells Trb3 regulates 
pathways which lead to a broader effect on MMP transcription. From these 
results alone one could hypothesise that Trb3 was in fact a pro-inflammatory 
protein, its expression leading to an increase in MMP expression and cartilage 
degradation. However, the Trb3 overexpression data also showed a reduction 
in MMP expression. It is hypothesised that within the cellular environment, for 
normal homeostasis and signalling to occur, a specific level of Trb3 is required 
within the cell. When this level is altered, either increased or decreased, there is 
dysregulation within the pathways, leading to a reduction in signalling. This may 
suggest that Trb3 is acting as a scaffold protein, as both overexpression and 
silencing of scaffolds has been shown to lead to inhibition of signalling 
(Morrison and Davis, 2003). The reason behind this is that low levels of the 
scaffold protein do not allow the proteins within the pathway to combine, and 
high levels could segregate the components of this pathway, preventing them 
interacting with other proteins within a particular pathway.  
In both SW1353 cells and HAC, Trb3 overexpression showed a reduction in 
MMP-13 only. This correlates with the data observed in HAC, as only MMP-13 
was affected, further underlining the notion that Trb3 specifically regulates 
MMP-13 in HAC. However, in SW1353 cells the overexpression and silencing 
data are somewhat at odds, as silencing of Trb3 had an effect on both MMP-1 
and -13. It is possible that the siRNA transfection efficiency was greater than 
that of the overexpression plasmid transfection efficiency. A certain level of 
transfection of Trb3 may be required in SW1353 cells in order to alter MMP-1 
levels, which was not attained during overexpression. As mentioned, the level of 
Trb3 within the cell may be of critical importance to whether signalling occurs or 
is dysregulated, and the level of Trb3 required may differ for different pathways. 
This may suggest that MMP-13 is more responsive to changes in Trb3 than 
MMP-1 in SW1353 cells. 
Trb3 silencing had no effect on c-fos or c-jun mRNA expression, suggesting that 
it was not directly involved in transcriptional regulation of these 2 proteins, 
unlike Trb1. However, Trb3 was shown to regulate both c-Fos protein 
abundance and c-Jun activation, demonstrating that Trb3 was involved in 
pathways that regulate AP-1. Trb3 may increase c-Fos protein abundance 
possibly through binding of c-Fos and stabilising it, although there is no 
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evidence of this within the literature. Alternatively, Trb3 may prevent c-Fos from 
being degraded; Trb3 has been shown to perform this role with other proteins, 
such as the Smad proteins (Park et al 2009). Trb3 may regulate c-Jun 
phosphorylation through regulation of the MAPK pathway, as this has been 
shown to regulate c-Jun phosphorylation (Han et al, 2001, Leppa et al, 1998), 
more of which will be discussed later. These results would be in agreement with 
that seen with the MMP-13 data, that Trb3 silencing caused a dysregulation in 
signalling. This dysregulation led to a reduction in c-Fos protein abundance and 
c-Jun phosphorylation, subsequently leading to a reduction in MMP-13 mRNA 
expression. Kiss-Toth et al. (2004) had previously demonstrated that Trb3 had 
the ability to regulate AP-1, demonstrating that both silencing and 
overexpression of Trb3 led to a reduction in AP-1 luciferase expression. This 
would be consistent with the MMP data, showing both silencing and 
overexpression of Trb3 led to a reduction in MMP-13 expression. 
As mentioned previously, the fact that Trb3 only appears to regulate MMP-13 in 
HAC, but also regulates AP-1; a transcription factor known to regulate both 
MMP-1 and -13, suggests that there is a greater level of complexity occurring in 
regards Trb3 regulation of MMP-13. This additional complexity may be in the 
form of other transcription factors in which Trb3 regulates which can combine 
with AP-1 in order to specifically regulate MMP-13. Therefore, ATF3 was 
investigated as a possible transcription factor that could abrogate AP-1 activity, 
the reason for this being discussed earlier. Both overexpression and silencing of 
Trb3 led to a reduction in ATF3 mRNA expression, which would be in 
agreement with that seen for the regulation of MMP-13 by Trb3. In addition, 
Trb3 silencing was also shown to reduce ATF3 protein abundance, which would 
be expected, as it effects mRNA expression. These results suggest that Trb3 
may regulate both AP-1 and ATF3, which can lead to a specific regulation of 
MMP-13, as discussed for Trb1. It is also possible that Trb3 regulates a number 
of other transcription factors which can abrogate AP-1 activity to specifically 
regulate MMP-13. Further research is therefore required in order to identify if 
other transcription factors are involved, and how they influence this 
transcriptional regulation. 
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5.4 Synopsis 
 
Trb1 and Trb3 appear to regulate MMPs in both SW1353 cells and HAC. This 
regulation may indeed be cell type specific. Within HAC there appeared to be 
regulation of MMP-13 but not MMP-1 for both Trb1 and Trb3, whereas in 
SW1353 cells both Trb1 and Trb3 appeared to regulate both MMP-1 and -13. 
This regulation of MMP-13 within HAC may be through regulation of the 2 
transcription factors AP-1 and ATF3. Both Trb1 and Trb3 appeared to regulate 
these 2 transcription factors. Trb1 and Trb3 both regulated the two AP-1 sub 
units c-Fos and c-Jun. However, this regulation appeared to be different 
between the Trb1 and Trb3 proteins, with Trb1 appearing to regulate AP-1 at 
the transcriptional level, whilst Trb3 appeared to regulate AP-1 at the protein 
level. Both silencing and overexpression of Trb3 had similar effects on the 
signalling pathways, suggesting that a specific level of Trb3 is required for 
signalling, and deviation from this level results in dysregulation of signalling. 
 
5.5 Summary 
 
• Trb1 overexpression led to a reduction in MMP-1 and -13 mRNA 
expression in SW1353 cells but only MMP-13 in HAC. 
 
• Trb1 overexpression led to a reduction in c-fos and c-jun mRNA 
expression in HAC, as well as ATF3. 
 
• Trb3 silencing led to a reduction in MMP-1 and -13 mRNA expression 
in SW1353 cells. Whilst Trb3 overexpression led to a reduction in 
MMP-13 only. 
 
• Trb3 silencing and overexpression led to a reduction in MMP-13 
mRNA expression, but had no effect on MMP-1 in HAC. 
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 • Trb3 silencing had no effect on c-fos or c-jun mRNA expression but 
reduced both c-Fos protein abundance and c-Jun activation in HAC. 
 
• Trb3 silencing and overexpression reduced ATF3 mRNA expression, 
and Trb3 silencing also reduced ATF3 protein abundance. 
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Chapter 6: The effect of Trb1 and Trb3 on the MAP kinase 
pathway 
 
6.1 Introduction 
 
The MAP kinase pathway, consisting of ERK, JNK and p38, plays a role in a 
vast number of cellular pathways, and is critical for cell growth, differentiation 
and survival (Pouyssegur et al, 2003). The MAP kinase pathway has been 
shown to play a major role in arthritic disease. MAPK activation has been 
shown to be increased in arthritis (Schett et al, 2000, Boileau et al, 2006), and it 
is involved in the progression of arthritis in animal models (Pelletier et al, 2003, 
Brown et al, 2008). As well as this, MAPK activation has been shown to be 
enhanced by pro-inflammatory stimuli including IL-1 (Schett et al, 2000), and is 
an important regulator of MMPs, including MMP-1 and -13 (Mengshol et al, 
2000, Han et al, 2001, Raymond et al 2006). In addition, one of the ways in 
which MAPKs are thought to regulate MMPs is through the AP-1 transcription 
factor (Han et al, 2001; Menghsol et al 2001), which as discussed previously is 
an important transcription factor in terms of MMP regulation (Clark et al, 2008). 
Trb1 and Trb3 have previously been shown to regulate expression of a number 
of proteins important in cellular signaling, including TGF-β (Chan, 2010; Chan et 
al 2007), ATF4 (Bowers et al, 2003) and C/EBP-α (Gilby et al, 2010). In 
addition, Trb1 and Trb3 have been previously shown to regulate the MAPK 
pathway (Kiss-Toth et al, 2004), and they have also been shown to bind 
MAP2Ks (Sung et al, 2007, Kiss-Toth et al, 2004). Work in the previous chapter 
demonstrated that both Trb1 and Trb3 have the ability to regulate the AP-1 
transcription factor. It was therefore hypothesised that Trb1 and Trb3 may 
regulate MMPs, and therefore cartilage turnover, through the MAPK pathway. 
 
The aims of this chapter were:- 
 
• Determine what MAP2Ks Trb1 and Trb3 interact with. 
• Investigate the effect of Trb1 and Trb3 on MAPK activation. 
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• Investigate the effect of MAP2K gene depletion and inhibition on Trb1 
and Trb3. 
 
6.2 Results 
 
6.2.1 MAPK activation during IL-1+OSM stimulation in SW1353 cells and HAC 
 
The role of Trb1 and Trb3 in the MAPK pathway were studied in both SW1353 
cells and HAC, as due to certain constraints which will be discussed it was not 
always possible to study this role solely in HAC. Therefore, it was initially 
investigated whether MAPKs had a similar activation profile during IL-1+OSM 
stimulation in both HAC and SW1353 cells, and thus SW1353 cells could be 
treated as a model for HAC in this context.  
The activation profiles for all MAPKs were very similar between HAC and 
SW1353 cells. They become activated by 20 minutes IL-1+OSM stimulation and 
then progressively decrease after this (Fig 6.1). 
 
 
Figure 6.1. MAPK activation during IL-1+OSM stimulation in SW1353 cells and HAC. p-ERK, p-p38, 
p-JNK and GAPDH abundance after stimulation with IL-1+OSM in SW1353 cells and HAC. Cells were 
serum-starved overnight before stimulation with IL-1 (0.5 ng/ml SW1353, 0.05 ng/ml HAC) + OSM (10 
ng/ml) for the indicated time points in 6 well plates. Cells were then lysed and proteins were separated by 
SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are representative of 2 
independent experiments, and from 2 separate donors with regard to HAC.  
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6.2.2 The interaction of Trb1 with MAP2Ks 
 
It was previously demonstrated by Kiss-Toth et al, (2004) that Trb1 had the 
ability to bind to MEK1 and MKK4 in HeLa cells. However, due to the apparent 
cell type specificity of Trb1 and Trb3, it was initially investigated which MAP2Ks 
Trb1 had the ability to bind to in the context of chondrocytes. The interaction of 
Trb1 and MEK1, MKK4, MKK6 and MKK7 was investigated using the protein 
complementation assay, as described previously (see chapter 4). This was 
investigated in SW1353 cells due to the low transfection efficiency of HAC, as 
discussed in chapter 4. 
Microscopic visualisation of fluorescence demonstrated that Trb1 interacted 
with all four of the MAP2Ks tested (MEK1, MKK4, MKK6 and MKK7) (Fig 6.2). 
In addition, depending on the MAP2K which Trb1 interacted with, the pattern of 
staining was different. Trb1-MEK1 demonstrated diffuse staining within the 
nucleus, as well as faint cytoplasmic staining. This was also similar for Trb1-
MKK4. Trb1-MKK6 demonstrated distinct punctate staining within the nucleus, 
whilst Trb1-MKK7 also demonstrated diffuse nuclear staining, but did not 
appear to show any cytoplasmic staining. Transfection efficiency was low; this 
was due to the fact that 2 plasmids were required to enter the cell, as previously 
discussed. 
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 Figure 6.2. Trb1 interacts with MAP2Ks in SW1353 cells. Fluorescent images of MAP2K (V1) and Trb1 
(V2) overexpression constructs in SW1353 cells. Cells were transfected with each construct in 8 well 
chamber slides (0.2 µg per construct) for 48 hours, as detailed in the Materials and Methods, then serum-
starved for 6 hours, fixed and visualised. Results are representative of 2 independent experiments. 
 
6.2.3 The effect of Trb1 overexpression on MAPK activation during IL-1+OSM 
stimulation in SW1353 cells 
 
As it was demonstrated that Trb1 could indeed interact with MAP2Ks in 
SW1353 cells, the effect of Trb1 on the activation of all 3 MAPKs (ERK, JNK 
and p38) in SW1353 cells was investigated. This was performed in SW1353 
cells rather than HAC, as unstimulated basal levels of protein phosphorylation in 
HAC were as high as stimulated levels when overexpression was performed 
with control plasmid, therefore it was not possible to determine if the HAC were 
performing as they should, i.e. increasing in phosphorylation with stimulation. 
Therefore throughout this thesis the effect of Trb1 and Trb3 on protein 
abundance during IL-1+OSM stimulation was only investigated in SW1353 
cells. Trb1 was initially shown to be overexpressed. Trb1 overexpression 
showed a reduction in both p38 and JNK activation, but had no effect on ERK 
activation during IL-1+OSM stimulation (Fig 6.3). 
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 Figure 6.3. Trb1 overexpression regulates MAPK activation during IL-1+OSM stimulation in SW1353 
cells. Trb1, p-ERK, p-p38, p-JNK and GAPDH abundance after transfection with Trb1 overexpression 
plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb1 overexpression 
plasmid in 6 well plates (0.9 µg DNA/well) for 48 hours and serum-starved overnight before stimulation 
with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and proteins separated by 
SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are representative of 3 
independent experiments. 
 
6.2.4 The effect of combined siRNA gene silencing of the MAP2Ks on Trb1 
protein abundance in HAC 
 
Due to the ability of Trb1 to bind to the MAP2Ks and also its apparent effect on 
MAPK activation it was hypothesised that the level of MAP2Ks within the cell 
may influence the levels of Trb1. In addition, it was also demonstrated by Kiss-
Toth et al. (2004) in HeLa cells that interaction of Trb1 with its MAP2K binding 
partners could stabilise Trb1. A combined silencing was performed as individual 
MAP2K silencing had no effect on Trb1 and Trb3 protein abundance (data not 
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shown). MEK1, MKK4, MKK6 and MKK7 were silenced as these were 
previously shown to bind Trb1 in the protein complementation assay (see Fig 
6.2).  
The combined silencing of the MAP2Ks had no effect on Trb1 protein 
abundance in HAC (Fig 6.5). The real time data demonstrated that the MAP2Ks 
were silenced at the mRNA level (Fig 6.4), however it could not be assessed 
whether the MAP2Ks were in fact silenced at the protein level due to poor 
results when immunoblotting chondrocyte lysates. 
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A                                                                 B 
 
C                                                                   D 
 
Figure 6.4. siRNA gene silencing of the MAP2Ks in HAC. mRNA expression analysis of MEK1 (A), 
MKK4 (B), MKK6 (C) and MKK7 (D) after transfection with the corresponding siRNA in HAC. Cells were 
transfected with siRNA in 96 well plates (25 nmol/siRNA/well) for 48 hours and serum-starved overnight 
before lysis. Total RNA was isolated, reverse transcribed to cDNA and MEK1, MKK4, MKK6 and MKK7 
expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA 
and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). 
*p<0.05, **p<0.01, ***p<0.001. Ct values were approximately 18.72 +/- 0.16 for 18S, 32.34 +/- 0.35 for 
MEK1, 42.07 +/- 0.52 for MKK4, 34.74 +/- 0.25 for MKK6, and 37.94 +/- 0.47 for MKK7 (+/- = standard 
error of the mean). 
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 Figure 6.5. The combined silencing of MAP2Ks has no effect on Trb1 protein abundance in HAC. 
Trb1 and GAPDH abundance after transfection with MEK1 MKK4, MKK6 and MKK7 siRNA in HAC. Cells 
were transfected with MEK1 MKK4, MKK6 and MKK7 siRNA in 96 well plates (25 nmol/siRNA/well) for 48 
hours and serum-starved overnight. Cells were then lysed and proteins separated by SDS-PAGE and 
analysed by immunoblotting for the indicated proteins. Results are representative of 4 independent 
experiments, from 4 separate donors. 
 
6.2.5 The interaction of Trb3 with MAP2Ks in SW1353 cells 
 
It had previously been demonstrated by Kiss-Toth et al. (2004) that Trb3 has 
the ability to bind to MEK1 and MKK7 in HeLa cells. Therefore the interaction of 
Trb3 with the four MAP2Ks MEK1, MKK4, MKK6 and MKK7 was assessed in 
SW1353 cells using the protein complementation assay. This was performed in 
SW1353 cells due to the low transfection efficiency of HAC, as discussed in 
chapter 4.  
Microscopic visualisation demonstrated that Trb3 interacted with all four of the 
MAP2Ks tested (MEK1, MKK4, MKK6 and MKK7) (Fig 6.6), as was the case 
with Trb1. In addition, as with Trb1, the staining pattern varied depending on 
which MAP2K Trb3 was bound to. Trb3-MEK1 interaction showed diffuse 
staining within the nucleus, as well as cytoplasmic staining, which was similar to 
Trb1-MEK1. Trb3-MKK4 interaction appeared to vary between cells; in some 
cells there appeared to be punctate staining, in others the staining appeared to 
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be diffuse. Trb3-MKK6 showed discrete punctate staining within the nucleus, as 
was also seen for Trb1-MKK6, as well as faint cytoplasmic staining. Trb3-MKK7 
also showed diffuse nuclear staining similar to Trb1-MKK7. As with Trb1-
MAP2Ks, the transfection efficiency was low. 
 
Figure 6.6. Trb3 interacts with MAP2Ks in SW1353 cells. Fluorescent images of MAP2K (V1) and Trb3 
(V2) overexpression constructs in SW1353 cells. Cells were transfected with each construct in 8 well 
chamber slides (0.2 µg per construct) for 48 hours, as detailed in the Materials and Methods, then serum-
starved for 6 hours, fixed and visualised. Results are representative of 2 independent experiments. 
 
6.2.6 The effect of Trb3 siRNA gene silencing on MAPK activation during IL-
1+OSM stimulation in SW1353 cells and HAC 
 
It has previously been demonstrated that Trb3 can influence MAPK activation in 
HeLa cells, with different levels of Trb3 having differing effects (Kiss-Toth et al, 
2004). In addition, it was shown in Figure 6.6 that Trb3 could interact with 
MAP2Ks. The effect of Trb3 on activation of all three MAPKs was therefore 
investigated. Trb3 was initially silenced, and the effect on MAPK activation 
during IL-1+OSM stimulation was explored in SW1353 cells. It was initially 
demonstrated that Trb3 was silenced at the protein level. Trb3 silencing showed 
a reduction in p38 activation during IL-1+OSM stimulation (Fig 6.7), no change 
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was seen for ERK or JNK activation. In addition Trb3 protein abundance 
appeared to increase with stimulation. 
 
Figure 6.7. Trb3 siRNA gene silencing regulates MAPK activation during IL-1+OSM stimulation in 
SW1353 cells. Trb3, p-ERK, p-p38, p-JNK and GAPDH abundance after transfection with Trb3 siRNA +/- 
IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb3 siRNA in 6 well plates  (100 
nmol/well) for 48 hours and serum-starved overnight before stimulation with IL-1 (0.5 ng/ml) + OSM (10 
ng/ml) for 20 minutes. Cells were then lysed and proteins separated by SDS-PAGE and analysed by 
immunoblotting for the indicated proteins. Results are representative of 3 independent experiments. 
 
The effect of Trb3 silencing on MAPK activation in HAC was also investigated. It 
was initially demonstrated that Trb3 was successfully silenced. Trb3 silencing 
led to a reduction in activation of all 3 MAPKs during IL-1+OSM stimulation (Fig 
6.8). This was unlike that seen in SW1353 cells, whereby only p38 activation 
was affected. 
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 Figure 6.8. Trb3 siRNA gene silencing regulates MAPK activation during IL-1+OSM stimulation in 
HAC. Trb3, p-ERK, p-p38, p-JNK and GAPDH abundance after transfection with Trb3 siRNA +/- IL-
1+OSM stimulation in HAC. Cells were transfected with Trb3 siRNA in 6 well plates (100 nmol/well) for 48 
hours and serum-starved overnight before stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 20 
minutes. Cells were then lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for 
the indicated proteins. Results are representative of 3 independent experiments, from 3 separate donors. 
 
6.2.7 The effect of Trb3 overexpression on MAPK activation during IL-1+OSM 
stimulation in SW1353 cells 
 
Due to the effect of Trb3 silencing on MAPK activation, in both HAC and 
SW1353 cells, Trb3 was overexpressed and MAPK activation observed during 
IL-1+OSM stimulation in SW1353 cells. It was initially demonstrated that Trb3 
was successfully overexpressed at the protein level; this was shown through the 
c-Myc tag on the Trb3 overexpression plasmid. Trb3 overexpression led to a 
reduction in activation in all 3 of the MAPKs during IL-1+OSM stimulation (Fig 
143 
 
6.9). This was in contrast to that observed when Trb3 was silenced in SW1353 
cells, as only p38 activation was affected.  
 
Figure 6.9. Trb3 overexpression regulates MAPK activation during IL-1+OSM stimulation in SW1353 
cells. Trb3, p-ERK, p-p38, p-JNK and GAPDH abundance after transfection with Trb3 overexpression 
plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb3 overexpression 
plasmid (1.2  µg DNA/well) for 48 hours and serum-starved overnight before stimulation with IL-1 (0.5 
ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and proteins separated by SDS-PAGE and 
analysed by immunoblotting for the indicated proteins. Results are representative of 3 independent 
experiments. 
 
6.2.8 The effect of combined siRNA gene silencing of the MAP2Ks on Trb3 
protein abundance in HAC 
 
It has been shown previously that the binding of Trb3 to its MAP2Ks can 
stabilise Trb3 in HeLa cells (Kiss-Toth et al, 2004). In addition to the data above 
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demonstrating the ability of Trb3 to bind to MAP2Ks, and also regulate MAPK 
activation, it was thought that the binding of Trb3 to MAP2Ks may also stabilise 
Trb3 in chondrocytes. The effect of combined silencing of MAP2Ks on Trb3 was 
therefore investigated in HAC. 
MEK1, MKK4, MKK6 and MKK7 were silenced as they were shown to bind Trb3 
in the protein complementation assay (see Fig 6.6). As was discussed for Trb1, 
combined silencing was performed, as individual MAP2K silencing was 
attempted, however, this had no effect on Trb1 and Trb3 protein expression 
(data not shown). 
The combined silencing of the MAP2Ks showed a reduction in Trb3 protein 
abundance (Fig 6.10). However, as discussed previously the real time data 
demonstrated that the MAP2Ks were silenced at the mRNA level (Fig 6.4). 
However, it could not be assessed whether the MAP2Ks were in fact silenced at 
the protein level due to poor results when immunoblotting chondrocyte lysates. 
Therefore, it could not be confirmed whether all of these MAP2Ks were silenced 
at the protein level, and therefore having an effect on Trb3 protein expression. 
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Figure 6.10. The combined silencing of MAP2Ks leads to a reduction in Trb3 protein abundance in 
HAC. Trb3 and GAPDH abundance after transfection with MAP2Ks MEK1, MKK4, MKK6 and MKK7 
siRNA in HAC. Cells were transfected with MAP2Ks MEK1, MKK4, MKK6 and MKK7 siRNA in 6 well 
plates (25 nmol/siRNA/well) for 48 hours and serum-starved overnight. Cells were then lysed and proteins 
separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are 
representative of 4 independent experiments, from 4 separate donors. 
 
6.2.9 The effect of the MEK inhibitor UO126 on Trb3 protein abundance during 
IL-1+OSM stimulation in HAC 
 
Due to MAP2K combined silencing influencing Trb3 protein abundance, the 
impact of inhibiting a specific set of MAP2Ks involved in a specific MAPK 
pathway, namely MEK1 and MEK2 and the ERK pathway was investigated. 
UO126 was used to inhibit the ERK pathway. UO126 exerts its biological effect 
by inhibiting MEK1 and MEK2, thereby inhibiting the ERK pathway (Favata et 
al, 1998).  
UO126 inhibition of the ERK pathway showed a reduction in Trb3 protein 
abundance at all concentratons. Stimulation with IL-1+OSM had no impact on 
this result (Fig 6.11). However, UO126 did not appear to be a specific inhibitor 
for the ERK pathway, inhibiting both p38 and JNK activation, even at low 
concentrations of UO126; however, this was to a lesser extent than ERK 
146 
 
inhibition. This would perhaps suggest that UO126 is affecting the activation of 
a number of MAP2Ks other than MEK1/2. Therefore it cannot be determined 
whether inhibition of a specific MAPK pathway, namely ERK, has an influence 
on Trb3 protein abundance. The conclusion from this result can only be that an 
overall inhibition of the MAPK pathway results in a reduction in Trb3 protein 
abundance. 
 
Figure 6.11. The MEK inhibitor UO126 leads to a reduction in Trb3 protein abundance in HAC. Trb3, 
p-ERK, p-p38, p-JNK and β tubulin abundance after addition of UO126 +/- IL-1+OSM stimulation in HAC. 
Cells were serum-starved overnight before addition of 1µM, 5µM or10µM UO126 for 1 hour before 
stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and proteins 
separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are 
representative of 2 independent experiments, from 2 separate donors. 
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6.3 Discussion 
 
Due to the effect of Trb1 and Trb3 on both AP-1 and ATF3 to regulate MMPs, a 
logical pathway to investigate was the MAP kinase pathway. This pathway is a 
key regulator of MMP-1 and -13 (Mengshol et al, 2000, Han et al, 2001, 
Raymond et al 2006), as well as being a regulator of AP-1 (Han et al, 2001, 
Leppa et al, 1998, Menghsol et al 2001). In addition, the MAPK pathway has 
also been implicated in ATF3 regulation, with p38 (Lu et al, 2007) and JNK 
(Hamdi et al, 2008) shown to regulate ATF3. 
Trb1 was shown to interact with all of the MAP2Ks tested (MEK1, MKK4, MKK6 
and MKK7) in SW1353 cells. This was contrary to previous data in a different 
cell line which demonstrated that Trb1 only interacted with MEK1 and MKK4 
(Kiss-Toth et al, 2004). This discrepancy may simply be due to cell type 
specificity, which is common for Trb1 and Trb3. However, the method of 
analysis of interaction was also different. Kiss-Toth et al. (2004), studied 
interaction by co-immunoprecipitation, whereas the method used here was the 
PCA method, which involved overexpressing both proteins of interest and 
observing their interaction through fluorescence. The PCA method is open to 
false results as overexpression of both proteins produces a somewhat artificial 
physiological environment within the cell, and may cause an interaction which 
may not occur physiologically. Therefore, it is possible that Trb1 has the ability 
to interact with all of these MAP2Ks, but under physiological conditions it 
preferentially binds to specific MAP2Ks, or possibly none. However, the co-
immunoprecipitation method is also open to error, as due to the mechanical and 
chemical stresses that occur through co-immunoprecipitation, proteins that in 
fact do interact physiologically may not co-immunoprecipitate. This may be why 
Trb1 was not shown to interact with the other MAP2Ks in this method. In order 
to help confirm interaction of Trb1 with these MAP2Ks in SW1353 cells, co-
immunoprecipitation could also be used, however as stated, a negative result 
would not necessarily indicate the proteins do not interact physiologically. In 
addition, mutation of amino acid sites known to be involved in interaction, and a 
subsequent lack of interaction, would also help to confirm the result. 
Interestingly, the fluorescent staining pattern varied depending on which 
MAP2K Trb1 interacted with. All showed strong nuclear staining, however some 
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also showed cytoplasmic staining (MEK1 and MKK4), and the nuclear staining 
pattern also differed from diffuse staining (MEK1, MKK4, MKK7) to punctate 
staining (MKK6). This may possibly provide evidence that the interactions which 
are occurring are in fact real, as if this was not the case, one may expect the 
staining pattern to be similar. In addition, this possibly demonstrates that Trb1 
may play individual specific roles for each MAP2K, rather than a common role 
for all of them. The punctate staining for MKK6 would suggest that Trb1:MKK6 
interaction may be occurring within specific organelles within the nucleus. 
Interestingly, as mentioned, all MAP2Ks show strong staining within the 
nucleus. MAP2Ks are not known to be nuclear proteins. This is possibly 
suggesting that as well as their role in MAPK activation, Trb1 may also be 
shuttling MAP2Ks into the nucleus in order to play an additional role within the 
cell, not yet identified. However, higher than normal physiological levels of these 
proteins may cause them to move into the nucleus. This has been 
demonstrated previously, whereby overexpression of NFκB has seen nuclear 
translocation without activation, which would not be expected (Carlotti et al, 
1999) 
Trb1 overexpression demonstrated a reduction in both p38 and JNK activation, 
but no effect on ERK in SW1353 cells. From the PCA results one would expect 
Trb1 to affect p38 activation as MKK6 regulates p38 activation. In addition Trb1 
interacting with MKK4 and MKK7 also supports Trb1 affecting JNK activation, 
as these are the 2 MAP2Ks which regulate JNK. However, ERK is regulated by 
the MAP2Ks MEK1 and MEK2, therefore one may expect Trb1 to also influence 
ERK activation, as it has been shown to bind MEK1. It is possible that MEK1 is 
in fact affected by Trb1 overexpression, but MEK2 is able to compensate for 
this, although it has not been investigated whether Trb1 also interacts with 
MEK2. It was previously demonstrated that Trb1 negatively regulates JNK 
activation, as well as ERK (Sung et al, 2007), however this may be cell type 
specific, and this was also in the context of LPS activation. 
These data would suggest that Trb1 is involved within the anti-inflammatory 
pathway, which had also been suggested by the MMP, AP-1 and ATF3 results. 
Overexpression of Trb1 may lead to a reduction in MAPK activation through 
interaction with MAP2Ks, which reduces both AP-1 and ATF3 expression, 
subsequently leading to a reduction in MMP expression. However, as 
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mentioned, without the ability to silence Trb1 the role of Trb1 cannot be verified, 
particularly in light of the way in which Trb3 appears to function, whereby both 
silencing and overexpression have similar effects. This effect on MAPK 
activation may suggest that Trb1 is binding to the MAP2Ks and inhibiting their 
activity. It is possible that Trb1 may be shuttling the MAP2Ks into the nucleus, 
as suggested by the interaction data, and this may be inhibiting their ability to 
interact with and phosphorylate the MAPKs within the cytoplasm.   
It would appear that the interaction of Trb1 with MAP2Ks does not stabilise 
Trb1, as a combined silencing of the MAP2Ks which Trb1 was shown to interact 
with (MEK1, MKK4, MKK6 and MKK7) showed no effect on Trb1 protein 
expression in HAC. This was based on the assumption that the MAPK 
pathways behave in a similar fashion in both HAC and SW1353 cells, as their 
activation profiles with IL-1+OSM stimulation were similar. This result was 
contradictory to that shown by Kiss-Toth et al. (2004), as they demonstrated 
that interaction of Trb1 with the MAP2Ks MEK1 and MKK4 led to an increase in 
Trb1 protein abundance. This may simply be due to cell type specificity. 
Alternatively, only a small percentage of Trb1 may bind MAP2K in HAC, 
therefore when MAP2KS are silenced this reduction in Trb1 cannot be detected. 
It is also possible in HAC, when MAP2Ks are not present, Trb1 has the ability to 
bind another protein, and become stable, or it simply does not require 
interaction for stability. However, the optimum amount of total siRNA used was 
100 nmol, meaning each MAP2K siRNA was at 25 nmol, rather than the normal 
100 nmol for a single siRNA. Silencing of these individual MAP2Ks may 
therefore not have been at a sufficient level to have an effect, although mRNA 
silencing data for the MAP2Ks showed silencing. Individual silencing of the 
MAP2Ks was also attempted, however no effect was seen. It is thought that this 
could possibly be due to redundancy, as the silencing of a single MAP2K may 
simply allow another MAP2K to bind to Trb1 and therefore stabilise it. 
Overexpression of the MAP2Ks, and analysis of Trb1 protein abundance, which 
was performed by Kiss-Toth et al. (2004), may provide an improved way to 
analyse the ability of MAP2Ks to stabilise Trb1, as redundancy for individual 
MAP2Ks would not be an issue in this case. 
Trb3, as with Trb1, also interacted with all 4 of the MAP2Ks tested (MEK1, 
MKK4, MKK6 and MKK7). This was not consistent with previous work by Kiss-
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Toth et al. (2004), which demonstrated through co-immunoprecipitation that 
Trb3 only interacted with MEK1 and MKK7. The possible reasons for this 
difference are discussed above. In addition, as with Trb1, depending on the 
MAP2K in which Trb3 was interacting with, the pattern of staining was different. 
Interestingly, this staining pattern was very similar for both Trb1 and Trb3. Due 
to the similarities seen within subcellular distribution between Trb1 and Trb3, 
this was not entirely unexpected. Trb3-MKK4 interaction, appeared to vary 
between cells, in some cells there appeared to be punctate staining, in others 
the staining appeared to be diffuse. This variation could possibly be due to the 
cells being in a different state within the cell cycle, although cells were serum 
starved prior to fixation. This ability of Trb1 and Trb3 to bind MAP2Ks within the 
nucleus would also be consistent with the ability of the MAPKs themselves to 
move from the cytoplasm to the nucleus (Sacks, 2006). 
There was a difference in the way in which Trb3 regulated MAPK activation 
between SW1353 cells and HAC. Trb3 silencing in HAC reduced activation of 
all 3 MAPKs, whereas in SW1353 cells only p38 was affected. This suggested 
that there may be cell type specific differences between HAC and SW1353 cells 
in the way in which Trb3 regulates MAPKs. The HAC data would actually be in 
concordance with the MAP2K-Trb3 interaction data in SW1353 cells, as all of 
the MAP2Ks that Trb3 was shown to interact with play a role in one of the 
MAPK pathways (p38 – MKK6, ERK – MEK1, JNK – MKK4/7). As mentioned 
previously, in SW1353 cells it was possible that ERK was not affected due to 
redundancy from MEK2. However, Trb3 was shown to bind both MKK4 and 
MKK7, therefore if this interaction was a true reflection on the effect of Trb3 on 
MAPKs one would expect JNK activation to be affected. This cell type specificity 
for MAPK regulation by Trb3 has been suggested previously by Sung et al. 
(2006), where they demonstrated that Trb3 overexpression had differing effects 
on the JNK-AP-1 pathway depending on the cell type. This cell type specificity 
for the MAPKs may explain the differences seen for Trb3 regulation of MMP-1 
and -13 between HAC and SW1353 cells seen in chapter 5. In addition, in 
SW1353 cells, stimulation appeared to increase Trb3 protein abundance 
suggesting stimulation may perhaps be preventing degradation of Trb3, which 
may be influencing signalling within the nucleus. 
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Trb3 overexpression in SW1353 cells showed a reduction in activation of all 3 
MAPKs. This result would be in agreement with the PCA interaction results, 
however, interestingly, it does not concur with the Trb3 silencing data in 
SW1353 cells. A possible reason for this may be that, as previously mentioned, 
the levels of Trb1 and Trb3 within the cell may be vital in the regulation of 
various pathways, and this may be specific for individual pathways. It is 
therefore possible that the overexpression levels of Trb3 were sufficient to affect 
all 3 MAPK pathways, however silencing of Trb3 was not at a sufficient level to 
influence all 3 MAPK pathways in SW1353 cells. This also suggested that p38 
is more susceptible to changes in Trb3 levels than ERK and JNK in SW1353 
cells. Kiss-Toth et al. (2004) demonstrated a similar occurrence, whereby 
alterations in Trb3 levels had differing effects on the MAPK pathway; low levels 
of Trb3 up-regulated ERK and JNK activation but inhibited p38, whilst higher 
levels inhibited all 3 MAPKs. Taking this reasoning into account, the MAPK data 
would concur with previous data, seen in chapter 5, for MMP-13, and ATF3, 
whereby both overexpression and silencing of Trb3 led to a dysregulation in 
signalling. This may therefore suggest that Trb3 can regulate MAPK activation 
through interaction with MAP2Ks, which can then regulate AP-1 and ATF3, 
which subsequently leads to transcriptional regulation of MMP-13. 
The role that Trb3 plays in MAPK regulation may also be influenced by the 
MAP2Ks themselves. It was demonstrated that the combined silencing of the 
MAP2Ks in which Trb3 was shown to interact with (MEK1, MKK4, MKK6 and 
MKK7) led to a reduction in Trb3 protein abundance. This therefore suggested 
that MAP2Ks can bind Trb3 and influence its protein level. This could possibly 
be through stabilisation of the Trb3 protein, or by preventing Trb3 proteasomal 
degradation. This would be in concordance with that demonstrated by Kiss-Toth 
et al. (2004), which showed that binding of Trb3 to MAP2Ks increased protein 
abundance, which they suggested was through stabilisation. As mentioned, 
individual MAP2K silencing was attempted however no effect was seen possibly 
due to redundancy of other MAP2Ks. 
In addition to the silencing of MAP2Ks, inhibition of MAP2Ks also appeared to 
impact Trb3 protein abundance. The MEK inhibitor UO126 led to a reduction in 
Trb3 protein abundance. Interestingly however, the MEK inhibitor did not 
appear to be specific for MEK, as one would only expect ERK activation to be 
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affected, however both JNK and p38 activation were also affected. This would 
suggest that UO126 may be inhibiting a number of MAP2Ks involved in all 3 
pathways. UO126 inhibits MEK through direct interaction, it is therefore possible 
that in binding and inhibiting these different MAP2Ks, UO126 prevents Trb3 
binding. The prevention of Trb3 binding may affect Trb3 protein abundance 
much in the same way as combined silencing of the MAP2Ks would. In order to 
assess if specific inhibition of the MEK pathway impacts Trb3 protein 
abundance one would require silencing of both MEK1 and MEK2, and the 
protein level assessed. 
Throughout this chapter the effect of Trb1 and Trb3 on the MAPKs was only 
investigated at the phospho level, and total protein abundance of the MAPKs 
was not investigated. Whilst this data indicates that Trb1 and Trb3 affect the 
abundance of the phopsho-MAPKs, it is entirely possible that this is due to Trb1 
and Trb3 affecting the total protein abundance, and should be investigated. 
However, the fact that Trb1 and Trb3 appear to interact with the MAP2Ks may 
suggest that they do influence activation of MAPKs rather than their abundance. 
 
6.4 Synopsis 
 
Both Trb1 and Trb3 bind to MAP2Ks and regulate the activation of MAPKs. 
Trb1 and Trb3 appeared to differ in their ability to regulate the 3 MAPK 
pathways. In addition, they may also be cell type specific, with differences 
between both HAC and SW1335 cells. One commonality from the data between 
Trb1 and Trb3 and both HAC and SW1353 cells was that Trb1 and Trb3 did not 
have a positive effect on MAPK activation. However, Trb1 was not silenced and 
MAPK activation assessed within these experiments. There may be differences 
in the way in which Trb1 and Trb3 are regulated within this pathway, as Trb3 
protein abundance was affected by MAP2K silencing whilst Trb1 was not. 
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6.5 Summary 
 
• The activation profile of the MAPKs during IL-1+OSM stimulation was 
very similar between both HAC and SW1353 cells. 
 
• Both Trb1 and Trb3 interacted with all of the MAP2Ks tested; MEK1, 
MKK4, MKK6 and MKK7 in SW1353 cells. In addition, depending on the 
MAP2K, the fluorescent staining pattern varied. 
 
• Trb1 overexpression led to a reduction in both p38 and JNK activation, 
but did not affect ERK in SW1353 cells. 
 
• Combined silencing of MEK1, MKK4, MKK6 and MKK7 had no effect on 
Trb1 but reduced Trb3 protein abundance in HAC. 
 
• Trb3 silencing led to a reduction in p38 activation but did not affect ERK 
or JNK in SW1353 cells. In HAC, Trb3 silencing reduced the activation of 
all 3 MAPKs. 
 
• Trb3 overexpression led to a reduction in activation of all 3 MAPKs in 
SW1353 cells. 
 
• The non-specific MEK inhibitor UO126 led to a reduction in Trb3 protein 
abundance in HAC. 
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Chapter 7: The effect of Trb1 and Trb3 on other signaling 
pathways known to regulate MMPs 
 
7.1 Introduction 
 
In addition to the MAPK pathways MMP regulation has been shown to involve a 
variety of other signaling pathways. The aim of the following chapter is to 
investigate some of those signaling pathways in relation to their regulation by 
Trb1 and Trb3. 
 
7.1.1 NFκB 
 
NFκB is a major transcription factor influencing many cellular pathways. NFκB is 
important in arthritis as it is a key mediator of pro-inflammatory cytokine 
signaling including IL-1 (Kapoor et al, 2011), which as discussed previously can 
regulate MMP expression (Goldring et al, 1994). In addition, NFκB has also 
been linked with arthritis progression (Takk et al, 2001). One of the roles of 
NFκB in arthritis is to regulate MMPs, as it has been shown to be involved in 
regulation of MMP-1 and -13 (Vincenti and Brinckerhoff 2002, Bondeson et al, 
2000). 
Trb1 and Trb3 have been shown to bind to NFκB through the p65 subunit and 
regulate this transcription factor (Ostertag et al, 2010, Duggan et al, 2010). 
However, this regulation does appear to be cell type specific (Kiss-Toth et al, 
2004). It was therefore hypothesised that Trb1 and Trb3 may regulate MMPs 
through the NFκB pathway in order to regulate cartilage degradation in arthritis. 
 
7.1.2 Akt 
 
The PI3K/Akt pathway plays many central roles in cellular signalling including 
that of cell survival, cell differentiation and cell cycle progression (Fayard et al, 
2005), as well as influencing the MAP kinase pathway (Ren et al, 2010). The 
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PI3K/Akt pathway has been associated with arthritis as it has been shown to be 
activated through pro-inflammatory stimuli involved in arthritis, including OSM 
(Godoy-Tundidor et al, 2005, Kim et al, 2002). In addition, the PI3K/Akt pathway 
has been shown to be involved in cartilage degradation (Hayer et al, 2009), as 
well as regulation of MMP-1 and -13 (Litherland et al, 2008). It has also been 
suggested that the PI3K/Akt pathway may have a protective role in arthritis as it 
has been shown to be involved in the maintenance of chondrocytes (Chrysis et 
al, 2005) and proteoglycan synthesis (Starkman et al, 2005). 
Trb3 has been suggested to be involved in the regulation of the PI3K/Akt 
pathway, as Trb3 has been shown to inhibit this pathway through preventing Akt 
phosphorylation (Du et al, 2003). In addition, it has been suggested that this 
influence of Trb3 on Akt may be a contributing factor to OA progression 
(Cravero et al, 2009), as Trb3 overexpression led to a reduction in Akt 
phosphorylation and an increase in chondrocyte cell death. It has also been 
demonstrated that there is cross talk between the PI3K/Akt and the MAPK 
pathways (Hong et al, 2008), of which Trb1 and Trb3 were shown to regulate in 
chapter 6. It was therefore hypothesised that Trb1 and Trb3 may regulate 
MMPs and cartilage turnover through the PI3K/Akt pathway. 
 
7.1.3 JAK/STAT 
 
The JAK/STAT pathway is a key pathway in many cellular events including 
proliferation, migration and apoptosis (Rawlings et al, 2004). JAKs regulate 
STATs which then cause transcription of a number of genes (Kisseleva et al 
2002, Korzus et al, 1997).  
The JAK/STAT pathway is thought to be important in arthritis, as it has been 
suggested that this pathway contributes to cartilage degradation in vivo 
(Finnegan et al, 2002, Ortmann et al, 2001, Shaw et al, 2003). This pathway 
has also been shown to regulate MMP-1 and -13 expression (Litherland et al, 
2010, Li et al, 2001, Mabrouk et al, 2007).  
It has previously been demonstrated that there is cross talk between the 
JAK/STAT and the MAPK pathways, in which the MAPK pathways can regulate 
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STAT phosphorylation (Rawlings et al, 2004). Due to the apparent ability of 
Trb1 and Trb3 to regulate a number of pathways involved in MMP regulation, as 
well as their ability to regulate the MAPK pathways, it was hypothesised that 
they may also regulate this pathway in order to regulate MMPs and cartilage 
turnover. 
 
The aims of this chapter were to:- 
 
• Determine whether Trb1 and Trb3 interact with the NFκB subunit p65. 
• Investigate the effect of Trb1 and Trb3 on the NFκB pathway. 
• Investigate the effect of Trb1 and Trb3 on Akt activation. 
• Investigate the effect of Trb3 on STAT activation.  
 
7.2 Results 
 
7.2.1 The NFκB pathway 
 
7.2.1.1 The interaction of Trb1 and the NFκB subunit p65 in SW1353 cells 
 
As mentioned, it has previously been demonstrated that Trb1 can bind the p65 
subunit of NFκB in adipocytes (Ostertag et al, 2010). It was therefore initially 
investigated whether Trb1 could interact with the NFκB subunit p65 in SW1353 
cells. SW1353 cells were used rather than HAC due to low transfection 
efficiency in HAC, as discussed previously. This interaction was observed by 
the PCA method detailed in chapter 4. Microscopic analysis demonstrated that 
both Trb1 and p65 interacted (Fig 7.1). This interaction was nuclear, with diffuse 
staining present within the nucleus. There appeared to be no cytoplasmic 
interaction between Trb1 and p65. 
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 Figure 7.1. Trb1 interacts with the NFκB subunit p65. Fluorescent images of p65 (V1) and Trb1 (V2) 
overexpression constructs in SW1353 cells. Cells were transfected with each construct in 8 well chamber 
slides (0.2 µg per construct) for 48 hours, as detailed in the Materials and Methods, then serum-starved for 
6 hours, fixed and visualised. Results are representative of 2 individual experiments. 
 
7.2.1.2 The effect of IKKβ siRNA gene silencing on MMP-1 and MMP-13 
expression during IL-1+OSM stimulation in SW1353 cells 
 
In order to determine whether NFκB regulated MMP-1 and -13 in chondrocytes, 
NFκB was inhibited and the mRNA expression of MMP-1 and -13 was 
observed. NFκB was inhibited through the silencing of IKKβ. As discussed in 
chapter 1, NFκB is inhibited through the binding of IκB. Upon stimulation, IKKβ 
phosphorylates IκB leading to its degradation, after which NFκB is active 
(Roman-Blas and Jimenez, 2006, Chakraborty et al, 2010). Therefore silencing 
of IKKβ will lead to binding of IκB to NFκB and its inhibition. 
SW1353 cells were used as it was not possible to silence IKKβ in HAC; this was 
possibly due to the specific siRNA sequence not being effective in HAC. It was 
initially demonstrated that IKKβ could be silenced (Fig 7.2). IKKβ silencing 
resulted in a reduction in both MMP-1 and -13 mRNA expression during IL-
1+OSM stimulation (Fig 7.3), suggesting that NFκB is involved in the regulation 
of MMP-1 and -13 in SW1353 cells. 
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 Figure 7.2. IKKβ siRNA gene silencing. mRNA expression analysis of IKKβ after transfection with IKKβ 
siRNA of SW1353 cells. Cells were transfected with IKKβ siRNA in 96 well plates (100 nmol/well) for 48 
hours and serum-starved overnight before lysis. Total RNA was isolated, reverse transcribed to cDNA and 
IKKβ expression assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S 
rRNA and the mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean), 
***p<0.001. Ct values for siCon were 15.26 +/- 0.17 for 18S and 26.11 +/- 0.13 for IKKβ. (+/- = standard 
error of the mean). 
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A                                                                            B 
 
Figure 7.3. IKKβ siRNA gene silencing leads to a reduction in MMP-1 and MMP-13 mRNA 
expression during IL-1+OSM stimulation in SW1353 cells.  mRNA expression analysis of MMP-1 (A) 
and MMP-13 (B) after transfection with IKKβ siRNA +/- IL-1+OSM stimulation of SW1353 cells. Cells were 
transfected with IKKβ siRNA in 96 well plates (100 nmol/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 6 hours before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and MMP-1 and MMP-13 expression assessed by real-time RT-PCR. Values 
were normalised to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured 
in hextuplicate, (+/- standard error of the mean). Results are combined data from 2 separate experiments, 
**p<0.01. Ct values for siCon were 15.72 +/- 0.09 for 18S, 25.87 +/- 0.51 for MMP-1 and 28.12 +/- 0.64 for 
MMP-13. (+/- = standard error of the mean). 
 
7.2.1.3 The effect of IKKβ siRNA gene silencing on IL-8 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells 
 
As it was shown that NFκB could regulate MMP-1 and -13, and that Trb1 could 
bind the p65 subunit of NFκB, it was then investigated whether Trb1 could 
regulate NFκB. In order to assess the effect of Trb1 on NFκB activation, IL-8 
was used as a surrogate for NFκB activation, as it had previously been 
demonstrated that NFκB is an important mediator of IL-8 synthesis (Aupperle et 
al, 2001).  
Initially it was confirmed that IL-8 could be used as a surrogate for NFκB 
activation, since IKKβ silencing in SW1353 cells showed a significant reduction 
in IL-8 mRNA expression during IL-1+OSM stimulation (Fig 7.4).  
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 Figure 7.4. IKKβ siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in SW1353 cells. mRNA expression analysis of IL-8 after transfection with IKKβ 
siRNA +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with IKKβ siRNA in 96 well plates 
(100 nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.5 ng/ml) + OSM (10 
ng/ml) for 6 hours before lysis. Total RNA was isolated, reverse transcribed to cDNA and IL-8 expression 
assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the 
mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). Results are 
combined data from 2 separate experiments, **p<0.01. Ct values for siCon were 16.82 +/- 0.34 for 18S 
and 26.84 +/- 0.35 for IL-8 (+/- = standard error of the mean). 
 
7.2.1.4 The effect of Trb1 overexpression on IL-8 mRNA expression during IL-
1+OSM stimulation in SW1353 cells and HAC 
 
The effect of Trb1 overexpression on IL-8 mRNA expression was next 
investigated in SW1353 cells. The overexpression of Trb1 showed a trend 
towards a reduction in IL-8 mRNA expression during IL-1+OSM stimulation, 
however this did not prove to be significant (p = 0.107) (Fig 7.5). 
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 Figure 7.5. Trb1 overexpression shows a trend towards a reduction in IL-8 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells. mRNA expression analysis of IL-8 after transfection with 
Trb1 overexpression plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb1 
overexpression plasmid in 96 well plates (0.04 μg DNA/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 6 hours before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and IL-8 expression assessed by real-time RT-PCR. Values were normalised 
to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, 
(+/- standard error of the mean). Results are combined data from 2 separate experiments. Ct values were 
19.53 +/- 0.21 for 18S and 28.11 +/- 0.56 for IL-8. (+/- = standard error of the mean). 
 
The effect of Trb1 overexpression on IL-8 mRNA expression was also 
investigated in HAC.  As in SW1353 cells, the overexpression of Trb1 showed a 
trend towards a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation, however this was not significant (p= 0.076) (Fig 7.6).  
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 Figure 7.6. Trb1 overexpression shows a trend towards a reduction in IL-8 mRNA expression 
during IL-1+OSM stimulation in HAC. mRNA expression analysis of IL-8 after transfection with Trb1 
overexpression plasmid +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb1 
overexpression plasmid in 96 well plates (0.2 μg DNA/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 24 hours before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and IL-8 expression assessed by real-time RT-PCR. Values were normalised 
to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, 
(+/- standard error of the mean). Results are combined data from 3 separate donors. Ct values for siCon 
were 23.62 +/- 0.38 for 18S and 36.48 +/- 0.57 for IL-8 (+/- = standard error of the mean). 
 
7.2.1.5 The effect of Trb1 overexpression on p65 protein abundance and 
activation during IL-1+OSM stimulation in SW1353 cells  
 
Due to the trend towards Trb1 affecting the NFκB surrogate IL-8, and the ability 
of Trb1 to interact with p65, the effect of Trb1 overexpression on p65 protein 
abundance and also its activation was investigated in SW1353 cells. It was first 
demonstrated that Trb1 was successfully overexpressed. Trb1 overexpression 
led to a reduction in p65 protein abundance and a reduction in p65 activation 
during IL-1+OSM stimulation (Fig 7.7). This correlated with the data showing 
the effect of Trb1 overexpression on IL-8 mRNA expression, which showed a 
reduction in IL-8. Trb1 overexpression had no effect on p65 protein abundance 
under basal conditions. 
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 Figure 7.7. Trb1 overexpression leads to a reduction in p65 protein abundance and p65 activation 
during IL-1+OSM stimulation in SW1353 cells. Trb1, p65, p-p65 and GAPDH abundance after 
transfection with Trb1 overexpression plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were 
transfected with Trb1 overexpression plasmid in 6 well plates (0.9 µg DNA/well) for 48 hours and serum-
starved overnight before stimulation with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 1 hour. Cells were then 
lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. 
Results are representative of 4 independent experiments. 
 
7.2.1.6 The interaction of Trb3 and the NFκB subunit p65 in SW1353 cells 
 
It was initially assessed whether Trb3 could interact with the NFκB subunit p65 
in SW1353 cells. As mentioned, it has previously been demonstrated that Trb3 
has the ability to interact with p65 and regulate NFκB signalling (Duggan et al, 
2010), and this may be somewhat cell type specific (Kiss-Toth et al, 2004). 
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Fluorescence microscopy demonstrated that Trb3 interacted with p65, with a 
diffuse staining pattern solely within the nucleus (Fig 7.8), as seen with Trb1 
and p65. 
 
Figure 7.8. Trb3 interacts with the NFκB subunit p65 in SW1353 cells. Fluorescent images of p65 (V1) 
and Trb3 (V2) overexpression constructs in SW1353 cells. Cells were transfected with each construct in 8 
well chamber slides (0.2 µg per construct) for 48 hours, as detailed in the materials and methods, then 
serum-starved for 6 hours, fixed and visualised. Results are representative of 2 independent experiments. 
 
7.2.1.7 The effect of Trb3 siRNA gene silencing on IL-8 mRNA expression 
during IL-1+OSM stimulation in SW1353 cells and HAC 
 
As it was demonstrated that Trb3 could bind to p65, it was then investigated 
whether Trb3 could regulate the NFκB surrogate IL-8.  
Trb3 silencing showed a significant reduction in IL-8 mRNA expression during 
IL-1+OSM stimulation in SW1353 cells (Fig 7.9). 
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 Figure 7.9. Trb3 siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in SW1353 cells. mRNA expression analysis of IL-8 after transfection with Trb3 
siRNA +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb3 siRNA in 96 well plates 
(100 nmol/well) for 48 hours and serum-starved overnight before addition of IL-1 (0.5 ng/ml) + OSM (10 
ng/ml) for 6 hours before lysis. Total RNA was isolated, reverse transcribed to cDNA and IL-8 expression 
assessed by real-time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the 
mean value plotted. Results are measured in hextuplicate, (+/- standard error of the mean). Results are 
combined data from 2 separate experiments, ***p<0.001. Ct values for siCon were 13.51 +/- 0.17 for 18S 
and 28.36 +/- 0.34 for IL-8. (+/- = standard error of the mean). 
 
The effect of Trb3 silencing on IL-8 mRNA expression was also investigated in 
HAC. Trb3 silencing led to a significant reduction in IL-8 mRNA expression 
during IL-1+OSM stimulation (Fig 7.10), as seen in SW1353 cells. 
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 Figure 7.10. Trb3 siRNA gene silencing leads to a reduction in IL-8 mRNA expression during IL-
1+OSM stimulation in HAC. mRNA expression analysis of IL-8 after transfection with Trb3 siRNA +/- IL-
1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 96 well plates (100 nmol/well) for 48 
hours and serum-starved overnight before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 24 hours 
before lysis. Total RNA was isolated, reverse transcribed to cDNA and IL-8 expression assessed by real-
time RT-PCR. Values were normalised to the housekeeping gene 18S rRNA and the mean value plotted. 
Results are measured in hextuplicate, (+/- standard error of the mean). Results are combined data from 4 
separate donors, ***p<0.001. Ct values for siCon were 20.68 +/- 0.23 for 18S and 28.63 +/- 0.45 for IL-8  
(+/- = standard error of the mean). 
 
7.2.1.8 The effect of Trb3 overexpression on IL-8 mRNA expression during IL-
1+OSM stimulation in SW1353 cells and HAC 
 
As Trb3 silencing appeared to have an impact on IL-8 mRNA expression, Trb3 
was also overexpressed in order to see its effect on IL-8; this was initially 
performed in SW1353 cells. Trb3 overexpression led to a significant reduction in 
IL-8 mRNA expression during IL-1+OSM stimulation (Fig 7.11). Both 
overexpression and silencing therefore resulted in a reduction in IL-8 
expression in SW1353 cells. 
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 Figure 7.11. Trb3 overexpression leads to a reduction in IL-8 mRNA expression during IL-1+OSM 
stimulation in SW1353 cells. mRNA expression analysis of IL-8 after transfection with Trb3 
overexpression plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb3 
overexpression plasmid in 96 well plates (0.04 μg DNA/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 6 hours before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and IL-8 expression assessed by real-time RT-PCR. Values were normalised 
to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, 
(+/- standard error of the mean). Results are combined data from 3 separate experiments, *p<0.05. Ct 
values for siCon were 13.59 +/- 0.18 for 18S and 25.90 +/- 0.88 for IL-8 (+/- = standard error of the mean). 
 
Trb3 was also overexpressed in HAC and IL-8 mRNA expression investigated. 
Trb3 overexpression showed a trend towards a reduction in IL-8 mRNA 
expression during IL-1+OSM stimulation (Fig 7.12), however, this result was not 
significant (p=0.098). Both overexpression and silencing therefore suggest a 
trend towards a reduction in IL-8 in HAC.  
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 Figure 7.12. Trb3 overexpression shows a trend towards a reduction in IL-8 mRNA expression 
during IL-1+OSM stimulation in HAC. mRNA expression analysis of IL-8 after transfection with Trb3 
overexpression plasmid +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 
overexpression plasmid in 96 well plates (0.2 μg DNA/well) for 48 hours and serum-starved overnight 
before addition of IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 24 hours before lysis. Total RNA was isolated, 
reverse transcribed to cDNA and IL-8 expression assessed by real-time RT-PCR. Values were normalised 
to the housekeeping gene 18S rRNA and the mean value plotted. Results are measured in hextuplicate, 
(+/- standard error of the mean). Results are combined data from 3 separate donors. Ct values for siCon 
were 24.44 +/- 0.35 for 18S and 36.73 +/- 1.18 for IL-8 (+/- = standard error of the mean). 
 
7.2.1.9 The effect of Trb3 siRNA gene silencing on p65 protein abundance and 
activation during IL-1+OSM stimulation in SW1353 cells and HAC 
 
Due to the effect of Trb3 silencing and overexpression on IL-8 mRNA 
expression, and the ability of Trb3 to interact with p65, Trb3 was silenced and 
the protein abundance of p65 as well as its activation was analysed in SW1353 
cells. The silencing of Trb3 protein expression was initially demonstrated. Trb3 
silencing showed a reduction in p65 protein abundance, as well as activation 
during IL-1+OSM stimulation (Fig 7.13). This would concur with that seen for IL-
8, where Trb3 silencing led to a reduction in IL-8 mRNA expression. Trb3 
silencing had no effect on p65 protein abundance under basal conditions. 
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 Figure 7.13. Trb3 siRNA gene silencing leads to a reduction in p65 protein abundance and p65 
activation during IL-1+OSM stimulation in SW1353 cells. Trb3, p65, p-p65 and GAPDH abundance 
after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with 
Trb3 siRNA in 96 well plates (100 nmol/well) for 48 hours and serum-starved overnight before stimulation 
with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 1 hour. Cells were then lysed and proteins separated by SDS-
PAGE and analysed by immunoblotting for the indicated proteins. Results are representative of 3 
independent experiments. 
 
The effect of Trb3 silencing on p65 protein abundance and activation was also 
investigated in HAC. The silencing of Trb3 protein expression was initially 
established. As in SW1353 cells, Trb3 silencing showed a reduction in p65 
protein abundance and activation during IL-1+OSM stimulation (Fig 7.14). This 
also correlated with the IL-8 data in HAC, where Trb3 silencing showed a 
reduction in IL-8 mRNA expression. As in SW1353 cells, Trb3 silencing had no 
effect on p65 protein abundance under basal conditions. 
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 Figure 7.14. Trb3 siRNA gene silencing leads to a reduction in p65 protein abundance and p65 
activation during IL-1+OSM stimulation in HAC. Trb3, p65, p-p65 and GAPDH abundance after 
transfection with Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were transfected with Trb3 siRNA in 
6 well plates (100 nmol/well) for 48 hours and serum-starved overnight before stimulation with IL-1 (0.05 
ng/ml) + OSM (10 ng/ml) for 1 hour. Cells were then lysed and proteins separated by SDS-PAGE and 
analysed by immunoblotting for the indicated proteins. Results are representative of 3 independent 
experiments, from 3 separate donors. 
 
7.2.1.10 The effect of Trb3 overexpression on p65 protein abundance and 
activation during IL-1+OSM stimulation in SW1353 cells 
 
Due to the effect of Trb3 silencing on p65, Trb3 was overexpressed and the 
effect on p65 protein abundance and p65 activation investigated in SW1353 
cells. It was initially demonstrated that Trb3 was overexpressed through its c-
Myc tag. As was observed with Trb3 silencing, overexpression of Trb3 led to a 
reduction in p65 protein abundance as well as activation during IL-1+OSM 
stimulation (Fig 7.15). This is consistent with the IL-8 data, where both silencing 
and overexpression of Trb3 showed a reduction in IL-8 mRNA expression. As 
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shown with Trb3 silencing, Trb3 overexpression had no effect on p65 protein 
abundance under basal conditions.  
 
Figure 7.15. Trb3 overexpression leads to a reduction in p65 protein abundance and p65 activation 
during IL-1+OSM stimulation in SW1353 cells. Trb3, c-Myc, p65, p-p65 and GAPDH abundance after 
transfection with Trb3 overexpression plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were 
transfected with Trb3 overexpression plasmid in 6 well plates (1.2 µg DNA/well) for 48 hours and serum-
starved overnight before stimulation with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 1 hour. Cells were then 
lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. 
Results are representative of 2 independent experiments. 
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7.2.2 Akt 
 
7.2.2.1 The effect of Trb1 overexpression on Akt activation during IL-1+OSM 
stimulation in SW1353 cells 
 
It was initially investigated whether Trb1 regulated Akt activation through 
phosphorylation in SW1353 cells. It was firstly established that Trb1 protein was 
overexpressed. Trb1 overexpression had no effect on Akt activation both under 
basal conditions and during IL-1+OSM stimulation (Fig 7.16). 
 
Figure 7.16. Trb1 overexpression does not affect Akt activation during IL-1+OSM stimulation in 
SW1353 cells. Trb1, p-Akt, and GAPDH abundance after transfection with Trb1 overexpression plasmid 
+/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb1 overexpression plasmid in 6 
well plates (0.9 µg DNA/well) for 48 hours and serum-starved overnight before stimulation with IL-1 (0.5 
ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and proteins separated by SDS-PAGE and 
analysed by immunoblotting for the indicated proteins. Results are representative of 3 independent 
experiments. 
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7.2.2.2 The effect of Trb3 siRNA gene silencing on Akt activation during IL-
1+OSM stimulation in SW1353 cells and HAC 
 
The effect of Trb3 silencing on Akt activation was also assessed; this was 
initially performed in SW1353 cells. It was firstly shown that Trb3 was silenced. 
Trb3 silencing led to an increase in Akt activation basally, however, there was 
no effect with IL-1+OSM stimulation (Fig 7.17).  
 
Figure 7.17. Trb3 siRNA gene silencing leads to an increase in Akt activation in SW1353 cells. Trb3, 
p-Akt, and GAPDH abundance after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of SW1353 
cells. Cells were transfected with Trb3 siRNA in 6 well plates (100 nmol/well) for 48 hours and serum-
starved overnight before stimulation with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then 
lysed and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. 
Results are representative of 3 independent experiments. 
 
The effect of Trb3 silencing on Akt activation was also assessed in HAC. It was 
initially established that Trb3 was silenced. The silencing of Trb3 had no effect 
on Akt activation either under basal conditions or during IL-1+OSM stimulation 
(Fig 7.18). 
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 Figure 7.18. Trb3 siRNA gene silencing has no effect on Akt activation in HAC. Trb3, p-Akt, and 
GAPDH abundance after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were 
transfected with Trb3 siRNA in 6 well plates (100 nmol/well) for 48 hours and serum-starved overnight 
before stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and 
proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are 
representative of 4 independent experiments, from 4 separate donors. 
 
7.2.2.3 The effect of Trb3 overexpression on Akt activation during IL-1+OSM 
stimulation in SW1353 cells 
 
Due to Trb3 silencing in SW1353 cells having an effect on Akt activation, Trb3 
was also overexpressed and the effect on Akt activation investigated in 
SW1353 cells. It was initially shown that Trb3 was overexpressed, 
demonstrated through the c-Myc tag. Trb3 overexpression led to a decrease in 
Akt activation during IL-1+OSM stimulation (Fig 7.19).  
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 Figure 7.19. Trb3 overexpression leads to a decrease in Akt activation during IL-1+OSM stimulation 
in SW1353 cells. Trb3, c-Myc, p-Akt and GAPDH abundance after transfection with Trb3 overexpression 
plasmid +/- IL-1+OSM stimulation of SW1353 cells. Cells were transfected with Trb3 overexpression 
plasmid in 6 well plates (1.2 µg DNA/well) for 48 hours and serum-starved overnight before stimulation 
with IL-1 (0.5 ng/ml) + OSM (10 ng/ml) for 20 minutes. Cells were then lysed and proteins separated by 
SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results are representative of 3 
independent experiments. 
 
7.2.3 JAK/STAT 
 
7.2.3.1 The effect of Trb3 siRNA gene silencing on STAT activation during IL-
1+OSM stimulation in HAC 
 
The effect of Trb3 silencing on STAT activation was investigated in HAC. IL-
1+OSM stimulation was performed at both 20 minutes and 60 minutes in order 
to investigate the effect of Trb3 on both STAT serine and STAT tyrosine 
phosphorylation. Both phosphorylation sites were investigated, as both sites 
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have been shown to be involved in MMP regulation (Zugowski et al, 2001; 
Litherland et al, 2010). It was initially determined that Trb3 was successfully 
silenced. Trb3 silencing led to a reduction in STAT1 serine phosphorylation at 
both 20 and 60 minutes of IL-1+OSM stimulation (Fig 7.20). No effect was seen 
on either STAT3 serine, STAT1 tyrosine or STAT3 tyrosine phosphorylation 
during Trb3 silencing. 
 
Figure 7.20. Trb3 siRNA gene silencing leads to a reduction in STAT1 serine activation during IL-
1+OSM stimulation in HAC. Trb3, p-STAT1 ser, p-STAT3 ser, p-STAT1 tyr, p-STAT3 tyr and GAPDH 
abundance after transfection with Trb3 siRNA +/- IL-1+OSM stimulation of HAC. Cells were transfected 
with Trb3 siRNA in 6 well plates (100 nmol/well) for 48 hours and serum-starved overnight before 
stimulation with IL-1 (0.05 ng/ml) + OSM (10 ng/ml) for 20 minutes and 60 minutes. Cells were then lysed 
and proteins separated by SDS-PAGE and analysed by immunoblotting for the indicated proteins. Results 
are representative of 3 independent experiments, from 3 separate donors.  
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7.3 Discussion 
 
7.3.1 NFκB 
 
NFκB has been shown to have the ability to regulate MMP-1 and -13. This has 
been demonstrated in the literature (Vincenti and Brinckerhoff, 2002, Mengshol 
et al, 2000), and also within this study. NFκB has also been shown to cooperate 
with AP-1 in order to regulate MMPs (Barchowsky et al, 2000). In addition, 
NFκB has been shown to cooperate with ATF3 (however this is as a co-
repressor rather than activator) (Liu et al, 2011), as well as regulating ATF3 
expression (Jack et al, 2006). Therefore, along with the MAPK pathway, NFκB 
may be important in the ability of Trb1 and Trb3 to regulate MMPs.  
Trb1 was shown to bind to the NFκB subunit p65 in SW1353 cells. This has 
previously been demonstrated in other cell types (Ostertag et al, 2010). The 
fluorescent staining pattern of this interaction was entirely nuclear. This possibly 
suggests that Trb1 may be involved in regulating the transcriptional activity of 
NFκB, as NFκB remains in the cytoplasm when inactive whilst post-activation it 
subsequently translocates to the nucleus where it is transcriptionally active 
(Roman-Blas and Jimenez, 2006, Chakraborty et al, 2010). This however may 
be an anomaly, as the PCA method involves overexpression of the proteins of 
interest, and it has previously been demonstrated that overexpression of NFκB 
can lead to its translocation to the nucleus without activation (Carlotti et al, 
1999). 
As mentioned, in order to study the effect of Trb1 and Trb3 on NFκB, IL-8 was 
used as a surrogate for NFκB activation. IL-8 was used as NFκB has been 
shown to be important in the mediation of IL-8 synthesis (Aupperle et al, 2001). 
This was further demonstrated through the silencing of IKKβ, which led to a 
reduction in NFκB activation, and demonstrated a significant reduction in IL-8 
mRNA expression. However, although NFκB appears to be the key regulator of 
IL-8, it has also been shown that JNK can regulate IL-8 expression 
independently of NFκB (Krause et al, 1998), and also to a lesser extent, p38 
has been shown to regulate IL-8 induction (Suzuki et al, 2000). Therefore, these 
results cannot be solely accepted to be an effect on NFκB without further 
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verification, especially as it was shown in chapter 6 that Trb1 and Trb3 have the 
ability to regulate the MAPK pathway. 
As had been suggested previously, it appeared that Trb1 may act in an anti-
inflammatory fashion within this pathway. Overexpression of Trb1 both in 
SW1353 cells and HAC showed a trend towards a reduction in IL-8 mRNA 
expression during pro-inflammatory IL-1+OSM stimulation. However, this was 
not significant. To support this anti-inflammatory effect of Trb1 on NFκB, 
suggested by the IL-8 data, Trb1 overexpression led to a reduction in p65 
protein abundance and p65 activation in SW1353 cells. This is in contrast to 
that shown by Ostertag et al. (2010), who demonstrated that Trb1 was pro-
inflammatory and a co-activator of NFκB transcriptional activity. This may be 
due to cell type specificity of Trb1. Trb1 only had an effect on p65 protein 
abundance during IL-1+OSM stimulation, suggesting that its anti-inflammatory 
action only occurs during this pro-inflammatory stimulation, and in a resting 
state Trb1 does not affect p65 expression. Due to the ability of Trb1 to bind p65 
in the absence of stimulation, one may have expected it to also affect p65 
protein abundance under basal conditions. Without the ability to silence Trb1, its 
anti-inflammatory affects cannot be confirmed, especially in light of the Trb3 
results on NFκB (discussed below), and other pathways. It is unknown whether 
Trb1 is exerting its effect on p65 at the transcriptional level or at the protein 
level. However, the fact that Trb1 binds p65 could suggest that Trb1 is exerting 
its effect at the protein level by affecting factors such as protein stability or 
degradation.  
Trb3 was also able to interact with p65 in SW1353 cells. This had previously 
been demonstrated in a different cell type (Duggan et al, 2010). The staining 
pattern was similar to that for Trb1, suggesting that Trb3 may also influence 
NFκB transcriptional activity. 
Using IL-8 as a surrogate for NFκB activation (discussed previously), the results 
suggested that Trb3 regulates NFκB in a similar way to MMP-13, ATF3 and 
MAPKs, in that both silencing and overexpression lead to a reduction in IL-8 
mRNA expression; this was consistent for both HAC and SW1353 cells. In 
addition, both silencing and overexpression of Trb3 in SW1353 cells, as well as 
silencing of Trb3 in HAC led to a reduction in p65 protein abundance and p65 
179 
 
activation, which would also concur with previous data, as well as confirming 
the IL-8 data. This may suggest that the level of Trb3 within the cell is critical for 
NFκB regulation, and deviation from a specific level leads to a dysregulation of 
signalling. As with Trb1, Trb3 only had an effect on p65 protein abundance 
during IL-1+OSM stimulation, suggesting that its effect on NFκB only occurs 
during this pro-inflammatory stimulation, and in a resting state Trb3 does not 
affect p65 abundance. In order to further investigate the effect of Trb1 and 3 on 
NFκB activation their effect on IκB-α abundance should be investigated, this 
would allow activation to be more thoroughly studied. As discussed previously, 
in order for NFκB activation to occur IκB is phosphorylated and degraded 
through the proteasome. 
These results suggest that Trb3 in both SW1353 cells and HAC regulates NFκB 
in a similar manner. In addition, these results lend credence to the fact that 
NFκB may be one of the transcription factors, along with AP-1 and ATF3, in 
which Trb3 regulates in order to regulate MMP-13 expression. 
 
7.3.1.1 Synopsis 
 
Both Trb1 and Trb3 have the ability to regulate NFκB, and this may be through 
interaction with the p65 subunit. Trb1 and Trb3 may regulate NFκB in a similar 
manner, whereby an alteration in Trb1 and Trb3 levels leads to a dysregulation 
in signalling. However, due to the inability to silence Trb1 this cannot be 
established. It may therefore be the case that Trb1 is anti-inflammatory and 
simply negatively regulates NFκB.  
 
7.3.2 Akt 
 
In terms of Trb1 and Trb3 regulation of signalling pathways, the PI3K/Akt 
pathway has been studied the most prolifically. This is in part due to the role in 
which this pathway plays in diabetes, and the negative way in which Trb3, in 
particular, regulates this pathway through prevention of Akt phosphorylation (Du 
et al, 2003). The dysregulation of this pathway by Trb3 has been suggested by 
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Cravero et al. (2009), to be important in chondrocyte survival, proteoglycan 
production, and therefore OA. With this in mind, and the ability of this pathway 
to regulate MMP-1 and -13 (Litherland et al, 2008), and cooperate with the 
MAPK pathway (Yart et al, 2009), the PI3K/Akt pathway may be an important 
mediator of Trb1 and Trb3 regulation of MMPs. 
Trb1 overexpression did not appear to have any effect on Akt activation in 
SW1353 cells. It has not been previously shown that Trb1 has any effect on Akt 
activation, only Trb2 and Trb3 have been shown to play a role in Akt activation 
(Du et al, 2003, Cravero et al 2009); this therefore concurred with previous 
literature. The PI3K/Akt pathway is regulated by OSM (Godoy-Tundidor et al, 
2005) perhaps more than the other pathways investigated so far. In addition, it 
has been shown previously that PI3K and Akt inhibition led to a reduction in 
OSM induced MMP-13 expression (Mabrouk et al, 2007). This result may 
therefore suggest that Trb1 is more important in regulating IL-1 mediated 
pathways, rather than those stimulated by OSM. In order to investigate this 
more thoroughly, the effect of Trb1 overexpression on signalling pathways in 
the presence of separate stimulations of IL-1 and OSM would be required. 
Trb3 appeared to negatively regulate Akt activation in SW1353 cells. Trb3 
silencing showed an increase in Akt activation under basal condition, whilst 
overexpression of Trb3 showed a reduction in Akt activation during IL-1+OSM 
stimulation. This concurred with what has previously been shown in the 
literature, where Trb3 is known to prevent Akt phosphorylation (Du et al, 2003, 
Cravero et al 2009). IL-1+OSM stimulation had no effect on Akt activation 
during Trb3 silencing; the level of phosphorylated Akt was the same both under 
basal conditions or with IL-1+OSM stimulation. This possibly suggested that 
optimal activation had been reached during stimulation, and therefore silencing 
of Trb3 could not enhance phosphorylation anymore, however under basal 
conditions this was not the case. The effect of Trb3 on Akt appeared to be cell 
type specific, as in HAC Trb3 silencing had no effect on Akt phosphorylation. 
This result was contradictory to that seen by Cravero et al. (2009), which stated 
that Trb3 overexpression led to a reduction in Akt phosphorylation in 
chondrocytes. However, Akt phosphorylation was investigated on Threonine 
308 in the Cravero paper, whilst in this study Akt phosphorylation on Serine 473 
was investigated, which may account for the difference. Nevertheless, it is 
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generally thought that the Serine 473 phosphorylation site is more important for 
full Akt activation (Martelli et al, 2010). 
 
7.3.2.1 Synopsis 
 
The regulation of Akt activation by Trb3 appeared to be cell type specific. Trb3 
appeared to negatively regulate Akt activation in SW1353 cells; however, it had 
no effect in HAC. Trb1 did not appear to regulate Akt activation when 
investigated in SW1353 cells. 
 
7.3.3 JAK/STAT 
 
The JAK/STAT pathway has been shown to be an important regulator of MMPs, 
and this has been reported to occur through the AP-1 subunit c-Fos (Litherland 
et al, 2010). As well as this, it has been suggested that the JAK/STAT pathway 
may work in conjunction with AP-1 to enhance MMP expression (Korzus et al, 
1997). Previous work in chapter 5 demonstrated that Trb3 appeared to regulate 
c-Fos protein abundance. The JAK/STAT pathway was therefore investigated. 
Trb3 silencing demonstrated a reduction in STAT1 serine phosphorylation 
during IL-1+OSM stimulation. Trb3 silencing had no effect on either STAT3 
serine, STAT1 tyrosine or STAT3 tyrosine phosphorylation, suggesting that 
Trb3 was specific for STAT1 serine. Whether this specificity was through JAK 
dependent phosphorylation or through another pathway remains to be 
elucidated. Trb3 may therefore regulate MMP-13 expression through regulation 
of STAT1 activation. 
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7.3.3.1 Synopsis 
 
Trb3 appeared to regulate the JAK/STAT pathway in HAC. This occurred 
through the serine phosphorylation of STAT1, and it appeared to be specific to 
this phosphorylation site.  
 
7.4 Summary 
 
• Trb1 and Trb3 interact with the NFκB subunit p65. 
 
• Trb1 overexpression showed a trend towards a reduction in IL-8 mRNA 
expression in HAC and SW1353 cells, as well as a reduction in p65 
protein abundance and activation in SW1353 cells. 
 
• Both silencing and overexpression of Trb3 led to a reduction in IL-8 
mRNA expression in HAC and SW1353 cells, as well as leading to a 
reduction in p65 protein abundance and p65 activation in SW1353 cells. 
 
• Trb3 silencing also led to a reduction in p65 protein abundance and 
activation in HAC. 
 
• Trb1 overexpression had no effect on Akt activation in SW1353 cells. 
 
• Trb3 silencing led to an increase in Akt activation in SW1353 cells but 
had no effect in HAC. Overexpression of Trb3 led to a decrease in Akt 
activation in SW1353 cells. 
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• Trb3 silencing led to a reduction in STAT1 serine phosphorylation, but 
had no effect on STAT1 tyrosine, STAT3 serine or STAT3 tyrosine 
phosphorylation in HAC. 
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Chapter 8: General Discussion 
 
Trb1-3 are a group of 3 proteins which have been shown to play a role in a 
number of cellular pathways, and are involved in a number of diseases. Trb1-3 
have previously been shown to play a role in a number of signalling pathways 
which are known to regulate MMPs including the MAPK pathway (Kiss-Toth et 
al, 2004), TGF-β/Smad pathway (Chan, 2010) and the PI3K/Akt pathway (Du et 
al, 2003). They have also been shown to regulate a number of transcription 
factors known to be involved in MMP regulation such as AP-1 (Kiss Toth et al, 
2004; Eder et al, 2008), ATF (Bowers et al, 2003) and NFκB (Duggan et al, 
2010; Ostertag et al, 2010). Trb3 has been implicated in OA and chondrocyte 
death (Cravero et al, 2009). Trb3 has also been shown to be up regulated in 
stress conditions such as ER stress and hypoxia (Ohoka et al, 2005; Bowers et 
al, 2003), which have been implicated in arthritis (Yudoh et al, 2005; Takada et 
al, 2011). 
Due to the ability of Trb1 and Trb3 to regulate signalling pathways and 
transcription factors involved in the regulation of the two major collagenases 
implicated in arthritis, MMP-1 and -13, as well as evidence of Trb3 being 
involved in arthritis, it was hypothesised that Trb1 and Trb3 proteins may 
regulate MMP-1 and -13 in order to regulate cartilage degradation in arthritis. 
The role of Trb1 and Trb3 in arthritis was studied in two cell types both primary 
Human Articular Chondrocytes (HAC), and the SW1353 human 
chondrosarcoma cell line. Ideally all experiments would have been performed in 
HAC, however, due to certain constraints such as cell availability and 
transfection efficiency, SW1353 cells were used as a model of HAC. Trb2 was 
not assessed within this thesis as previous work within the lab demonstrated 
that Trb2 did not regulate MMP-1 and -13 expression (Duncan, 2010).  
Throughout this thesis the effect of Trb1 on the various signalling pathways 
could only be assessed through its overexpression, as Trb1 could not be 
effectively and specifically silenced. Trb1 silencing was attempted through 
siRNA and shRNA, both of which proved unsuccessful or non-specific. The 
reason for this unsuccessful silencing was unknown, however, it was 
hypothesised that it was possibly due to Trb1 mRNA having a very short half-life 
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of less than 1 hour (Sharova et al, 2009). This would prevent silencing of Trb1, 
as any of the mRNA that was being silenced would quickly be degraded, and 
new functional mRNA synthesised before an effect could be seen. This would 
correlate with the fact that Trb3 has been shown to have a longer half-life and 
was successfully silenced.  
Pro-inflammatory cytokines have been shown to play a major role in both OA 
and in particular RA. They mediate signalling pathways, including those 
mentioned above, which lead to cartilage degradation. There are many 
cytokines involved in this with a major one being IL-1 (Feldman et al, 1996; 
Scott et al, 2010; McInnes and Schett, 2007; Goldring et al, 1994). OSM a 
member of the IL-6 family has also been shown to have a role in arthritis 
(Plater-Zyberk et al, 2001). IL-1 and OSM have been shown to work 
synergistically in terms of cartilage degradation and MMP expression (Cawston 
et al, 1995; Cawston et al, 1998; Rowan et al 2003; Fearon et al, 2006), 
therefore this is a potent cytokine stimulus. This stimulus was therefore used 
throughout this thesis in order to mimic a pro-inflammatory environment in vitro. 
As well as these cytokines being able to regulate various signalling pathways, it 
was demonstrated within this thesis that IL-1+OSM stimulation also regulates 
Trb1 and Trb3, leading to an increase in Trb1 and Trb3 at both the mRNA and 
protein level in HAC. In addition, IL-1+OSM stimulation led to an increase in 
both Trb1 and Trb3 protein abundance within the cytoplasm in SW1353 cells. 
This suggested that Trb1 and Trb3 were responsive to pro-inflammatory stimuli 
and may therefore play a role in modulating the response of these signalling 
cascades during arthritis. Both Trb1 and Trb3 were also responsive to stress 
conditions, demonstrating an up-regulation in protein abundance during serum 
starvation in HAC. Both Trb1 (Ostertag et al, 2010) and, as mentioned 
previously, Trb3 (Ohoka et al, 2005; Bowers et al, 2003) have been shown to be 
responsive to cellular stress, which is a feature of arthritis (Yudoh et al, 2005; 
Takada et al, 2011). 
It was initially assessed whether Trb1 and Trb3 had the ability to regulate MMP-
1 and -13 during pro-inflammatory stimulation with IL-1 and OSM. The ability of 
Trb1 and Trb3 to regulate these two MMPs appeared to be somewhat cell type 
specific, with Trb1 overexpression and Trb3 silencing leading to a reduction in 
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both MMP-1 and -13 in SW1353 cells, but only affecting MMP-13 in HAC. This 
is not surprising as Trb1 and Trb3 have often been shown to be cell type 
specific (Hegedus et al, 2006; Kiss-Toth et al, 2004; Duggan et al, 2010), and it 
has previously been shown that there are differences in MMP signalling 
pathways between primary human chondrocytes and SW1353 cells (Borden et 
al, 1996, Mengshol et al, 2000). These results, however, suggested that Trb1 
and Trb3 may be somewhat specific for MMP-13 in HAC. Trb3 overexpression 
also led to a reduction in MMP-13. This was somewhat unexpected as one 
would expect overexpression and silencing to have opposing effects. It is 
therefore hypothesised that within the cellular environment, for normal 
homeostasis and signalling to occur, a specific level of Trb3 is required within 
the cell. When this level is altered, either increased or decreased, there is 
dysregulation within the pathways, leading to a reduction in signalling.  
In order to regulate MMP-13 expression in HAC both Trb1 and Trb3 regulate 
the MMP transcription factor AP-1. Trb1 overexpression showed a reduction in 
mRNA expression of both AP-1 subunits c-fos and c-jun, whilst Trb3 silencing 
had no effect on the mRNA expression but showed a decrease in c-Fos nuclear 
protein abundance and c-Jun activation. Although both Trb1 and Trb3 appeared 
to regulate AP-1, the above result suggests the way in which they regulate AP-1 
may be different. Both Trb1 and Trb3 were also shown to regulate the MMP 
transcription factor ATF3. Trb1 overexpression showed a reduction in ATF3 
mRNA expression whilst both silencing and overexpression of Trb3 led to a 
reduction in ATF3 mRNA expression, as well as silencing showing a reduction 
in ATF3 nuclear protein abundance. AP-1 is not specific for MMP-13 (Litherland 
et al, 2010), therefore this specificity of MMP-13 regulation by Trb1 and Trb3 
may come from the ATF3 transcription factor, as work in our lab demonstrated 
that ATF3 silencing led to a reduction in MMP-13 mRNA expression, but had no 
effect on MMP-1 (Macdonald, 2013). Further evidence for this is the fact that 
both overexpression and silencing of Trb3 led to a reduction in ATF3, much in 
the same way Trb3 affects MMP-13. 
It was hypothesised that Trb1 and Trb3 may regulate AP-1, which subsequently 
regulates ATF3; these two transcription factors may combine to regulate MMP-
13, as it has been previously demonstrated that c-Jun can induce ATF3 
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expression (Mei et al, 2008). In addition, work within our lab demonstrated that 
IL-1+OSM-induced ATF3 is AP-1-dependent (Macdonald, 2013).  
It was unknown how Trb1 and Trb3 may be regulating AP-1 and through which 
pathways. The MAPK pathway was investigated, as this has previously been 
shown to be important in MMP regulation (Han et al, 2001; Raymond et al 2006; 
Mengshol et al 2000), and one way in which they regulate MMPs is through the 
AP-1 transcription factor (Minden et al, 1997; Leppa et al, 1998; Han et al, 
2001). In addition, the MAPK pathways have also been implicated in ATF3 
regulation (Lu et al, 2007; Hamdi et al, 2008). Both Trb1 and Trb3 were shown 
to regulate the MAPK pathways, with Trb1 overexpression leading to a 
reduction in both p38 and JNK activation in SW1353 cells. Trb3 appeared to 
once again demonstrate cell type specificity, with silencing of Trb3 showing a 
reduction in the activation of all 3 MAPK pathways in HAC, but only affecting 
p38 in SW1353 cells. However, interestingly, overexpression of Trb3 in 
SW1353 cells did reduce activation of all 3 MAPK pathways. This perhaps 
suggests that Trb3 does have the ability to regulate all of the MAPKs in 
SW1353 cells, as it does in HAC. This is further supported by the fact that the 3 
MAPK pathways have very similar activation profiles during IL-1+OSM 
stimulation in both HAC and SW1353 cells, suggesting they may be regulated in 
a similar manner. A possible reason why Trb3 silencing does not reduce the 
activation of all 3 MAPK pathways in SW1353 cells may be due to the fact that, 
as discussed, the level of Trb3 within the cell may be important. Trb3 silencing 
may produce a particular level of Trb3 that does not inhibit JNK or ERK 
activation, but does affect p38 in SW1353 cells. This has been previously 
demonstrated by Kiss-Toth et al. (2004), whereby alterations in Trb3 levels had 
differing effects on the MAPK pathway. This result may suggest that p38 is 
more responsive to changes in Trb3 levels than JNK or ERK in SW1353 cells.  
Trb1 and Trb3 may regulate MAPK activation through the binding of MAP2Ks, 
as it was demonstrated that both Trb1 and Trb3 have the ability to bind MEK1, 
MKK4, MKK6 and MKK7 in SW1353 cells. Collectively these MAP2Ks are 
involved in all 3 MAPK pathways, further supporting the hypothesis that Trb1 
and Trb3 have the ability to regulate all 3 MAPK pathways. The reason why 
Trb1 was not seen to regulate ERK was unknown, however, as suggested with 
Trb3, the level of Trb1 may be critical in its ability to regulate pathways. In 
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addition, the ERK pathway is also regulated by the MAP2K MEK2, therefore 
there may be redundancy whereby ERK is regulated through MEK2, although it 
is possible that Trb1 may also bind MEK2. These were the only MAP2Ks tested, 
therefore Trb1 and Trb3 may have the ability to bind all of the MAP2Ks. It is 
possible that the binding of Trb3 to the MAP2Ks stabilises Trb3, as combined 
silencing of MEK1, MKK4, MKK6 and MKK7 showed a reduction in Trb3 protein 
abundance. This has been demonstrated previously by Kiss-Toth et al, (2004), 
who showed binding of Trb1 and Trb3 to the MAP2Ks increased their protein 
levels. Further to this, inhibition of MAPK activation through MAP2K inhibition 
also showed a reduction in Trb3 protein levels. Interestingly however, this was 
not the case for Trb1, which was not affected by MAP2K silencing or inhibition 
of MAP2Ks (data not shown), suggesting Trb1 and Trb3 may be regulated in 
different ways. This was further demonstrated by the fact that Trb3 appears to 
be degraded through the proteasome, as demonstrated by addition of the 
proteasome inhibitor MG132, whereas Trb1 does not. 
Trb1 and Trb3 may also regulate AP-1, in particular the subunit c-Fos, through 
the JAK/STAT pathway. Trb3 silencing was shown to reduce STAT1 activation, 
and the JAK/STAT pathway has been shown to regulate c-Fos (Litherland et al, 
2010). STATs have also been shown to regulate MMPs directly through binding 
to their promoters (Zugowski et al, 2011), which may be another way in which 
Trb1 and Trb3 regulates MMP expression. The regulation of this particular 
pathway by Trb1 and Trb3 has not been previously discussed within the 
literature. 
In addition to their ability to regulate the AP-1 and ATF3 transcription factors in 
order to regulate MMP expression it was investigated whether Trb1 and Trb3 
could also regulate NFκB. Trb1 and Trb3 have previously been shown to 
regulate NFκB (Duggan et al, 2010; Ostertag et al, 2010). The NFκB 
transcription factor has been shown to be important in arthritis, acting as a key 
mediator of pro-inflammatory pathways (Kapoor et al, 2011), as well as being 
associated with MMP expression (Vincenti and Brinckerhoff, 2002). The MAPK 
pathway has also been shown to be an important regulator of NFκB 
(Mukkherjee and Sikka, 2006; Larsen et al 2005), it was therefore hypothesised 
that through their role in MAPK activation Trb1 and Trb3 may regulate NFκB. 
The role of Trb1 and Trb3 in regulating NFκB appeared to be similar to the way 
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in which they regulate other pathways discussed. Trb1 overexpression showed 
a trend towards a reduction in the NFκB surrogate IL-8 in HAC and SW1353 
cells, as well as showing a reduction in p65 protein abundance and activation in 
SW1353 cells. Whilst Trb3 silencing and overexpression in SW1353 cells and 
HAC showed a reduction in IL-8 (overexpression was not significant in HAC but 
showed a strong trend), as well as a reduction in p65 protein abundance and 
activation (overexpression data only shown in SW1353 cells). This result for 
Trb3 further supports the hypothesis that it is the level of Trb3 within the cell 
that is critical for correct signalling to occur, and divergence above or below a 
certain level leads to a dysregulation in signalling. Trb1 and Trb3 may also 
regulate NFκB through direct interaction with the transcription factor, as both 
Trb1 and Trb3 were shown to interact with the NFκB subunit p65. This 
interaction was solely isolated to the nucleus, possibly suggesting that Trb1 and 
Trb3 may play a role in regulating the transcriptional ability of NFκB.  
It is interesting however that the effect of Trb3 on Akt activation did not show 
both overexpression and silencing reducing Akt activation, as has been seen 
with other pathways. Trb3 acted solely as a negative regulator of Akt activation 
in SW1353 cells, with silencing of Trb3 increasing Akt activation and 
overexpression reducing it. This was not surprising in the sense that Trb3 is 
known to negatively regulate Akt activation (Du et al, 2003), and this has been 
proposed to be an important factor in insulin signalling and diabetes (Liu et al, 
2010). In addition, this regulation of Akt by Trb3 has been suggested to play a 
role in OA development and chondrocyte cell death (Cravero et al, 2009). Again 
Trb3 showed cell type specificity, as it did not appear to affect Akt activation in 
HAC, but did in SW1353 cells. This result would therefore contradict the 
Cravero data, however Akt phosphorylation was only investigated on serine 473 
within this thesis, whilst the phosphorylation of threonine 308 was investigated 
in the Cravero paper, which may account for the difference. Unlike many of the 
other pathways discussed, in which Trb1 and Trb3 have both been shown to 
regulate, the Akt pathway did not appear to be one of them, as Trb1 
overexpression did not have an effect on Akt phosphorylation in SW1353 cells. 
Throughout this thesis the effect of Trb1 and Trb3 on various signalling 
pathways has been investigated in both SW1353 cells and HAC. As mentioned 
previously, SW1353 cells are used as a model for HAC, though there are 
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limitations. It has previously been demonstrated that within the presence of IL-
1β SW1353 cells have reduced expression levels of anabolic genes compared 
to chondrocytes. However, in terms of catabolic genes they more closely 
resemble one another, in particular MMP-1 and -13, as well as NFκB and IL-6, 
which would positively reflect the use of SW1353 cells within this study 
(Gebauer et al, 2005).  
Within this thesis, there have been differences seen between SW1353 cells and 
HAC in terms of the ability of Trb1 and Trb3 to regulate signalling pathways. 
Perhaps the most striking difference being between the regulation of Akt by 
Trb3, which showed no effect in HAC, whereas Akt was negatively regulated in 
SW1353 cells. It is possible that the other differences seen between HAC and 
SW1353 cells in relation to the other pathways studied may be due to the levels 
of Trb1 and Trb3 required to influence the various pathways which differ 
between HAC and SW1353 cells, as overexpression and silencing appeared to 
have differing effects, as in the case for MAPK and MMP regulation. It would 
appear however that tribbles may be more specific for MMP-13 than MMP-1 in 
HAC, whilst in SW1353 cells they may regulate both MMP-1 and -13. However, 
overall in terms of the way that Trb1 and Trb3 regulate the signalling pathways 
investigated there appears to be many similarities between HAC and SW1353 
cells. 
This thesis has demonstrated the ability of Trb1 and Trb3 to regulate a number 
of different signalling pathways within a pro-inflammatory disease context. It 
was shown that Trb1 and Trb3 through regulation of these signalling pathways 
can regulate transcription factors important in MMP regulation, and as such 
regulate MMPs, suggesting their ability to regulate cartilage degradation. The 
ability of Trb1 and Trb3 to regulate MMPs, and how they regulate MMPs has 
not been previously investigated. There were however limitations to this thesis; 
it was not possible to silence Trb1, therefore the true nature of Trb1 regulation 
could not be investigated. This may be important in light of the way in which 
Trb3 can regulate many pathways with both silencing and overexpression 
having similar effects. In addition, SW1353 cells were used for some 
experiments due to certain constraints, and as discussed above, these cells do 
not always perfectly mimic HAC. 
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Throughout this thesis the Trb1 results would suggest that it is anti-inflammatory 
and has the ability to down regulate MMP expression. It is hypothesised that 
this is through interaction with MAP2Ks, leading to an inhibition of MAPK 
activation, which inhibits the MMP transcription factor AP-1 subunits c-fos and 
c-jun mRNA expression, as well as ATF3 and NFκB (Fig 8.1). It is possible that 
these transcription factors cooperate together in order to regulate MMP 
expression, but may also work independently. The regulation of ATF3 by Trb1 
may be through its regulation of AP-1. In addition, Trb1 may regulate NFκB 
directly through interaction with p65. The anti-inflammatory ability of Trb1 would 
be in agreement with previous work within our lab that suggested that Trb1 may 
be involved in the IL-4 pathway (Duncan, 2010). This pathway is a known anti-
inflammatory cytokine pathway that has been shown to reduce both MMP-1 and 
-13 levels (Borghaei et al, 1998). Trb1 may work through this pathway in order 
to reduce MMP expression. It is therefore postulated that overexpression of 
Trb1 within an in vivo model of arthritis may be protective. However, as 
mentioned previously, Trb1 could not be silenced, therefore without the ability to 
silence Trb1 expression its anti-inflammatory capability cannot be confirmed. 
The role of Trb3 in regulating many of the pathways discussed appears to be 
more complex than simply up regulating or down regulating signalling. In many 
instances both overexpression and silencing of Trb3 led to a down regulation of 
signalling. As mentioned, the levels of Trb3 within the cell may be critical, and 
the level of Trb3 required may vary for different pathways, as some pathways 
may be more responsive than others. This may suggest that Trb3 is acting as a 
scaffold protein, as both overexpression and silencing of scaffolds has been 
shown to lead to inhibition of signalling (Morrison and Davis, 2003). As 
discussed previously, the reason behind this is that low levels of the scaffold 
protein do not allow the proteins within the pathway to combine, and high levels 
could segregate the components of this pathway, preventing them interacting 
with other proteins within a particular pathway. It is therefore hypothesised that 
Trb3 through the binding of MAP2Ks has the ability to regulate MAPK 
activation, which can regulate the MMP transcription factors AP-1, ATF3 and 
NFκB, which then leads to the regulation of MMP-13 and cartilage degradation 
(Fig 8.1). Trb3 may also regulate NFκB directly by binding to its p65 subunit. 
Trb3 could also regulate MMP expression through an alternative pathway, as it 
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has been shown to regulate the JAK/STAT pathway, which can subsequently 
regulate MMP-13 expression. Regulation of MMP expression by this pathway 
may be through regulation of AP-1, or by direct transcriptional regulation. It is 
also possible there is cross talk between these 2 pathways. It is therefore 
theorised that both silencing and overexpression of Trb3 in an in vivo model of 
arthritis would lead to protection.  
A recent study performed within this lab investigated the effect of Trb3 on 
cartilage degradation in vivo. Trb3 was silenced in a DMM mouse model. Trb3 
silencing demonstrated reduced MMP-13 expression, as well as protection to 
cartilage degradation. This study therefore compliments the in vitro Trb3 data 
seen within this thesis. 
 
 
Figure 8.1. The hypothetical pathway of Trb1 and Trb3 regulation of MMP-13 in HAC. Trb; Tribbles, 
MAP2K; Mitogen activated protein kinase kinase, IL-8; Interleukin-8, MAPK; Mitogen activated protein 
kinase, p; phosphorylation, NFκB; Nuclear factor κ B, AP-1; Activating protein-1, ATF3; Activating 
transcription factor, MMP-13; Matrix metalloproteinase-13, STAT; Signal transducers and activators of 
transcription. 
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The results within this thesis demonstrate that both Trb1 and Trb3 have the 
ability to regulate a number of important pathways involved in MMP regulation 
in chondrocytes, within a pro-inflammatory context, and they appear to regulate 
many of the same pathways. It is possible that they have opposing roles within 
this context with Trb1 being anti-inflammatory and Trb3 being pro-inflammatory. 
This knowledge of how Trb1 and Trb3 may be involved in signalling pathways 
which regulate MMP expression and therefore cartilage degradation may help in 
future treatments for arthritis.  
 
8.1 Summary of possible future studies 
 
• Investigate the effect of Trb1 and Trb3 on other transcription factors 
known to regulate MMPs, in particular MMP-13, such as RUNX2 and 
C/EBP-α. 
 
• Silence individual MAPK pathways using combinations of specific 
MAP2K siRNAs in order to decipher if specific MAPK pathways effect 
Trb1 and Trb3 expression. 
 
• Investigate the effect of Trb1 and Trb3 on MAP2K mRNA expression and 
protein abundance. 
 
• Investigate the effect of Trb1 and Trb3 to regulate the signalling 
pathways discussed in the presence of other cytokine stimuli such as 
TNF-α, in order to investigate whether Trb1 and Trb3 regulate signalling 
pathways through other cytokine pathways. 
 
• Determine the role which Trb1 and Trb3 play within the individual IL-1 
and OSM pathways, by stimulating separately and investigating the 
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effects on the pathways discussed, this may be relevant in pathways 
such as Akt and JAK/STAT, which have been shown to be regulated 
through the OSM pathway. 
 
 
• Co-immunoprecipitation for Trb1 and Trb3 with the MAP2Ks and NFκB, 
in order to verify their interaction. 
 
• Mutation of Trb1 and Trb3 binding sites and protein complementation 
assay with MAP2K and NFκB in order to verify their interaction. 
 
• Investigate the effect of IL-1+OSM stimulation on Trb1 and Trb3 
interaction, as well as the interaction of Trb1 and Trb3 with the MAP2Ks 
and NFκB. Including real-time observation of these interactions and 
cellular localisation with and without stimulation. This will allow 
investigation of Trb1 and Trb3 interactions within a pro-inflammatroy 
context, which may differ compared to basal conditions. This will also be 
more relevant in terms of an arthritic context. 
 
 
• Investigate the effect of IL-1+OSM stimulation on Trb1 and Trb3 
proteasomal degradation through treatment with MG132. 
 
 
• Immunofluorescence in order to verify the cellular distribution of Trb1 and 
Trb3. 
 
 
• Investigate the effect of Trb1 and Trb3 on the other major collagenase 
MMP-8. This will give a greater indication on the specificity of Trb1 and 
Trb3 for MMP-13, or whether they act in a broader context. 
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• Investigate the effect of Trb1 and Trb3 on TIMPs, in order to greater 
understand how Trb1 and Trb3 may regulate MMPs. 
 
• Investigate the effect of Trb1 and Trb3 on ADAMTS-4 and -5, in order to 
investigate wether Trb1 and Trb3 can regulate proteoglycan degradation 
as well as collagen type II degradation. 
 
• Investigate the effect of Trb1 and Trb3 overexpression on STAT 
activation. 
 
• Investigate the effect of Trb1 and Trb3 on JAK regulation. 
 
• Investigate the effect of Trb3 on PI3K. 
 
 
• Investigate the effect of Trb1 and Trb3 on the various pathways on 
collagen type II coated plates, in order to give a greater physiological 
significance. 
 
• Investigate the effect of Trb1 and Trb3 on other proteins within cartilage, 
such as fibronectin and anchorin. 
 
 
• Investigate the effect of Trb3 overexpression, as well as Trb1 silencing 
and overexpression on cartilage degradation and MMP expression in a 
mouse model. 
Each of these experiments will further provide a greater understanding of the 
roles in which Tribbles may play in regulating cellular pathways in order to 
regulate proteases involved in cartilage degradation. This greater understanding 
may help in finding future treatments for arthritis. 
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Appendix A - Overexpression plasmid maps 
 
A 
pCDNA3.1-trb1-mycHis
6560 bp
 
B 
pCDNA3.1-trb3-mycHis
6515 bp
 
Trb1 (A) and Trb3 (B) overexpression plamid maps. Trb; Tribbles, AmpR; Ampicillin resistance, CMV; 
Cytomegalovirus, ORF; Open reading frame, SV; Simian virus, NeoR; Neomycin resistance, His; Histidine. 
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 pMD2 lentiviral envelope plasmid. AmpR; Ampicillin resistance, ORF; Open reading frame, Fsp; 
Fusarium oxysporum, CMV; Cytomegalovirus, SV40; Simian virus, bGlob; β globin, MscI; Murine stem cell 
virus, Eag; E. agglomerans, NotI Nocardia otitidis-caviarum, VSVG; Vesicular stomatis virus glycoprotein, 
PstI; Providencia Stuartii.  
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 pCMV lentiviral packaging plasmid. AmpR; Ampicillin resistance, ORF; Open reading frame, Fsp; 
Fusarium oxysporum, CMV; Cytomegalovirus, SV40; Simian virus 40, bGlob; β globin, MscI; Murine stem 
cell virus, Eag; E. agglomerans, NotI; Nocardia otitidis-caviarum, VSVG; Vesicular stomatis virus 
glycoprotein, PstI; Providenia Stuartii.  
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TRIPZ and GIPZ lentiviral plasmids. Ampr; Ampicillin resistance; rtTA3; reverse tetracycline 
transactivator 3, Puror; Puromycin resistance, LTR; Long terminal repeat, cPPT; Central polypurine tract, 
Zeo; Zeomycin, CMV; Cytomegalovirus, GFP; Green fluorescent protein, IRES: Internal ribosome entry 
site, RFP; Red fluorescent protein, SV40; Simian virus 40.  
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 Venus fluorescent protein plasmid. AmpR; Ampicillin resistance, ORF; Open reading frame, GFP; 
Green fluorescent protein, YFP; Yellow fluorescent protein, EcoRI; E.coli restriction enzyme I, SV40; 
Simian virus 40, MSCV; Murine stem cell virus, NeoR; Neomycin resistancance, KanR; Kanamycin 
resistance, Lac; Lactose, EBV; Epstein Bar virus, BGH; Bovine growth hormone, NotI; Nocardia otitidis-
caviarum, CMV; Cytomegalovirus. 
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